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Abstract 
 
 
Type  II  pneumocytes  are  responsible  for  the  synthesis  and  secretion  of  pulmonary 
surfactant, which lines the alveoli of the lungs.  Its presence as a monolayer at the air-
liquid interface in the alveoli diminishes surface tension, thus reducing the tendency of 
alveoli  to  collapse  during  expiration.    For  this  effect  to  be  sustained,  however,  the 
integrity of the surfactant components needs to be maintained.  In this study it has been 
demonstrated that when cultured type II pneumocytes are exposed to lipoprotein-free 
serum (LFS) the level of lyso-phosphatidylcholine (lyso-PC) in the secreted surfactant 
phospholipids is elevated.  The lyso-PC content of secreted phospholipids in serum-
supplemented cultures increased 5.4-fold with a concomitant decline in the level of 
phosphatidylcholine (PC) when compared to cells grown in absence of LFS.  This effect 
is without doubt the result of hydrolysis of surfactant phosphatidylcholine by serum 
phospholipase A2 (PLA2)-like activity.  Given that many cases of respiratory trauma are 
associated with leakage of serum into the alveoli, this enzyme may be a significant 
contributor  to  surfactant  inactivation  and  the  onset  of  adult  respiratory  distress 
syndrome  (ARDS).    Subjecting  human  LFS  to  DEAE-Sepharose  chromatography 
demonstrated that the enzyme, which stimulates the production of lyso-PC, co-elutes 
with albumin and is biochemically distinct from the secretory form of PLA2.  Testing of 
commercially purified human serum albumin (HSA) also showed the presence of this 
enzymatic activity, indicating that the serum factor not only co-elutes with albumin but 
is  possibly  bound  to  it.    This  is  supported  by  the  fact  that,  when  subjected  to 
polyacrylamide gel electrophoresis, the activity associated with LFS and human serum       iv 
albumin  (HSA)  has  an  almost  identical  elution  profile.  Furthermore,  when  partially 
purified preparations of  these were subjected to IEF electrophoresis, both yielded a 
similar double protein-banding pattern.  Although the predominant band had similar 
migratory properties to that of albumin (pI of approximately 4.5) it was not possible, 
given that the IEF involves a denaturing gel, to assign the PLA2-like activity to either of 
these  two  bands.    The  present  study  has  also  revealed  that  exposure  of  type  II 
pneumocytes to recombinant human serum albumin (rHSA) stimulates the secretion of 
phospholipids and is almost as effective as LFS in enhancing the level of lyso-PC in the 
media.  The latter observation implies that rHSA is able to directly generate lyso-PC 
and suggests that PLA2 activity may be an innate activity of albumin.  
Neonatal respiratory distress syndrome (NRDS) is a significant cause of mortality in 
preterm human infants.  Because underdevelopment of the lungs is known to contribute 
to the pathogenesis of NRDS, corticosteroid treatment using synthetic glucocorticoids 
has  been  widely  used  to  accelerate  maturation  of  the  type  II  alveolar  cells  and  to 
prematurely initiate synthesis of surfactant.  Dexamethasone has no effect upon the rate 
of synthesis of surfactant lipids when applied directly to cultured foetal type II cells.  
However, if type II cells are exposed to medium previously conditioned by cultured 
lung fibroblasts in the presence of dexamethasone, then there is a significant elevation 
(17.3%  increase)  in  the  rate  of  surfactant  lipid  synthesis.    This  indirect  effect  of 
dexamethasone, presumably acting via the production of fibroblast pneumocyte factor 
(FPF), is significantly greater if both the fibroblasts and type II cells are derived from 
female foetal rats (47.6% increase in PC synthesis) as compared to those derived from 
male foetuses (19.0% increase). The present study has confirmed that there are sex-
specific  and  gestational  age  differences  in  the  glucocorticoid  receptor  level  of  lung 
fibroblasts  but  not  of  type  II  cells,  thus,  regulation  of  the  appearance  of  the       v 
glucocorticoid receptor in foetal lungs in the later stages of gestation appears to be both 
sex- and cell-specific. The interaction of glucocorticoids with their specific receptor has 
also been shown to indirectly affect the rate of surfactant secretion.  This study has 
demonstrated that β-adrenergic receptors are present and functional in cultures enriched 
with foetal type II pneumocytes. The β-adrenoreceptor activity is elevated if the type II 
cells are exposed to glucocorticoids but, as has been shown in this study, the elevation 
of receptor activity is significantly greater if the type II cells are exposed to media that 
had been previously conditioned by fibroblasts in the presence of glucocorticoids.  Both 
of these effects are more pronounced if the type II cells were derived from female 
foetuses rather than from males, despite the cells being grown under similar conditions. 
The observed elevation in β-adrenergic receptor activity in type II cells exposed to 
either  glucocorticoids  or  fibroblast-conditioned  media  has  been  shown  to  lead  to  a 
greater  physiological  response  to  the  β-agonist,  (—)-isoproterenol,  as  measured  by 
surfactant lipid secretion. Indeed, there is a very strong correlation (r = 0.962) between 
the β-adrenergic receptor activity and the ability of agonists to stimulate phospholipid 
secretion from type II cells. Given that the enhanced β-adrenergic receptor activity of 
type II cells and the resultant cellular response to β-agonists is higher if the cells are 
treated  with  FCM  rather  than  with  dexamethasone,  it  is  suggested  that  these 
glucocorticoid-induced responses may be indirect via an increased release of FPF from 
lung fibroblasts.  
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 Chapter 1  Literature Review 
 
  1 
1.0 General Introduction 
Surrounded  by  lukewarm  amniotic  fluid,  the  healthy  mammalian  foetus  enjoys  a 
peaceful and privileged existence, without having to worry about gas exchange and 
other functions provided by the placenta.  Adjustment to extrauterine life requires the 
induction  of  numerous  functions,  one  of  which  is  the  production  of  pulmonary 
surfactant by the lung.  Pulmonary surfactant is a complex and highly active material 
composed of lipids and four specific surfactant associated-proteins, which is found in 
the fluid lining the alveolar surface of the lung (Whitsett and Weaver, 2002) (Figure 
1.1).    Surfactant  prevents  alveolar  collapse  at  low  lung  volume,  and  preserves 
bronchiolar  patency  during  normal  and  forced  respiration  (Johansson  and  Curstedt, 
1997;  Maina  et  al.,  2010;  Possmayer  et  al.,  2010).    In  addition,  it  is  involved  in 
protection of the lungs from injuries and infections caused by inhaled particles and 
micro-organisms (Griese, 1999).  If the lungs are immature at birth, characterised by a 
deficiency  of  surfactant,  the  newborn  will  develop  neonatal  respiratory  distress 
syndrome  (NRDS),  a  condition  that  can  nowadays  be  treated  by  administration  of 
exogenous surfactant (Smyth et al., 1983; Griese, 1999; Jobe and Ikegami, 2000; Suresh 
and Soll, 2002; Amato et al., 2003; Chotigeat et al., 2008). Various other lung diseases 
are associated with surfactant abnormalities and, in some of these diseases, replacement 
therapy  is  on  the  horizon  but,  for  the  majority,  a  better  understanding  of  the  basic 
physiological processes is required.  
1.1   Composition of surfactant 
Pulmonary surfactant is represented by several different structural entities.  The major 
forms being (i) lamellar bodies, which are characteristic inclusion organelles of type II  
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Figure 1.1  Micrograph of the alveolar space with a magnified diagram of the air-
liquid  interface  with  formation  of  pulmonary  surfactant  films  (Whitsett  and 
Weaver, 2002). 
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pneumocytes  and  represent  the  intracellular  reservoirs  of  surfactant  (Wright  and 
Clements,  1987),  (ii)  tubular  myelin,  a  complex  bilayer  structure  formed  from  the 
lamellar bodies, which is considered to be the main source for the formation of the 
surface-active  monolayer  (Hook  et  al.,  1986),  and  (iii)  the  extracellular  pool, 
comprising the monolayer of lipids and proteins lining the alveolar lumen (Schurch et 
al.,  1995).    Pulmonary  surfactant  is  heterogeneous  with  respect  to  biochemical 
composition, morphological organization and specific biophysical functions (Robertson, 
1984).  In addition, surfactant isolated for testing is likely to comprise active surfactant, 
newly secreted surfactant and surfactant that is ready for recycling and removal from 
the alveolar lining.  
It  is  well  established  that  pulmonary  surfactant  contains  several  types  of  lipids, 
including  cholesterol,  triglycerides  and  free  fatty  acids  (King,  1982;  Johansson  and 
Curstedt,  1997;  Veldhuizen  et  al.,  1998;  Orgeig  and  Daniels,  2001;  Piknova  et  al., 
2002) but is quantitatively strongly dominated by phospholipids (Fig. 1.2).  The two 
major classes of phospholipids are phosphatidylcholine and phosphatidylglycerol with 
the former constituting 70%-80% of the lipids and the latter 5%-10% (King, 1982; Lang 
et al., 2005). This lipid composition is well conserved in all adult vertebrates studied 
except the chicken (Shelley et al., 1984) and  rhesus monkey (Egberts et al., 1987) in 
which  surfactant  contains  little  or  no  phosphatidylglycerol.    About  40-50%  of  the 
phosphatidylcholine in surfactant is disaturated with both fatty acids being palmitic acid 
as  determined  using  ESI-MS  (Mukherjee  et  al.,  2008).    This  dipalmitoyl-
phosphatidylcholine  (DPPC)  is  thought  to  be  the  component  of  surfactant  that  is 
responsible  for  reduction  of  the  surface  tension  to  very  low  values  during  dynamic 
compression (Holm et al., 1996; Veldhuizen et al., 1998; Piknova et al., 2002).  One  
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Figure 1.2  Relative composition of surfactant from canine lung lavage. 
 
Chol,  cholesterol;  DG,  diacylglycerol;  LBPA,  lyso(bis)phosphatidic  acid;  LPC, 
lysophosphatidylcholine;  MG,  monoacylglycerol;  PS,  phosphatidylserine;  TG, 
triacylglycerol.  The numbers indicate the percentage composition.  Data taken from 
Metcalfe et al. (1980). 
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end of the DPPC molecule contains the choline residue, which is polar and hydrophilic, 
while  the  other  end  contains  the  palmitic  acid  residues  and  is  thus  non-polar  and 
hydrophobic.  This amphipathic property allows them to align at the alveolar air-liquid 
interface.  
The  role  of  phosphatidylglycerol  (PG)  is  less  well  understood.    In  early  foetal 
development the concentration of PG in amniotic fluid and in foetal tracheal aspirates is 
very low (Hallman et al., 1977). However, it increases either late in gestation in some 
species, including humans (Hallman et al., 1977), rats (Egberts and Noort, 1986), and 
lambs  (Egberts  et  al.,  1986)  or  shortly  after  birth  in  rabbits  (Hallman  and  Epstein, 
1980).  The finding that babies who delivered before PG was detectable in amniotic 
fluid samples suffered from respiratory distress syndrome (RDS) (Hallman et al., 1977), 
suggested  that  PG  may  play  an  important  role  in  the  physiological  function  of 
surfactant.  Moreover, surfactant with PG was shown to have better physio-chemical 
characteristics for ensuring alveolar stability (Hallman et al., 1976; Koppenol et al., 
1997) supporting the argument that PG has an important role in pulmonary surfactant 
(Dhand et al., 1999). 
Phosphatidylglycerol is the most variable surfactant component in different mammalian 
species.    It  is  greatly  reduced  in  cats  (Shelley  et  al.,  1984),  adult  rhesus  monkeys 
(Egberts  et  al.,  1987)  and  guinea  pigs  (Khan  et  al.,  1985)  and  replaced  with 
phosphatidylinositol (PI) as the major acidic phospholipid in both the lamellar body 
fraction and the alveolar surfactant fraction.  Furthermore, in adult cat surfactant the 
percentage of PG is four to five times lower than that in the surfactant of humans, rats, 
rabbits and dogs (Shelley et al., 1984).  Some evidence suggests that PG is not essential 
for at least some functions of surfactant.  Newborn rabbits show no sign of respiratory 
distress even though their surfactant contains a low level of PG for several hours after Chapter 1  Literature Review 
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birth (Hallman and Epstein, 1980; Hallman et al., 1985).  Furthermore, in adult rabbits, 
the percentage of PG is still very low, which suggests that postnatal adaptation of the  
surfactant composition does not occur (Shelley et al., 1984).  Additionally, studies by 
Beppu et al. (1983) and  Hallman et al. (1985) were unable to detect any dysfunction of 
lung surfactant in adult rabbits in which the surfactant was made deficient in PG by the 
administration of inositol.  In these studies the PG deficiency was balanced by a boost 
in the level of phosphatidylinositol (PI), which could effectively substitute for PG. 
Similar  conclusions  were  reached  when  an  excess  of  myo-inositol  (Hallman  and 
Epstein, 1980) or an injection of N-nitroso-N-methylurethane (Liau et al., 1985) were 
used to induce a deficiency of PG.  Myo-inositol, in fact, results in an increase in the 
pool size of alveolar surfactant (Hallman and Epstein, 1980).  Some studies have shown 
that there is a positive correlation between the PI levels in surfactant and serum and a 
negative correlation between the PG level and serum myo-inositol level ((Hallman et 
al., 1982; Bleasdale et al., 1983; Hallman et al., 1985; Egberts and Noort, 1986).  These 
studies clearly reveal that the presence of PG is not crucial for the normal function of 
surfactant.  However, it is certainly possible that PG may be important in other aspects 
of surfactant function or metabolism (Egberts and Noort, 1986). For instance, human 
infants who are born prior to the prenatal increase in PG level are more likely to suffer 
from NRDS than those born after (Hallman et al., 1977), suggesting a definite role for 
PG in the function of surfactant.  It is possible that the presence of PG helps in the 
association of surfactant apoproteins with phospholipids (King and Martin, 1980; King 
et al., 1983), and there is a correlation between the level of PG in the monolayer and the 
presence of SP-B protein (Yu and Possmayer, 1990).  
 Proteins  are  an  essential  component  of  pulmonary  surfactant  and  have  extensive 
biophysical  interactions  with  the  phospholipids.    They  can  affect  the  structure  and Chapter 1  Literature Review 
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properties of lipid bilayers in the aqueous phase and the behaviour of interfacial films 
(Yu and Possmayer, 1988; Wang et al., 1995; Henry et al., 1996; Veldhuizen et al., 
1996; Dhand et al., 1998; Fehrenbach, 2001; Orgeig et al., 2010).  Four lung surfactant 
proteins  have  been  identified:  two  high  molecular  weight  proteins,  SP-A  (an 
octadecamer with a molecular weight of each polypeptide chain of ~26 kDa) and SP-D 
(a dodecamer with a molecular weight of each polypeptide chain of ~39 kDa), that are 
both  water  soluble,  and  two  low  molecular  weight  proteins,  SP-B  (a  dimer  with  a 
molecular weight of each polypeptide chain of ~8.7 kDa) and SP-C (a monomer with a 
molecular weight of ~4kDa), that are both highly hydrophobic (Yu and Possmayer, 
1988; Shimizu et al., 1991; Van Eijk et al., 1995; Dhand et al., 1998; Fehrenbach, 2001; 
Orgeig et al., 2010).  Although both of these groups of proteins were first described 
more than three decades ago (King et al., 1973), controversy still exists because the 
amounts  and  the  types  of  proteins  that  co-isolate  with  surfactant  depend  upon  the 
method  of  isolation  and  the  animal  species  used.    In  addition,  several  groups  have 
reported  that  other  proteins  co-isolate  with  surfactant  including  albumin, 
immunoglobulin G (King et al., 1973), immunoglobulin A (Paciga et al., 1980), and 
secretory  uteroglobin  (Guy  et  al.,  1992).    The  function  of  these  latter  proteins  in 
surfactant is not known.  However, it has been suggested that immunoglobulins may 
help in the defence against infection (Paciga et al., 1980), and uteroglobin may have a 
vital role in increasing the half-life of surfactant and in reducing the level of eicosanoids 
through phospholipase A2 inhibition (Guy et al., 1992). 
Several factors have been shown to affect the composition of surfactant, most notably 
diet.    It  has  been  demonstrated  that  feeding  rats  during  late  pregnancy  with  a  diet 
deficient in vitamin A leads to a 30-60% reduction in the blood retinol and results in a 
delay in the maturation of the lung in the offspring (Chailley-Heu et al., 1999).  At term, Chapter 1  Literature Review 
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the  lung  surfactant  phospholipids  were  reduced  by  21%  and  the  major  surfactant 
phospholipid DPPC was reduced by 27%.  The decrease in surfactant phospholipids and 
DPPC was inversely correlated with the plasma retinol levels, which is accompanied by 
a reduced expression of the gene for fatty acid synthase, a key enzyme in the synthesis 
pathway for surfactant phospholipid precursors.  The amounts of SP-A, SP-B, and SP-C 
were  also  diminished  (Chailley-Heu  et  al.,  1999).    Also  a  significant  positive 
association has been observed between dietary vitamin C intake and pulmonary function 
(Hu et al., 1998).   
In contrast, rats receiving a choline deficient lipotropic diet, although having a 46% 
decrease in the choline content of the lungs when compared with controls, have a PC 
pool that seems to be unchanged (Yost et al., 1985).  These findings imply that other 
mechanisms may contribute to compensate for the choline deficiency and may involve 
allosteric  regulation  of  CTP-phosphocholine  cytidylyltransferase,  the  presumed  rate-
limiting enzyme in the de novo synthesis of PC (Yost et al., 1985).  Supplementation of 
the diet of infant rats for ten days with arachidonic acid and/or docosahexaenoic acid 
showed that the function and phospholipid composition of the surfactant was unaffected 
by the fatty acid content of the diet (Yeh et al., 1999).  
 
1.2   Metabolism of pulmonary surfactant 
1.2.1   Surfactant synthesis  
Several lines of evidence suggest that the alveolar type II cell is the site of synthesis of 
surfactant lipids.  Type II cells contain unique subcellular organelles called lamellar 
bodies which consist of stacks of lamellae, which have the appearance of phospholipid 
bilayers, an electron dense core, which appears to be proteinaceous, and the surrounding 
limiting  membrane  (Kikkawa  et  al.,  1975;  Dobbs,  1990;  Fehrenbach,  2001).    The Chapter 1  Literature Review 
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phospholipid composition of isolated lamellar bodies is virtually identical to that of 
lavage phospholipids (Hallman et al., 1981; King, 1984; Chander et al., 1986).  The 
finding that isolated type II cells in culture labelled with radioactive [U-
14C] glycerol 
and [
14C] acetate as precursors can be stimulated to secrete phospholipids with a similar 
composition to that of the alveolar phospholipids provides additional evidence that the 
type II cell secretes these lipids (Dobbs et al., 1982; Dobbs et al., 1985; Mason, 1987).  
In addition, a more recent study of lung development has shown that the synthesis of 
surfactant phospholipids by type II cells depends on lung maturity (Kresch et al., 1996).  
These  findings  indicate  that  a  developmental  increase  in  the  basal  secretory  rate 
correlates with the morphological differentiation of the cell (Kresch et al., 1996).  In 
contrast, the lipid composition did not show any significant difference in the secreted 
material (content of phosphatidylglycerol, phosphatidylserine and phosphatidylinositol) 
between type II cells derived from 21-day foetal rats and adult rats (Griese et al., 1992). 
Type II cells represent about 15% of the cell population of the lung parenchyma (Haies 
et  al.,  1981).    A  characteristic  of  these  cells  is  the  presence  of  surfactant  storage 
organelles, the lamellar bodies that are surrounded by a limiting membrane that fuses 
with  the  plasma  membrane  upon  secretion  (Haagsman  and  Van  Golde,  1991; 
Fehrenbach, 2001; Andreeva et al., 2007).  The notion that type II cells are the sole 
producers  of  surfactant  comes  from  many  morphological  and  biochemical  studies.  
However,  although  the  lipid  composition  of  the  alveolar  surfactant  recovered  from 
lavage and intracellular lamellar bodies are strikingly similar, the lamellar bodies lack 
SP-D  (Voorhout  et  al.,  1992)  and  have  a  significantly  lower  content  of  SP-A 
(Oosterlaken-Dijksterhuis et al., 1991). SP-A constitutes only about 1% of total lamellar 
body protein compared to about 50% of alveolar lavage surfactant protein (Oosterlaken-
Dijksterhuis et al., 1991) indicating that a relatively small amount of secreted SP-A is Chapter 1  Literature Review 
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released from the lamellar bodies (Fraslon-Vanhulle et al., 1993).  However, evidence 
for the unique role of type II cells comes from studies on the localisation of surfactant 
protein  synthesis.    In  situ  hybridisation  indicates  that  the  only  site  of  SP-A  gene 
expression in the human lung is the type II cell (Haagsman and Van Golde, 1991), and 
that SP-A is synthesised and processed by isolated type II cells (Haagsman and Van 
Golde,  1991).      SP-B  has  also  been  localised  to  type  II  cells  (Henry  et  al.,  1996).  
Furthermore,  cultured  type  II  cells  synthesise  phospholipids  from  a  variety  of 
radioactive precursors with a high proportion of DPPC and PG (Mason et al., 1976; 
Dobbs et al., 1982; Andreeva et al., 2007). Moreover, the enzymes required for these 
synthetic processes have been localised in the microsomal fraction of type II cells (Jobe 
et al., 1981; Chander et al., 1983; Crecelius and Longmore, 1983).  
Some  evidence  suggests  that  lamellar  bodies  are  not  the  sole  organelle  involved  in 
surfactant synthesis.  Although there have been reports that lamellar bodies contain 
some of the synthetic enzymes (Casals et al., 1989), they lack others needed for PC 
synthesis (Baranska and Van Golde, 1977) thus excluding them as the site of lipid 
synthesis.    The  pathway  of  lipid  and  protein  synthesis  has  been  traced  by  electron 
microscopic  autoradiography  (Chevalier  and  Collet,  1972)  and  provides  substantial 
information  on  the  synthesis  and  storage  of  pulmonary  surfactant.  The  majority  of 
surfactant phospholipids would appear to be synthesised in the endoplasmic reticulum 
of the type II cells and then transferred from the endoplasmic reticulum to the Golgi 
apparatus, then to the lamellar bodies.  The stored phospholipids are bound by a limiting 
membrane,  which  is  characterised  by  typical  lysosomal/endosomal  (Wasano  and 
Hirakawa, 1994) as well as by specific integral membrane proteins (Zen et al., 1998) 
probably involved in intra-cellular trafficking.  The lamellar body membrane is further 
equipped  with  transport  proteins  for  regulation  of  internal  acidic  pH  and  high  Ca
2+ Chapter 1  Literature Review 
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(Wadsworth  and  Chander,  2000).    Immunoelectron  microscopy  confirmed  a  similar 
pathway for SP-B and SP-C, and by means of double- and triple-labelling, the different 
steps  of  processing  and  maturation  of  SP-B  and  SP-C  were  localised  to  specific 
intracellular structures (Vorbroker et al., 1995).  Although the pathway of both SP-A 
and SP-D also involved endoplasmic reticulum and Golgi apparatus, mature SP-D is 
barely detectable in lamellar bodies (Zhang et al., 2006), implying that other organelles 
or even cell types may be involved.  It is thought that SP-D is released via a constitutive 
pathway and a subpopulation of lamellar bodies has been proposed to be involved in 
recycling (Herbein et al., 2000).  The lamellar bodies are considered to be the site where 
surfactant lipids and proteins are first associated and assembled into the final storage 
form of surfactant (Williams, 1977) as the biochemical composition of this intracellular 
storage  form  is  largely  identical  to  the  composition  of  the  extracellular  material 
obtained by BAL (Baritussio et al., 1981).   
Among mammals, phosphatidylcholine (PC) is derived from the CDP-choline pathway 
(Figure 1.3).  Following its uptake into the cell, choline is phosphorylated by choline 
kinase  in  an  ATP-dependent  reaction.    CTP-cholinephosphate  cytidylyltransferase 
(CCT)  subsequently  catalyses  the  formation  of  the  activated  cytidine  intermediate, 
CDP-choline.  Finally, choline phosphotransferase mediates the transfer of the choline 
phosphate moiety of CDP-choline to diacylglycerol to yield PC.  It has been estimated 
that  this  pathway  (Epstein  and  Farrell,  1975;  Batenburg,  1992;  Fehrenbach,  2001; 
Andreeva  et  al.,  2007)  produces  more  than  90%  of  newly  synthetised  PC.    An 
alternative approach for the net synthesis of PC involves the successive methylation of 
phosphatidylethanolamine  but  this  pathway  is  of  less  importance  in  the  lung 
(Batenburg, 1992), and while synthesis of PC from choline is increased, methylation of  
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Figure  1.3    Pathways  involved  in  the  synthesis  of  phosphatidylcholine  and 
disaturated phosphatidylcholine. 
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PE  is  decreased  (Pelech  and  Vance,  1984).    Recent  studies  on  the  key  regulatory 
enzyme of PC biosynthesis, CTP-cholinephosphate cytidylyltransferase, show that this 
enzyme may be subtly connected to the lipid traffic (Dunne et al., 1996).  Confirmation 
of the physiological rationale for this regulatory mechanism can be inferred from kinetic 
studies  of  CTP-cholinephosphate  cytidylyltransferase,  which  imply  that  the  lipid 
binding domain functions in an inhibitory capacity in the absence of lipids within the 
cell  (Clement  and  Kent,  1999).    It  has  been  found  that  CTP-cholinephosphate 
cytidylyltransferase  contains  a  true  lipid-binding  amphipathic  α-helical  segment 
(Weinhold et al., 1991; Dunne et al., 1996). 
Type II cells also have the potential to generate DPPC de novo by remodeling through a 
deacylation-reacylation of unsaturated PC.  The removal of the unsaturated fatty acyl-
group  from  the  sn-2 position  of  an  unsaturated  PC  requires  phospholipase  A2.  
Alternatively,  the  unsaturated  acyl-group  at  the  sn-2  position  of  an  unsaturated  PC 
species  is  transferred  to  the  vacant  OH-group  of  lysophospholipid  via  a  CoASH-
dependent  transacylation.    The  resulting  lysophosphatidylcholine  is  reacylated  with 
palmitoyl-CoA to form DPPC (Haagsman and Van Golde, 1991).  
 
1.2.2   Incidence of surfactant synthesis 
The synthesis of surfactant in foetal type II cells starts in the early part of gestation and 
is dramatically accelerated in the late prenatal period (Fraslon-Vanhulle et al., 1994; 
Andreeva et al., 2007).  SP-A, SP-B and SP-C and their mRNAs appear during this 
period and reach a maximum level before birth (Smith, 1984b).  Consistent with this is 
the fact that pulmonary fatty acid synthesis in the foetal lung displays a peak in this 
period of accelerated surfactant elaboration (Fraslon-Vanhulle et al., 1994).  This high 
lipogenic rate is accompanied by increased activities of related enzymes.  In particular, Chapter 1  Literature Review 
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a peak in the activities of fatty acid synthase and acetyl-CoA carboxylase has been 
reported  (Fraslon-Vanhulle  et  al.,  1994).    Measurements  of  the  abundance  of  the 
mRNAs for fatty acid synthase, acetyl-CoA carboxylase, ATP-citrate lyase and malic 
enzyme in vivo (Batenburg and Whitsett, 1989) and in explant cultures (Fraslon and 
Batenburg, 1993) indicated that pretranslational regulation of these enzymes is involved 
in the developmental increase in the rate of fatty acid synthesis.  The recent finding that 
the level of mRNA for CTP-phosphocholine cytidylyltransferase, the enzyme catalysing 
the rate-regulatory step in PC formation, increased in foetal lung in explant culture is 
also in agreement with a pretranslational regulation of the latter enzyme in whole lung 
tissue (Fraslon and Batenburg, 1993; Andreeva et al., 2007).  Although results from a 
number of studies indicated that in late gestation, hormones, especially glucocorticoids, 
are  involved  in  the  acceleration  of  the  synthesis  of  both  the  phospholipids  and  the 
proteins of surfactant, these hormones do not appear to initiate differentiation.  This is 
concluded from the observation that surfactant accumulated in explant cultures in the 
absence of hormones (Gross and Narine, 1989) and that the antiglucocorticoid drug RU-
486 failed to prevent the start of lung maturation in vivo (Fraslon and Batenburg, 1993).  
 
1.2.3   Acceleration of surfactant synthesis 
The activity of various enzymes involved in the synthesis of DPPC has been shown to 
be increased by glucocorticoids (Ballard, 1989).  Administration of glucocorticoids just 
prior to normal maturation leads to an increased glucose utilization and accelerated 
glycogenolysis  in  addition  to  an  elevated  level  of  phospholipid  synthesis  and  an 
enhanced rate of lung maturation (Smith, 1984a).  However, these steroids act directly 
upon lung fibroblasts to induce the production of fibroblast-pneumocyte factor (FPF), 
which  then  acts  upon  the  adjacent  type  II  cells  to  induce  surfactant  phospholipid Chapter 1  Literature Review 
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synthesis (Smith, 1978; Post and Smith, 1984; Post et al., 1986; Sweezey et al., 1998; 
Samtani et al., 2006). The above observations indicate that the rate of synthesis of 
surfactant in the type II cells is dependent upon the action of this factor.  However, it 
has been reported that high levels of androgens alter the response to the administration 
of  glucocorticoids,  thus  accounting  for  the  slower  onset  of  surfactant  phospholipid 
formation in male foetuses (Adamson and King, 1984). 
In  contrast,  the  response  to  glucocorticoid  administration  can  be  enhanced  when 
administered together with triiodothyronine.  It has been shown that these hormones 
have a synergistic effect on the development and stability of the foetal lung as well as 
on  phosphatidylcholine  synthesis  and  lamellar  body  secretion  (Schellenberg  et  al., 
1988). The use of glucocorticoids together with insulin and/or prolactin leads to a two-
fold  increase  in  lamellar  body  phospholipid  concentration  compared  to  controls 
(Mendelson and Boggaram, 1991). Glucocorticoids also enhanced expression of mRNA 
for SP-B (Ahmad et al., 1996) as well as promoting stability of SP-A mRNA (Seidner 
et al., 1996).  Dexamethasone has also been shown to block production of transforming 
growth factor β (TGFβ), which otherwise blocks the maturation of type II cells (Torday 
and Kourembanas, 1990; McDevitt et al., 2007).  
Epidermal growth factor has been demonstrated to contribute to the normal onset of 
lung maturation by elaborating a fibroblast-derived factor that stimulates synthesis of 
phospholipids in type II pneumocytes (Sen and Cake, 1991).  EGF has a concentration-
dependent  effect,  promoting  an  increase  in  the  level  of  FPF  independent  of 
glucocorticoids (Sen and Cake, 1991). 
Recent research has suggested that neuregulin-1β (NRG-1), a growth factor involved in 
many  different  stages  of  human  development,  has  the  same  stimulatory  effect  on 
surfactant synthesis in type II pneumocytes. Furthermore, the stimulatory effect on FPF Chapter 1  Literature Review 
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was inhibited by the addition of a NRG-1β neutralising antibody (Dammann et al., 
2003). Moreover, receptors for NRG-1β have been identified in human foetal lung cells 
as early as 24 weeks of gestation (Bueter et al., 2006).  
 
1.2.4   Acceleration of surfactant secretion 
 
Subsequent to its synthesis, surfactant is secreted from the lamellar bodies into the 
alveolar lumen.  The cellular and molecular mechanisms that are involved in this 
secretory event are not fully understood.  Images of lamellar bodies apparently 
undergoing exocytosis have been reported in several microscopic studies (Ryan et 
al., 1975; Kliewer et al., 1985).  Electron micrographic images suggest that the 
limiting  membrane  that  surrounds  the  lamellar  body  fuses  with  the  plasma 
membrane of the type II cell (Kliewer et al., 1985) via a Ca2+‐dependant process 
(Haller et al., 2001).  More recently, this fusion process has been shown to involve 
an  interaction  with  a  soluble  protein,  annexin,  the  cellular  distribution  and 
phosphorylation  state  of  which  is  altered  when  the  cells  are  treated  with  a 
secretagogue (Chattopadhyay et al., 2003; Chander et al., 2009).  What is established 
is that the material secreted from alveolar type II cells is chemically and physically 
similar  to  the  lung  surfactant  obtained  by  endobronchial  lavage  and  is 
morphologically similar to the material seen in the alveoli of foetal and adult lung 
(Dobbs et al., 1982).  The available evidence suggests that most of the components 
of  surfactant  are  secreted  together.    Specific  activity‐time  curves  for  the 
appearance of PC, DPPC, PG, and cholesterol are all similar (Wright and Clements, 
1987).    SP‐B  as  well  as  SP‐C  secretion  is  also  coordinated  with  phospholipid 
secretion  (Henry  et  al.,  1996).    Endogenously  synthesised  SP‐A  is  secreted Chapter 1  Literature Review 
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independently  of  lamellar  bodies  and  of  the  secretory  pathway  for  the  lipid 
components of surfactant (Hawgood, 1989). 
Several  different  experimental  systems  provide  strong  support  for  the  concept  that 
phospholipid secretion is influenced by a variety of agonists acting via a number of 
different signal transduction mechanisms (Wright and Clements, 1987; Chander and 
Fisher, 1990). Agents that stimulate secretion include β-adrenergic agonists, A2 and P2 
purinoceptor agonists, ionophores that increase intracellular Ca
2+ levels, synexin, and 
protein kinase C activators (Griese et al., 1992; Chander et al., 2001). 
Adrenergic agents act on type II cells directly via adrenergic receptors to increase the 
cellular levels of 3’-5’cyclic monophosphate (cAMP) (Brown and Langmore, 1981) and 
to stimulate secretion of surfactant (Kresch et al., 1996).  It has also been shown that the 
β-adrenergic agonist, terbutaline, activates cAMP-dependent protein kinase, suggesting 
that phosphorylation of cell proteins is involved in the secretory event (Griese et al., 
1992).  Cell actin, which is closely associated with lamellar bodies, is phosphorylated 
via a cAMP-dependent process and cAMP alters the distribution of actin in type II cells.  
These  findings  suggest  that  one  pathway  for  β-adrenergic  stimulation  of  surfactant 
release  is  by  cAMP-dependent  protein  kinase-mediated  phosphorylation  of  actin 
(Wright and Clements, 1987).  According to these studies, cAMP is likely to be an 
intracellular ‘second messenger’ in type II cells.  The presence of A23187, has also 
been reported to increase cAMP in these cells (Dobbs et al., 1986a).  However, because 
A23187  also  mobilises  Ca
2+,  there  is  support  for  the  concept  that  Ca
2+,  as  well  as 
cAMP, plays a role in the regulation of surfactant secretion (Dobbs et al., 1986a). 
The mechanism by which ATP stimulates phosphatidylcholine is more complex.  There 
is evidence that ATP occupancy of the P2 receptors on the type II cell is linked to 
activation  of  the  phosphoinositide-specific  phospholipase  C,  which  results  in  the Chapter 1  Literature Review 
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generation of inositol trisphosphate and diaglycerols (Griese et al., 1991).  These result 
in  activation  of  Ca
2+/calmodulin-dependent  protein  kinase  and  protein  kinase  C, 
respectively. 
It has also been demonstrated that a number of regulatory peptides, such as gastrin-
releasing peptide (GRP) and bombesin, are associated with the secretion of surfactant 
phospholipids.  The effect of GRP has been shown to result in the activation of protein 
kinase  C  and  Ca
2+/calmodulin-dependent  protein  kinase,  whereas  cAMP-dependent 
protein kinase is not involved in the response to this agent (Asokananthan and Cake, 
1996). 
 
1.2.5   Intra-alveolar metabolism 
The metabolism of surfactant after it is released into the alveoli is not well understood.  
It has been demonstrated that surfactant exists in several different physical forms in 
both  the  alveoli  and  the  lavage  material.    These  forms  include  densely  packed 
multilamellar  structures  that  resemble  recently  secreted  lamellar  contents,  a  unique 
lattice-like structure called tubular myelin, a surface film, multilamellar and unilamellar 
vesicles  and  distinct  structures  thought  to  be  open-ended  bilayers  (Wright  and 
Clements, 1987; Veldhuizen et al., 1998).  A study of the relationship between these 
forms and the conversion of one form to another, show that the lamellar body contents 
expand and form a complex tubular myelin when they encounter the microenvironment 
of the alveolar space, and that this process is triggered by the presence of calcium (King 
et al., 1983).  The mechanism by which the complex consisting of bilayers generates a 
monolayer is not known.  It is generally agreed that the monolayer is enriched in DPPC, 
which reduces surface tension at the air-liquid interface (Hildebran et al., 1979; Wright, 
1990).  However, although DPPC seems to be the main component responsible for the Chapter 1  Literature Review 
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tensioactive properties of surfactant, other lipid and protein components are thought to 
facilitate  the  transport  of  the  phospholipid  to  the  alveolar  air-liquid  interface.   
Particularly  important  is  the  participation  in  this  process  of  the  two  hydrophobic 
proteins, SP-B and SP-C (Gil et al., 1995).  This study, using electron spin resonance 
spectroscopy, demonstrated that these proteins altered the structure at the monolayer 
surface causing an increase in the surface polarity (Gil et al., 1995).  Calcium and PG 
have  also  been  demonstrated  to  be  involved  in  this  process  (King  et  al.,  1983).  
Moreover,  these  latter  authors  propose  that  calcium  might  induce  a  change  in  the 
structure of the proteins, and serve an ionic bridge between the PG and the proteins to 
facilitate electrostatic binding (King et al., 1983). 
Improved surfactant activity has also been generated by the addition of SP-A.  This 
alters the spreading of surfactant and accelerates the way lipids are squeezed out in a 
Ca
2+-dependent fashion (Cockshutt et al., 1990).  SP-A has also been shown to have a 
protective function by minimizing the inhibitory effect of fibrinogen and albumin upon 
surfactant (Cockshutt et al., 1990; Hallman et al., 1991) 
 
1.2.6   Clearance of surfactant from the alveolar space 
Results from several studies of different experimental design suggest that type II cells 
can internalise surfactant components and that the internalised material can be either 
recycled or degraded (Jacobs et al., 1985; Fisher et al., 1987; Young et al., 1993).  As 
mentioned  above,  the  type  II  cell  can  act  as  a  source  of  newly  synthesised  active 
material, but can also be involved in surfactant clearance.  The type II cell reutilises its 
own produced material and this raises the question of why it acts in this way?  Perhaps, 
it  is  more  efficient  in  terms  of  energy  conservation  for  the  cell  to  recycle  material Chapter 1  Literature Review 
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already produced, or alternatively it may otherwise result in a build up of material if it is 
not recycled.  
Ultrastructural studies of recycling of labeled surfactant proteins and lipids implied that 
multivesicular  bodies  were  precursor  compartments  in  the  process  of  recycling  of 
protein and lipid into the lamellar bodies (Jacobs et al., 1985; Fisher et al., 1987).  The 
uptake or clearance of PC has been most thoroughly studied because it is the major 
component  of  surfactant.    An  experimental  design  to  quantitate  the  clearance  and 
recycling  of  surfactant  in  3-day-old  rabbits  has  shown  that  recycling  occurs  at  a 
relatively fast rate (Jacobs et al., 1985).  It has been estimated that the amount of PC in 
the alveolar wash was ~6.7 µmol and ~0.65 µmol/h of PC moved from the alveolar 
space into the lamellar bodies.  Based on this calculation, it appears that ~10% of the 
alveolar pool is recycled per hour (Jacobs et al., 1985) back into type II cells.  The 
hypothesis  that  surfactant  is  recycled  is  also  supported  by  a  tracer  study  in  which 
radioactive precursors were injected intravenously into the adult rabbit and the activities 
of the lavage and lamellar body phospholipids were analysed (Hallman et al., 1981).  
The results of this experiment suggest that the radiolabeled lipid remains for several 
days  and  that  the  specific  activities  in  both  lavage  and  lamellar  bodies  became 
approximately equal a long time after the pulse label was introduced and did not fall to 
zero  even  100  h  after  the  intravenous  injection  (Hallman  et  al.,  1981).    A  similar 
conclusion was made in a study of human preterm infants using stable isotopes (Bunt et 
al., 1998). 
The efficiency of reutilization of phospholipid has been shown to vary with age.  Jobe 
et al. (1989) determined that the rate of uptake of phosphatidylcholine into lamellar 
bodies was slower in premature lambs than in older animals.  The basis to this variation 
is not known, as there is little knowledge of the factors that regulate the amount of lipid Chapter 1  Literature Review 
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that is recycled or degraded.  It has, however, been suggested that this process may be 
stimulated by β-adrenergic agonists and cAMP (Fisher et al., 1987).  
1.3   Biophysical function of pulmonary surfactant 
The notion that surface tension is more important than the tissue elastic forces for the 
expansion and compression of the lung, was first expressed in 1929 by Von Neergaard.  
The  surface  tension  of  the  alveolar  air-water  interface  provides  a  retractive  force 
opposing lung inflation.  The presence of surfactant in the fluid film can lower air-water 
surface tension to near zero values (Griese, 1999; Daniels and Orgeig, 2001).  This 
ensures  that  the  alveoli  remain  open  during  the  whole  respiratory  cycle,  which 
facilitates adequate oxygenation of the blood and also reduces the work of breathing.   
Enhorning and Holm (1993) have shown that a lack of surfactant not only leads to 
collapse of the alveoli but also of closure of the bronchioli, suggesting that surfactant is 
also needed to prevent collapse of these small cylindrical airways, through which the air 
is conducted. 
Low surface tension is also important for ensuring that a nett fluid flow is directed from 
the  alveolar  space  into  the  interstitium  (Guyton  et  al.,  1984).    This  process  is  of 
particular importance in the alveoli, because of their small diameter.  In such areas, with 
relatively high surface tension, a thicker fluid film could develop.  Thus, functional 
surfactant  prevents  liquid  accumulation  in  the  alveoli  while,  at  the  same  time, 
maintaining a thin fluid film (Guyton et al., 1984).  A lack of surfactant, conversely, 
leads  to  the  accumulation  of  fluid  (oedema)  in  the  airspace  (Guyton  et  al.,  1984).  
Pulmonary surfactant also plays a role in the physical removal of particulate material 
and damaged cells from the alveoli and small airways by the “mucociliary escalator” 
(Jarstrand, 1984). Chapter 1  Literature Review 
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To maintain the function of the pulmonary system it is important that the production, 
secretion,  reassembly  and  clearance  of  pulmonary  surfactant  are  all  functioning 
optimally.  Disruption of any one or more of these processes is likely to lead to the loss 
of  stability  of  the  lung.    For  example,  a  reduced  capacity  to  synthesise  pulmonary 
surfactant is recognised as the principal cause of neonatal respiratory distress syndrome 
(NRDS) in premature infants.  
 
1.4   Histopathology of Respiratory Distress Syndrome 
Prematurity is the leading cause of morbidity and mortality in the first month of life 
(Griese  and  Westerburg,  1998).    The  major  factor  contributing  to  neonatal  death  is 
respiratory distress syndrome (NRDS) caused by structural pulmonary immaturity and a 
deficiency of surfactant in the developing lung (Griese and Westerburg, 1998; Jobe and 
Ikegami, 2000; Suresh and Soll, 2002).  This disease is also associated with pulmonary 
oedema,  bronchiolar  epithelial  disruption,  and  leakage  of  plasma  proteins  into  the 
airways and alveoli (Cott et al., 1987; Liu et al., 1997; Wang and Notter, 1998). 
The  lungs  from  infants  dying  from  NRDS  show  a  spectrum  of  histopathological 
features, varying with the degree of maturation of the pulmonary parenchyma, as well 
as with the duration of the disease.  The expansion pattern is distinctly abnormal with 
liquid-filled  or  collapsed  alveoli  adjacent  to  aerated  and  over-distended  terminal 
conducting  airways  (Robertson,  1984).    This  pattern,  known  as  “atelectasis  of 
prematurity” is explained by the tendency of the air-liquid interface to return to the 
bronchiolar level at end expiration, and by the increased resistance to aeration attributed 
to capillarity in finer conducting airways.  In the surfactant-deficient immature lung this 
latter  resistance  implies  a  risk  of  bronchiolar  over-distension  during  the  inspiration 
phase, with disruption of the airway epithelium (Robertson, 1984).  In general, more Chapter 1  Literature Review 
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unresorbed foetal pulmonary fluid or intra-alveolar oedema is present in lungs from 
infants dying during the early course of the disease (DeSa, 1969).  Many, but not all, of 
the RDS cases in the newborn are seen to be the result of a functionally immature 
respiratory  system  with  a  deficiency  in  surfactant  production  (Griese,  1999).    This 
surfactant deficiency results clinically in NRDS and produces the pathologic picture of 
hyaline membrane disease with its typical histology of patchy atelectasis accompanied 
by hyaline membranes lining terminal air spaces (Griese, 1999) 
1.5   Biochemical studies on RDS  
In order to control the maturity of the surfactant system, more detailed analyses have 
been  performed  on  the  composition  of  pulmonary  surfactant  in  NRDS.    Avery  and 
Mead were the first to directly document functional pulmonary surfactant deficiency in 
the  watery  lung  extract  of  infants  dying  from  NRDS  (hyaline  membrane  disease) 
(Avery and Mead, 1959).  Immunohistochemical studies demonstrated a lack of SP-A in 
infants dying prior to the 48
th hour of life and intense staining of proliferating type II 
cells  for  SP-A  in  those  surviving  >48 h  (Markgraf  et  al.,  1990).    In  neonates  with 
NRDS, the most striking and consistent finding is a lack of, or greatly reduced amounts 
of, PC and PG.  This was accompanied by increased surface tension and decreased 
amounts  of  total  phospholipid  and  SP-A  (Griese,  1999).    However,  it  is  not  clear 
whether the observed differences in phospholipid composition differentiate infants with 
NRDS with surfactant deficiency from those with non-permanent tachypnoea of the 
newborn (Griese, 1999).  
A hereditary deficiency of SP-B resulting in abnormalities of the surfactant protein pool 
has been shown to also cause RDS (Nogee et al., 1994).  It was concluded from genetic 
analysis of three siblings who suffered from RDS, that a mutation in the SP-B gene Chapter 1  Literature Review 
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(causing  a  single  amino  acid  substitution)  is  responsible  for  SP-B  deficiency  and  a 
consequent proteinosis, which is associated with RDS (Nogee et al., 1994). 
It  is  generally  recognised  that  the  risk  of  NRDS  is  about  28%  greater  in  diabetic 
pregnancies  than  in  the  normal  population  (Cruz  et  al.,  1976).    Several  lines  of 
experiments  have  shown  that  hyperinsulinism  inhibits  the  incorporation  of  both 
palmitate and glucose into saturated phosphatidylcholine  (Sosenko et al., 1980; Mulay 
and McNaughton, 1983).  Moreover, insulin may delay the maturation of the lung and 
effect a decrease in cholinephosphate cytidylyltransferase activity, which also tends to 
promote NRDS (Mulay and McNaughton, 1983).   
Several investigators have suggested that some of the pulmonary pathology seen with 
NRDS may include some impairment of lung surfactant activity as a result of increased 
alveolar protein levels (Ikegami et al., 1984; Seeger et al., 1985; Holm et al., 1988).  
These  findings  suggest  that  the  proteins  are  affecting  the  concentration  of  lung 
surfactant at the air-liquid interface.  Such an effect could be either due to chemical 
interactions  between  the  plasma  proteins  and  the  surfactant  phospholipids  or  to  a 
competition  of  the  plasma  proteins  with  surfactant  phospholipids  for  space  at  the 
air-liquid interface during the process of adsorption. 
 
1.6   The inhibition of surfactant function by plasma proteins 
A  variety of  lung injuries,  including those associated with adult respiratory distress 
syndrome  (ARDS)  or  the  pathological  sequelae  of  neonatal  respiratory  distress 
syndrome  (NRDS),  result  in  an  increased  alveolar  permeability  to  solutes  and  the 
formation of protein-rich alveolar oedema (Griese, 1999).  It has been suggested that at 
least part of the impaired lung function seen in NRDS and ARDS may be due to the 
plasma  protein-induced  inhibition  of  the  surface  activity  of  pulmonary  surfactant Chapter 1  Literature Review 
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(Ikegami et al., 1984; Holm et al., 1988; Ueda et al., 1994).  Many investigators have 
reported inhibitory effects of plasma proteins on the biophysical activity of surfactant in 
vitro (Cott et al., 1987; Manalo et al., 1996) and in vivo (Lachmann et al., 1994; Ueda et 
al.,  1994;  Yukitake  et  al.,  1995).    These  studies,  and  many  others,  indicate  that 
surfactant inhibition is dependent on the type of inhibitor and its concentration, the 
concentration  of  surfactant  phospholipids  and  the  presence  of  surfactant-associated 
protein. 
Surfactant adsorption properties have been characterised in the presence or absence of 
exogenous protein using a Wilhelmy slide apparatus as described by Holm et al. (1988), 
and  indicate that albumin, fibrinogen  and  haemoglobin are all capable of  inhibiting 
surfactant adsorption in a manner which is dependent upon the surfactant concentration.  
It  has  been  shown  that  the  inhibition  of  the  adsorption  facility  and  surface-tension 
lowering ability of calf lung surfactant extract (CLSE) by albumin, haemoglobin or 
fibrinogen  may  be  completely  abolished  by  centrifugation  of  the  protein  surfactant 
mixture at 12,500 g.  Furthermore, albumin, haemoglobin and fibrinogen (1.25 mg/mL) 
were shown to inhibit the adsorption of a high concentration of CLSE (0.32 mg/mL), 
normally unaffected by the addition of exogenous protein, when the CLSE was injected 
into the sub-phase under the preformed protein surface film.  In contrast, the injection of 
large amounts of these proteins (2.5 mg/mL) into the sub-phase beneath a preformed 
CLSE surface film was without effect even when the CLSE concentration was only 0.06 
mg/mL,  a  surfactant  concentration  normally  inhibited  by  even  small  amounts  of 
exogenous protein (Holm et al., 1988).  It has thus been suggested that these proteins 
may  inhibit  surfactant  function  by  competing  with  the  surfactant  phospholipids  for 
space  at  the  air-liquid  interface,  rather  than  via  molecular  interactions  between  the 
proteins and surfactant (Ikegami et al., 1984; Holm et al., 1988).  Chapter 1  Literature Review 
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The concept that the inhibition of lung surfactant biophysical activity is dependent upon 
surfactant  concentration  has  practical  relevance,  particularly  when  studying  the 
pathophysiology of acute lung injuries with pulmonary oedema.  For example, Holm 
et al. (1988) have shown that adult rabbits exposed to 100% oxygen show minimal 
changes  in  bronchoalveolar  lavage  surface  activity  and  pulmonary  pathophysiology 
even  though  permeability  and  protein  levels  are  elevated.    However,  when  alveolar 
protein  levels  are  decreased  by  50%  the  oxygen-exposed  rabbits  exhibited  greatly 
deteriorated  lung  mechanical  properties  and  abnormal  surface  activity  (Holm  et  al., 
1988).  Ennemma et al. (1988) have suggested that at least two populations of alveoli 
might  exist  in  these  diseased  lungs  -  one  affected  by  oedema  and  interference  to 
surfactant function and one showing no sign of oedema or surfactant inactivation.  
 The attempted treatment of ARDS by instillation of surfactant into the lung has until 
now been disappointing.  This may have been caused by the presence of surfactant 
inhibitors  in  the  lung  oedematous  fluid.    Seeger  et  al.  (1985)  showed  that  fibrin 
monomer  and  fibrinogen  are  potent  inactivators  of  pulmonary  surfactant,  but  the 
inactivation  of  surfactant  could  be  partially  reversed  by  adding  plasmin  to  the 
fibrin/surfactant mixture.  Another serum protein that inhibits surfactant function has 
been  isolated  in  preterm  lambs  (Ikegami  et  al.,  1984).    This  protein,  which  in  its 
dimerised form has a molecular weight of 110 kDa, seems to leak into the airspace of 
the  immature  lung  after  the  onset  of  ventilation  and  might  be  involved  in  the 
pathogenesis of neonatal respiratory distress syndrome.  
The  influence  of  the  acute  inflammatory  phase  C-reactive  protein  (CRP)  on  the 
adsorption  of  porcine  pulmonary  surfactant  from  the  subphase  into  an  air-water 
interface has also been investigated (McEachren and Keough, 1995).  CRP was shown 
to diminish the ability of surfactant to rapidly adsorb to the air-water interface at a Chapter 1  Literature Review 
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molar ratio of 0.02 : 1.0 (protein : phospholipid).  On a weight basis, CRP was found to 
be  more  effective  than  fibrinogen  in  reducing  the  adsorption  rate  of  surfactant 
(McEachren and Keough, 1995).  It has also been demonstrated that the effect of CRP 
requires the presence of calcium and is reversed by the addition of phosphatidylcholine 
at a molar ratio of 300 : 1 (phosphatidylcholine : CRP).  It has been proposed that the 
potent inhibition of surfactant adsorption by CRP is primarily a result of a specific 
interaction  between  CRP  and  the  phosphatidylcholine  headgroup  in  the  sub-phase 
(McEachren and Keough, 1995).  
The presence of serum proteins in the alveolar space not only changes the biophysical 
activity of pulmonary surfactant but also changes its chemical composition.  It has been 
shown that the profile of individual phospholipids in ARDS patients is different when 
compared to normal subjects.  For example, Gregory et al. (1991) demonstrated that the 
levels  of  PC  and  PG  are  decreased  with  increasing  levels  of  phosphatidylinositol, 
lysophosphatidylcholine,  phosphatidylserine,  phosphatidyl-ethanolamine  and 
sphingomyelin.  These changes in the surfactant composition may be related to altered 
surfactant recycling and synthesis by injured alveolar type II cells. 
However, the changes in chemical composition of pulmonary surfactant also appear to 
be associated with increased activity of phospholipase A2 (Kim et al., 1995; Kwatia et 
al., 2007).  Elevated phospholipase A2 activity has been found in the plasma of patients 
with  sepsis  or  pancreatitis  (Vadas  and  Pruzanski,  1986;  Vadas  et  al.,  1992b)  two 
conditions  associated  with  ARDS.    Moreover,  the  elevated  levels  of  serum 
phospholipase A2 activity strongly correlate with an increased risk of ARDS (Vadas et 
al.,  1992b;  Nakos  et  al.,  2005).    In  experimental  animals,  lung  microsomal 
phospholipase A2 activity is increased with septic shock with no changes in the activity 
of lysophosphatidylcholine acyltransferase activity (Casals et al., 1982; Vadas et al., Chapter 1  Literature Review 
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1992a).  The potential importance of elevated lung phospholipase A2 activity in the 
pathophysiology  of  ARDS  is  supported  by  the  observation  that  intratracheal 
administration  of  phospholipase  A2  can  induce  lung  injury,  including  pathological 
features  typical  of  those  seen  in  the  lung  in  ARDS,  such  as  alveolar  oedema, 
accumulation of inflammatory cells and alveolar thickening (Edelson et al., 1991).  An 
experiment preformed by Mehta et al. (1990) provides direct evidence of increased 
leucocyte  phospholipase  A2  activity  as  well  as  high  lyso-PC  levels  in  patients  with 
asthma, suggesting that most of the lyso-PC  (as much as 81%) could be generated by 
this enzyme.  The concept that phospholipase A2 might be involved in inactivation of 
pulmonary surfactant was supported by recent experiments performed in vivo by Arbibe 
et  al.  (1998).    They  found  that  both  endogenous  phospholipase  A2,  produced  after 
lipopolysaccharide  (LPS)  administration,  and  after  intratracheal  administration  of 
exogenous recombinant guinea pig phospholipase A2, generated lipid derivatives in the 
alveolar space and produced a loss of surfactant phospholipid content as well as a 2-fold 
increase in the level of lyso-PC.  Administration of LY311727, a specific phospholipase 
A2  inhibitor,  reduced  the  mass  of  free  fatty  acid  and  the  lyso-PC  content  by  60% 
(Arbibe et al., 1998).  
The  hydrolysis  of  surfactant  phospholipids  is  regulated  by  the  surfactant-associated 
proteins.  In particular, SP-A plays a major role in regulating surfactant hydrolysis by 
acting  as  a  specific  inhibitor  of  phospholipase  A2  in  a  calcium-dependent  manner 
(Cockshutt et al., 1990; Arbibe et al., 1998). The inhibitory role of SP-A is particularly 
important  to  consider  in  the  light  of  clinical  studies,  which  reported  a  pronounced 
decrease in the SP-A concentration in ARDS patients (Gregory et al., 1991; Hallman et 
al., 1991; Lewis and Jobe, 1993).  Thus, a marked decline in the level of alveolar SP-A 
may promote an excessive catabolism of surfactant phospholipids.  Chapter 1  Literature Review 
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 The mechanism of lyso-PC inhibition of surfactant activity is not fully understood.  
The inhibition of lung surfactant phospholipids by lyso-PC follows different kinetics to 
that of serum protein inhibition and, in contrast to the latter, is not reversed by the 
addition of SP-A (Cockshutt et al., 1990).  The inhibition by lyso-PC is almost entirely 
eliminated  when  large  amounts  (10%  by  weight)  of  palmitic  acid  are  added  to  the 
surfactant (Cockshutt and Possmayer, 1991).  Lyso-PC, on the other hand, has a conical 
shape, which accounts for its detergent properties and ability to form micelles.  The 
addition  of  small  amounts  of  lyso-PC  to  phospholipid  mixtures  slightly  enhances 
phospholipid  adsorption,  presumably  by  increasing  the  fluidity  of  the  bilayers 
(Cockshutt and Possmayer, 1991).  However, adsorption of lyso-PC onto the air/liquid 
interface may lead to disruption of the monolayer upon compression because the large 
hydrated polar head group and single acyl chain of lyso-PC would interfere with the 
regular packing of DPPC.  Thus, the presence of palmitate may compensate for the 
lyso-PC in the monolayer (Cockshutt and Possmayer, 1991).  An alternative explanation 
is  that  lyso-PC  interferes  with  the  interactions  between  the  low  molecular  weight 
proteins SP-B and SP-C and the surfactant lipids which lead to the enrichment of DPPC 
in the monolayer and hence to the reduction of surface tension (Yu and Possmayer, 
1990).   
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2.1  Introduction 
Pulmonary surfactant, as recovered by bronchoalveolar lavage, is a complex mixture of 
multiple forms of lipoprotein aggregates, which can be separated into various fractions 
according to size, density, structure, function and chemical composition.  Under normal 
conditions  pulmonary  surfactant  components  act  to  stabilize  the  lung  by  reducing 
surface tension and thus minimizing the work of breathing.  
 Despite more than four decades of intensive research on lung surface-active material, 
the  physiological  stimuli  and  the  biochemical  mechanisms,  which  stimulate  its 
production in vivo, are not fully understood (Dobbs et al., 1987; Wright and Clements, 
1987;  Johansson  and  Curstedt,  1997;  Gobran  and  Rooney,  2004).    However,  it  is 
generally  accepted  that  secretion  of  pulmonary  surfactant  can  be  improved  by 
ventilation,  even  though  the  biological  mechanism  of  this  process  remains  to  be 
elucidated (Lachmann et al., 1994; Griese, 1999; Krishnan and Brower, 2000; Stevens 
et al., 2007; Chotigeat et al., 2008).   It has also become clear that the factors regulating 
pulmonary surfactant production in the adult lung may be quite different from those 
which are involved in foetal lung maturation and differentiation of the type II cells 
(Fraslon and Batenburg, 1993).  There is considerable evidence that surfactant secretion 
is regulated by at least two distinct signalling mechanisms. One group of agonists, such 
as β-adrenergic agonists (Griese et al., 1992; Gobran and Rooney, 2004), have their 
effect  by  elevating  intracellular  levels  of  3’-5’cyclic  monophosphate  (cAMP).  
A second group, including various growth factors (Asokananthan and Cake, 1996) and 
Ca
2+ (Dobbs et al., 1986a), have been shown to modulate secretion of surfactant via 
activation of the Ca
2+/calmodulin-dependent protein kinase and protein kinase C (Sano 
et al., 1985; Rooney, 2001).  All of these secretagogues also stimulate the secretion of Chapter 2  Serum and surfactant secretion 
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the  surfactant-associated  hydrophobic  proteins  B  (SP-B)  and  C  (SP-C)  but  do  not 
stimulate the secretion of the hydrophilic surfactant proteins A (SP-A) and D (SP-D) 
(Gobran and Rooney, 2001).  
Previous reports (Cott et al., 1987; Dobbs et al., 1987; Scott, 1987) demonstrated that 
serum supplementation also enhanced phosphatidylcholine secretion from type II cells 
derived from adult lungs.  The mechanism by which serum components stimulate this 
secretion is not fully established.  Numerous studies have shown that the presence of 
serum accelerated foetal lung type II cell differentiation (Fraslon and Batenburg, 1993), 
resulting in an altered morphological appearance of the lamellar inclusions (Cott et al., 
1987), and activated the acidic fibroblast growth factor (Leslie et al., 1990).  However, 
its mode of action in stimulating surfactant secretion is not known.  Images of lamellar 
bodies  apparently  undergoing  exocytosis  have  been  reported  in  several  microscopic 
studies (Ryan et al., 1975; Kliewer et al., 1985) and the electron micrographs suggest 
that  the  limiting  membrane  that  surrounds  the  lamellar  body  fuses  with  the  plasma 
membrane of the type II cell (Kliewer et al., 1985; Cott et al., 1987).  In addition, since 
multivesicular bodies have been involved in the intracellular transport and assembly of 
synthesized and endocytosed surfactant materials, the apparent increase in the number 
of  these  organelles  in  cells,  cultured  in  the  presence  of  serum,  may  be  a  clear 
morphologic indication of increased surfactant synthesis (Cott et al., 1987). 
Recent studies suggest that the leakage of serum or plasma proteins into airways and the 
alveoli has been associated with several lung diseases, including neonatal and adult 
respiratory distress syndrome (RDS).  These diseases result from reduced surfactant 
activity and can be exacerbated by the presence of plasma proteins in the alveolar space, 
which results in the inhibition of surfactant function (Hodson et al., 1978; Smyth et al., 
1983; O'Hare et al., 1997; Crocker et al., 2000; Jobe and Ikegami, 2000; Nakos et al., Chapter 2  Serum and surfactant secretion 
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2005).    This  inhibitory  action  of  plasma  proteins  had  also  been  suggested  as 
compromising the efficacy of treatment with exogenous surfactant (Lewis and Jobe, 
1993; Lachmann et al., 1994; O'Hare et al., 1997). 
Plasma  contains  an  array  of  protein  and  non-protein  components,  which  act  with 
different  potencies  as  inhibitors  of  surfactant  function.    These  include  fibrinogen, 
haemoglobin, albumin, cholesterol, platelet-activating factor and neutrophils (Seeger et 
al., 1985; Holm and Notter, 1987; Holm et al., 1999; Galani et al., 2010).  There are 
two mechanisms by which these agents operate: (i) physical interactions, which result in 
competition between plasma proteins and surfactant phospholipids for space at the air-
liquid  interface  during  the  process  of  adsorption  and  which  prevent  surfactant 
phospholipid molecules from forming a film at the air-liquid interface (Holm et al., 
1988),  and  (ii)  chemical  interactions  with  the  surfactant  phospholipids  and  the 
apo-proteins, which can change the three dimensional configurations of the surfactant 
components.  This includes effects on both the lipids (serum phospholipases, C-reactive 
protein and mannose-binding protein) and the proteins (proteases, surfactant apo-protein 
antibodies)  (Amirkhanian  et  al.,  1991;  Yukitake  et  al.,  1995).    As  an  example, 
phospholipase  A2  (PLA2),  which  is  present  in  plasma  and  hydrolyses 
phosphatidylcholine to the inactive lyso-phosphatidylcholine form, has been implicated 
in the pathogenesis of a variety of pulmonary diseases including ARDS and asthma 
(Edelson et al., 1991; Arbibe et al., 1997; Nakos et al., 1997; Jaross et al., 2002). 
2.1.1 Diversity, regulation and function of phospholipase A2 
The existence of enzymes catalysing the release of fatty acids from phospholipids was 
proposed  over  a  hundred  years  ago,  when  it  was  observed  that  incubation  of 
phosphatidylcholine with pancreatic juice resulted in the formation of free fatty acids 
(Bokay,  1877).    The  subsequent  finding  in  1903,  that  cobra  venom  converted Chapter 2  Serum and surfactant secretion 
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phosphatidylcholine  into  products  that  resulted  in  the  hemolysis  of  red  blood  cells 
(Kyes, 1903) directed this research towards the phospholipid-hydrolysing enzymes in 
snake venoms.  Later studies by Delazenne and Fourneau (1914) showed that some of 
these  enzymes  were  able  to  catalyse  the  hydrolysis  of  a  fatty  acid  from 
phosphatidylcholine.  More  recently,  these  types  of  enzymes  were  categorised  into 
phospholipase A1, A2, C and D on the basis of their positional specificity (see Figure 
2.1), which became apparent using isotopically-labelled substrates.  It was these latter 
studies that provided the basis for the intracellular phospholipases A being designated 
as  A1  (heat  labile  and  hydrolysing  the  fatty  acyl  bond  at  carbon  1  of  the  glycerol 
backbone of phospholipids) and A2 (heat stable and hydrolysing the fatty acyl bond at 
the carbon 2 position) (Van Deenen et al., 1963; Van Den Bosch and Van Deenen, 
1965). 
Phospholipase A1 and A2 activities have been found in almost every cell examined.  
Thus, such activities have been described in plants (Fujikawa et al., 2005), bacteria 
(Nishijma et al., 1977), amoeba (Vargas-Villarreal et al., 1998), insects (Park et al., 
2005), land snakes, sea snakes and sea kraits (Pahari et al., 2007) and many mammalian 
tissues, including spleen, lung, liver, kidney (Yoshikawa et al., 2001; Lee et al., 2003), 
brain (Green et al., 2008), retina (Sastry et al., 1999), heart (Sudhir, 2005), pancreas 
(Seilhamer et al., 1986), erythrocytes (Doley et al., 2004), platelets (Moscardo et al., 
2006),  and  alveolar  macrophages  (Tsukahara  et  al.,  1999).  Phospholipase  A2 
[E.C 3.1.1.4] thus belongs to a group of enzymes, the phospholipases, which are widely 
distributed in nature and function to hydrolyse phospholipids.  Phospholipid substrates 
of  PLA2  are  derived  from  D-glycerophosphate,  however  they  are  conventionally 
considered as being derivatives of L-glycerophosphate. The International Union of Pure  
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Figure 2.1  Schematic representation of phospholipid hydrolysis by phospholipases 
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and Applied Chemistry (IUPAC) has adopted a stereo specific term “sn” for natural 
phospholipids considered as L-isomers.    For consistency, the position of the fatty acid 
on the glycerol moiety of the phospholipids will always be stated using a numerical 
notation of the carbon, for example, sn-2 (Pernas et al., 1990). 
Mammalian membranes include four classes of phospholipid.  Three of them have a 
glycerol  backbone  with  fatty  acids  at  the  carbon-1  and  carbon-2  positions  and  a 
phosphorylated base (choline, ethanolamine, glycerol, serine or inositol) at carbon-3 of 
the  glycerol  moiety.    The  three  classes  are  1,2  diacyl  phospholipids  (lecithins), 
1-alk-1-enyl-2-acyl-phospholipids  (plasmalogens)  and  1-alkyl-2acyl-phospholipids.  
The  fourth  class  is  sphingomyelin  with  a  ceramide  group  linked  to  phosphocholine 
through its primary hydroxyl group.  Sphingomyelin is the only phospholipid in the 
membranes that is not derived from glycerol.  Instead, the backbone is sphingosine, an 
amino alcohol that contains a long, unsaturated hydrocarbon chain.  In sphingomyelin, 
the amino group of the sphingosine backbone is linked to a fatty acid by an amide bond 
(Thompson and Tillack, 1985). 
The turnover of these phospholipids varies depending on the cell type, the position of 
the cell within the cell-cycle and intracellular location of the membrane.  Changes in 
phospholipid levels may occur independently of cell growth (Pasternak and Bergeron, 
1970)  or,  as  is  the  case  of  lymphocytes,  precede  growth  (Pasternak  and  Friedrichs, 
1970).    It  has  been  demonstrated  that  cells  in  the  G1-phase  rapidly  synthesise  and 
degrade phospholipids whilst maintaining a constant total membrane phospholipid mass 
(Jackowski,  1994).    By  contrast,  phospholipid  turnover  decreases  in  the  S-phase  to 
allow the cells to double their membrane phospholipid content in preparation for cell 
division, and the synthesis and degradation of membrane phospholipid components are 
at  their  lowest  level  in  the  G2  and  M  phases  (Jackowski,  1996).    It  has  also  been Chapter 2  Serum and surfactant secretion 
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demonstrated that the inhibition of the Ca
2+-independent PLA2 directly regulates cell 
proliferation,  arresting  cells  in  the  G1-phase  of  the  cell  cycle  (Zhang  et  al.,  2006).  
Moreover,  calcium  transport  within  mitochondria  has  been  linked  to  PLA2  activity 
(Lenting et al., 1987; Lenzen et al., 1989).  The PLA2-regulated release of arachidonic 
acid from cellular phospholipids and the subsequent “arachidonic acid cascade” have 
been  implicated  in  the  changes  occurring  during  normal  cell  growth  and  in  tumour 
formation (Leslie et al., 1988; Seegers et al., 2002). 
The characterization of phospholipase A2 is complex because of the insoluble nature of 
the substrates.  Most mammalian PLA2 is membrane-bound, which makes purification 
difficult. Pancreatic PLA2, however, is soluble and is present in high concentration in 
pancreatic secretions.  It is relatively easy to purify and concentrate, perhaps by a factor 
of 100- to 200-fold, to levels required for characterization and further experimentation. 
PLA2  from  tumours,  on  the  other  hand,  is  in  low  concentration  and  may  require 
purification by a factor of 13,000-fold to obtain enough catalytic activity or protein for 
characterization (Van Den Bosch, 1980). 
Two  other  enzymes  are  capable  of  liberating  fatty  acids  from  the  sn-2  position  of 
phospholipids.  These are lecithin:cholesterol acyltransferase (LCAT; EC 2.3.1.43), and 
platelet-activating factor acetylhydrolase (PAF-AH; EC 3.1.1.47).  LCAT is synthesized 
predominantly  in  the  liver  and  secreted  into  the  bloodstream,  where  it  is  found 
predominantly associated with high-density lipoproteins (HDL).  Within HDL, LCAT is 
associated with apoA-1, which is the principal activator of this enzyme (Chung et al., 
1979).  LCAT  catalyses  the  hydrolysis  of  the  fatty  acid  from  the  sn-2  position  of 
phosphatidylcholine and transfers the fatty acid to cholesterol to form a cholesteryl ester 
(Albers et al., 1986).  Although the primary function of LCAT is the esterification of 
cholesterol, it is known to catalyze several reactions not involving cholesterol.  These Chapter 2  Serum and surfactant secretion 
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include the release of free fatty acid from PC (Aron et al., 1978), the transfer of long-
chain acyl groups from PC to lyso-PC (Subbaiah et al., 1980), the transfer of a short-
chain  acyl  group  (acetate)  from  platelet-activating  factor  (PAF)  to  lyso-PC  and  the 
hydrolysis of water-soluble esters (Bonelli and Jonas, 1989)).  Based on SDS-PAGE 
analysis it has been estimated that the molecular weight of LCAT is 66-68 kDa (Albers 
et  al.,  1986).    The  in  vivo  source  of  PAF-AH  is  not  known,  although  it  has  been 
suggested that macrophages are the likely source of plasma PAF-AH (Stafforini et al., 
1990).    In vitro  studies  have  shown  that  plasma  PAF-AH  mRNA  is  induced  when 
human monocytes differentiate into macrophages and this is paralleled by an increase in 
the secretion of PAF-AH into the medium (Elstad et al., 1989).  The enzyme from 
macrophages is biochemically and immunologically identical to that present in human 
plasma (Stafforini et al., 1990).  PAF-AH catalyses the hydrolysis of the acetyl group at 
the sn-2 position of PAF, which produces biologically inactive lyso-PAF and acetate 
(Stafforini et al., 1997).  PAF-AH also hydrolyzes oxidised phospholipids produced by 
the peroxidation of polyunsaturated fatty acyl residues in the sn-2 position (Stremler et 
al., 1991).  This activity belongs to a family of intracellular PAF acetylhydrolases that 
differ from the plasma enzyme by a variety of criteria, although they all require a short-
chain residue at the sn-2 position and are Ca
2+-independent (Stafforini et al., 1990).  
The apparent molecular weight of the monomeric PAF-AH is 43 kDa, as determined by 
SDS-PAGE  (Stafforini  et  al.,  1990).  Plasma  PAF-AH  circulates  in  the  blood  as  a 
complex with lipoproteins.  In humans, 70% of plasma PAF-AH is associated with 
low-density lipoproteins (LDL) and 30% is bound with high-density lipoproteins (HDL) 
whereas in rodents, plasma PAF-AH activity is primarily found in the HDL fraction 
(Stafforini et al., 1997). Chapter 2  Serum and surfactant secretion 
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There  are  at  least  three  distinct  classes  of  mammalian  PLA2,  which  are  classified 
according to the positions of the disulphide bridge between Cys-11 and Cys-77 and the 
characteristic three-amino acid “elapid loop” composed of residues 54-56 (Heinrikson 
et al., 1977).  The secretory pancreatic form is type I, a form which is also found in the 
lung (Seilhamer et al., 1986; Sakata et al., 1989).  The type I PLA2 form, contains 
7 disulphide bridges, is about 126 amino acids in length and is encoded by a single gene 
associated with chromosome 12 (Dennis, 1994). 
Type II PLA2 lacks the 11-77 disulfide bridge, has a carboxyl-terminal extension of 
6 amino acids, and terminates in a half-cysteine joined to Cys-50 near the catalytic site 
His-48 (Dennis, 1994).  Mammalian type II PLA2 occurs in trace amounts in tissues 
such as spleen, liver, platelets, and synovial fluid and is secreted from various cells of 
the immune system in response to appropriate stimuli (Kramer et al., 1989; Yoshikawa 
et al., 2001; Lee et al., 2003).  This form of the enzyme has been associated with the 
pathologies  of  several  diseases  involving  sepsis,  pathogenesis  of  disorders  of  the 
cardiovascular, gastrointestinal, and pulmonary systems and inflammation (Niewoehner 
et al., 1989; Mehta et al., 1990; Kim and Bonventre, 1993; Kim et al., 1995; Jaross et 
al., 2002).  The type II enzyme has a sequence of amino acids that suggests it is a 
protein that is highly conserved between species.  Mammalian PLA2 types I and II share 
approximately 30-40% amino acid homology, however 18 amino acids are invariantly 
conserved in all functional low molecular weight PLA2s (Davidson and Dennis, 1990). 
The type V PLA2 has been characterized from both human (Chen et al., 1994), and rat 
(Chen et al., 1994).  The mature enzyme, with a calculated molecular mass of 13.6 kDa, 
contains neither the elapid loop of type I nor the acid-carboxyl extension of type II 
PLA2.  The type V gene product is expressed initially as a prepeptide with the first 
20 amino acids representing a signal peptide that is subsequently cleaved. Additional Chapter 2  Serum and surfactant secretion 
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distinguishing properties of this ~14 kDa PLA2 are features such as an activity optimum 
at pH 7-9 and a requirement for 1-10 mM Ca
2+ for maximal activity (Tischfield, 1997).  
A number of different forms of the cellular PLA2 have also been identified.  Kim and 
co-workers (1991) purified cytosolic PLA2 from rabbit platelets and demonstrated that 
this  88  kDa  enzyme  exhibits  a  fatty  acid  preference  and  hydrolyses  phospholipids 
bearing an arachidonoyl residue at the sn-2 position more effectively than those with a 
linoleoyl  residue.    With  phosphatidylcholine  or  phosphatidylethanolamine  as  the 
substrate, the catalytic activity of the purified enzyme increased sharply in the presence 
of between 10
-7 and 10
-6 M calcium ion, indicating that it could be regulated by less 
than micromolar concentrations of Ca
2+.  A novel, calcium-independent, cytosolic PLA2 
of molecular mass of 40 kDa has also been purified (Hazen et al., 1990).  The purified 
enzyme possesses a pH optimum of 6.4 and catalyses the regiospecific cleavage of the 
sn-2 fatty acid from diradyl glycerophospholipids.  An acidic intracellular PLA2 from 
rat lung has also been studied.  Crude Ca
2+-independent PLA2 was detected in both the 
lysosomal fraction and the lamellar body fraction of type II lung cells (Fisher et al., 
1992; Wang et al., 1994).  The enzyme has been purified 550-fold and gave a relative 
molecular  weight  of  15 kDa  by  SDS-PAGE.    The  apparent  molecular  mass  was 
recovered in part by renaturation of protein from the gel.  Even though its apparent 
molecular weight is similar to the secretory PLA2, an N-terminal sequence analysis 
revealed no homology with any of the sequenced PLA2s.  
Phospholipase  A2,  in  general,  is  one  of  the  smallest  enzymes  and,  apart  from  the 
exceptions mentioned above, has a molecular weight of ~14 kDa.  It is water soluble 
and particularly unusual in terms of its heat stability.  Boiling pancreatic PLA2 at 100ºC 
for 5 minutes only reduces its activity by 5% (Schroder et al., 1980).  In addition, there Chapter 2  Serum and surfactant secretion 
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are common features such as pH 7-9 activity optima and the requirement for 1-10 mM 
Ca
2+ for maximal activity. 
There is extensive evidence to support the involvement of PLA2 in the pathophysiology 
of  various  inflammatory  diseases  (Franson  et  al.,  1978;  Vadas  et  al.,  1992b; 
Kostopangiotou  et  al.,  2008)  and  it  has  been  demonstrated  to  be  present  in  the 
circulation  in  very  high  concentration  in  septic  disease.    It  interacts,  possibly 
synergistically, with other mediators such as interleukin-6 (IL-6), interleukin-1 (IL-1) 
and tumor necrosis factor (TNF) to subsequently generate platelet-activating factor and 
active metabolites of arachidonic acid (Pruzanski and Vadas, 1990a).  In rheumatic 
disease,  PLA2  has  been  shown  not  only  to  affect  articular  cartilage  (Pruzanski  and 
Vadas, 1990b) but also serves as an index of disease activity in rheumatoid arthritis (Lin 
et al., 1996) and juvenile rheumatoid arthritis (Pruzanski et al., 1994), where marked 
increases  in  the  blood  level  of  secretory  non-pancreatic  PLA2  were  observed.    A 
significant positive correlation was found between the circulating level of PLA2 and 
both  the  erythrocyte  sedimentation  rate  and  neutrophil  count,  while  a  significant 
negative correlation was noted with the level of albumin and haemoglobin.  In patients 
suffering respiratory diseases, it can cause changes in the composition of lung surfactant 
(Niewoehner et al., 1989) resulting in an induction of alveolar epithelial injury and 
increased  levels  of  lysophosphatidylcholine  (lyso-PC).    Chemical  degradation  of 
dipalmitoylphosphatidylcholine in lung type II pneumocytes has been demonstrated by 
Fisher and Dodia (1996) and Hite and co-workers (1998) and clinical states, associated 
with adult respiratory distress syndrome (ARDS), have been reported to have elevated 
levels  of  free  fatty  acids  in  the  plasma  (Niewoehner  et  al.,  1987).    The  content  of 
lysophosphatidylcholine (lyso-PC) was shown to be increased in the bronchoalveolar 
lavage fluid (BALF) of humans (Kim et al., 1995) and animals in which ARDS was Chapter 2  Serum and surfactant secretion 
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induced with oleic acid (Casals et al., 1989).  Elevated PLA2 activity was found in the 
plasma (Franson et al., 1978; Vadas et al., 1992a; Vadas et al., 1992b; Nakos et al., 
2005) of patients with sepsis or pancreatitis, two conditions known to be associated with 
ARDS.  Pulmonary surfactant degradation, as observed in ARDS (Kim et al., 1995), 
can be explained by enhanced PLA2 activity.  This is supported by the observation that 
there  is  a  close  correlation  between  the  level  of  lyso-PC  and  increased  leukocyte 
phospholipase  A2  activity  (Mehta  et  al.,  1990;  Arbibe  et  al.,  1998).    The  potential 
importance of elevated lung PLA2 in the pathophysiology of ARDS is supported by the 
observation  that  intratracheal  administration  of  PLA2  can  induce  lung  injury  with 
interstitial and alveolar edema, accumulation of inflammatory cells, and alveolar wall 
thickening  (Edelson  et  al.,  1991;  Attalah  et  al.,  2003),  pathological  features 
characteristic of ARDS.  
These findings have prompted this more detailed investigation of the effects of human 
serum and possibly PLA2 (as serum is a natural source of secretory PLA2) on surfactant 
secretion  and  composition  of  secreted  phospholipids  using  cultured  foetal  type  II 
pneumocytes.  Given that lung injury can lead to the leakage of serum into the alveolar 
space, it was considered important to ascertain whether serum contains any other forms 
of  PLA2  that  have,  to  date,  not  been  identified  that  could  contribute  to  surfactant 
inactivation and thus lead to the development of ARDS.  It is proposed that, if a novel 
form  of  PLA2  is  detected,  further  studies  will  be  undertaken  to  characterise  this 
enzymatic activity.  
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2.2  Materials and Methods 
2.2.1 Animals 
Nineteen-day  pregnant  rats  of  the  Wistar  albino  strain  of  Rattus  norvegicus  were 
obtained from the Animals Resource Centre, Murdoch, Western Australia.  Male and 
female  rats  were  caged  together  overnight  and,  when  a  vaginal  smear  detected  the 
presence of sperm, the next day was designated day zero of pregnancy and is accurate to 
within  ±  8h.    All  experiments  were  approved  by  the  Murdoch  University  Animal 
Experimentation Ethics Committee and met the National Health and Medical Research 
Council guidelines. 
2.2.2 Materials 
L-3-Phosphatidylcholine  1,2-di[1-
14C]-palmitoyl  (54  mCi/mmole)  and  [methyl-
3H]-
choline  chloride  (81  Ci/mmole)  were  purchased  from  the  Radiochemical  Centre, 
Amersham,  Buckinghamshire,  UK.    Collagenase  A  (Clostridium  histolyticum) 
(0.70 U/mg) was obtained from Boehringer Mannheim GmbH, Mannheim, Germany.  
Eagle’s minimal essential medium (MEM) and newborn calf serum were supplied by 
Trace Biosciences Pty Ltd, New South Wales, Australia.  Penicillin G, streptomycin 
sulfate,  lipoprotein-deficient  human  serum,  bovine  serum  albumin,  solubilised 
β-amphotericin (fungizone) and arachidonic acid were products of Sigma Chemicals, St 
Louis, Missouri, USA.  Chloramphenicol was supplied by NBL Gene Sciences Ltd, 
Northumberland, UK.  The supplier for L-glutamine was Gibco Laboratories, Chagrin 
Falls,  Ohio,  USA.    Human  albumin  essentially  fatty  acid  and  globulin  free,  human 
albumin crystallized and lyophilised, and human albumin fraction V were purchased 
from Sigma Chemicals, St Louis, Missouri, USA.   FSA Laboratories, Leicester, UK 
was the supplier of Optiphase ‘Hisafe’ II scintillant. PD-10, DEAE CL-6B and HiTrap Chapter 2  Serum and surfactant secretion 
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Heparin-Sepharose columns were products of Amersham Pharmacia Biotech Pty Ltd, 
New South Wales, Australia.  The supplier for VLDL (very low density lipoprotein), 
LDL  (low  density  lipoprotein),  HDL  (high  density  lipoprotein),  phospholipase  A2 
(PLA2)  from  porcine  pancreas,  CGP-7514A  hydrochloride,  EGTA,  bromophenacyl 
bromide was Sigma Chemicals, St Louis, Missouri, USA.  Calbiochem-Novabiochem 
Pty  Ltd,  New  South  Wales,  Australia  was  the  supplier  of  palmitoyl  trifluoromethyl 
ketone and methyl arachidonyl fluorophosphonate. Recombinant human serum albumin 
was  obtained  from  ProspecTany  Technogene  Ltd,  Israel.    The  supplier  for 
1,2 bisheptanoyl thio-glycerophosphocholine was Sapphire Bioscence Ltd, New South 
Wales, Australia.  Filters (0.22 and 0.45 µm) were purchased from Millipore Pty Ltd, 
North Ryde, Australia.  All other reagents were of analytical grade. 
2.2.3 Methods 
2.2.3.1 Preparation of materials for cell culture 
(i)  Charcoal treatment of newborn calf serum 
Endogenous steroids were removed from newborn calf serum (NBCS) by incubating it 
at 37°C with sterile acid-washed activated charcoal (50 mg/mL serum) for 30 minutes.  
The  charcoal  was  removed  by  two  successive  centrifugations,  each  at  27000  g  for 
45 minutes at 4°C in a Beckman J2-21 M/E centrifuge using a JA-20 rotor (Beckman 
Instruments,  Palo  Alto,  CA,  USA).    The  supernatant  was  twice  filtered  through  a 
Millipore  filtering  system,  which  consisted  of  a  borosilicate  glass  funnel  with  a 
Millex-GS filter, a 250 mL reservoir and Buchner flask attached to a vacuum manifold 
(Millipore Corp, Bedford, MA, USA).  The first filtration used a 0.45 µm GS filter and 
the second a 0.22 µm GS filter.  Aliquots of either 23 mL or 11.5 mL of this charcoal-Chapter 2  Serum and surfactant secretion 
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treated  newborn  calf  serum  were  stored  at  -20°C  or  used  immediately  for  the 
preparation of culture medium. 
(ii) Preparation of rat immunoglobulin G 
Blood collected from adult rats was centrifuged at 1000 rpm (200 g) for 10 minutes and 
the  serum  stored  at -20°C.    This  was  diluted  1:2  with  saline  and  made  up  to  45% 
ammonium  sulphate  with  saturated  ammonium  sulfate,  pH  7.2.    This  was  then 
centrifuged at room temperature for 15 minutes at 2150 rpm (1000 g) and the pellet was 
resuspended in 45% ammonium sulphate.  The suspension was centrifuged at 3000 rpm 
(2100 g) for 30 minutes at room temperature and the pellet resuspended in 50 mM 
Tris-HCl buffer (pH 9.0) and dialysed (3500 MW cut-off membrane) against Tris-HCl 
for a minimum of 48 hours at 4°C.  During dialysis the Tris-HCl was replaced three 
times.  The protein concentration was measured and adjusted to 1 mg/mL.  The purified 
material  was  dispensed  into  3.0  mL  or  6.0  mL  aliquots  and  stored  at  –20°C  until 
required. 
Three mL of 1 mg IgG/mL was added to each Falcon 1001 plate and sterilised under 
ultraviolet for  at  least  1  hour.    Before  use,  each  plate  was  washed  four  times  with 
10.0 mL of BSS. 
(iii) Preparation of balanced salt solution (BSS) 
Saline  and  buffer  solution  were  prepared  at  20-fold  the  required  concentration  and 
stored at 4°C until required.  The 20-fold concentrated saline contained 2.74 M NaCl, 
54  mM  KCl,  20 mM  CaCl2,  and  20  mM  MgCl2.    The  20-fold  concentrated  buffer 
contained  119  mM  NaHCO3,  3 mM  NaH2PO4,  27  mM  Na2HPO4,  and  111  mM 
D-glucose.  As required, aliquots of both the saline and the buffer were added to filtered 
water in the ratio 50 mL saline, 50 mL buffer and 850 mL water.  The solution was Chapter 2  Serum and surfactant secretion 
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adjusted to pH 7.4, made up to 1 L with water and sterilised by filtration through a 0.22 
µm Millipore GS filter.  This balanced salts solution (BSS) was stored for a maximum 
of one week at 4°C and discarded if not used.  
(iv) Preparation of fungizone 
A fungizone solution was prepared by adding 10 mL of Milli-Q filtered sterile water to 
a vial containing 100 mg of fungizone and subsequently rinsing the vial with a further 
10  mL  of  Milli-Q  filtered  sterile  water  to  give  a  final  concentration  5.0  mg/mL.  
Aliquots were stored in 1.0 mL and 2.0 mL portions at -20°C until required. 
 (v) Preparation of culture media 
Eagle’s  minimal  essential  medium  (MEM)  was  stored  in  a  desiccator  at  4°C  until 
required.  Reconstitution was performed as recommended by the manufacturer, and the 
solution  was  supplemented  with  0.2  %  NaHCO3  and  0.00174  %  phenol  red  (final 
concentrations).  Glutamine (0.44 g), penicillin G (71.5 mg), chloramphenicol (50 mg) 
and streptomycin (0.1525 g) were always added.  The pH was adjusted to 7.4 and the 
medium filter sterilised by filtration through a 0.22 µm Millipore GS filter.  Fungizone 
was added to the medium in the ratio 75 µL to each 104.35 mL portion giving a final 
concentration of 3.6 µg fungizone/mL.  To yield complete medium (“MEM complete ”) 
charcoal-treated newborn calf serum was added to give a final concentration of 10% 
serum.  Both MEM and MEM complete media were stored at 4°C until required. 
2.2.4 Isolation of type II pneumocytes 
Sterile techniques were used  during all cell isolation procedures, all of  which were 
preformed  at  room  temperature  unless  otherwise  stated.  Pregnant  rats  of  19  days 
gestation were anaesthetised using a 80% CO2 and 20% O2 gas mixture, then killed Chapter 2  Serum and surfactant secretion 
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using asphyxiation with 100% CO2 for 2 minutes and the foetuses were delivered by 
Caesarian section.  The contents of the foetal thoracic cavity were removal and placed 
in  a  Petri  dish  containing  BSS.    Contaminating  tissues  such  as  heart,  airways  and 
thymus  were  removed.    The  lungs  were  then  dried  briefly  on  sterile  napkins  and 
chopped to approximately 0.1 mm (with two traverses, one perpendicular to the other) 
on a McIlwain tissue chopper (The Mickle Laboratory Engineering Co, Surrey, UK).  
The chopped tissue was then placed in a conical screw-cap culture flask containing 
0.75 mL BSS per lung.  Collagenase A was added at 0.078 mg/mL of BSS and the flask 
gassed with carbogen (5% CO2 and 95% O2) for 1.5 minutes, before being incubated for 
15 minutes in a shaking water-bath at 37°C.  Digestion was stopped by the addition of 
at least an equal volume of cold BSS.  The cells were then filtered through 2 layers of 
sterile French voile gauze into Kimax screw-cap centrifuge tubes.  To maximise the 
number of cells harvested the gauze was squeezed with sterile forceps.  The cells were 
sedimented  by  centrifugation  at  approximately  300  rpm  (20  g)  for  2  minutes  in  a 
Beckman GRP Centrifuge (Beckman Instruments, Palo Alto, CA, USA) at 4°C.  The 
supernatant was aspirated, the cell pellets resuspended in the same volume of BSS and 
the washing step repeated.  Following the final aspiration, the cells were resuspended 
using pre-warmed serum-free Eagle’s MEM and plated onto 1001 Optilux Petri dishes 
(Falcon Labware, Becton Dickinson, Lincoln Park, New Jersey, USA), which had been 
previously coated with rat IgG, in a volume of 12 mL per plate containing the cells from 
the lungs of approximately 24 foetuses. These plates were incubated for 1 hour at 37°C.  
During this incubation most lung cells adhere to the IgG through their Fc receptors. 
However, type II pneumocytes lack Fc receptors and therefore do not adhere to the IgG-
coated plates (Dobbs et al., 1986b) thus facilitating their segregation from other lung 
cells present in the cell suspension.  Thus, the supernatant from the IgG plates was Chapter 2  Serum and surfactant secretion 
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removed  and  charcoal-treated  newborn  calf  serum  was  added  to  achieve  a  final 
concentration of 10 %  (v/v).  Complete MEM (2.5 mL) was then added to Falcon 
Primaria 60 x 15 mm polystyrene culture plates (Becton Dickinson Labware, Oxnard, 
CA, USA) prior to the addition of 0.5 mL of the cell suspension.  
Pneumocyte type II cells were incubated in a Forma Scientific (model 3250) water-
jacketed CO2 incubator with a water-humidified atmosphere of 5% CO2 and 95% air.  
Manual determination of the CO2 levels was made using a Bacharach Fyrite test kit 
(Bacharach Instruments Co, Pittsburg, Pennsylvania, USA).  Hibitane solution (10%) 
was added to the water tray at the bottom of the incubator.  A constant temperature of 
37°C was monitored through the 4 days of culture.  After an initial 24 hours in culture, 
the media was removed, the plates washed once with 2 mL BSS, pre-warmed to 37°C to 
remove unattached or non-viable cells and 3 mL fresh MEM complete, pre-warmed to 
37°C,  was  added.    After  72  hours  in  culture  the  plates  were  fully  confluent  and 
consisted predominantly of type II pneumocytes.  A typical culture after 96 hours of 
incubation is shown in Figure 2.2.  
2.2.5  Determination  of  choline-containing  phospholipid 
secretion from type II pneumocytes 
2.2.5.1 Condition for phospholipid secretion 
At the completion of approximately 72 hours in culture, the serum-supplemented MEM 
was removed and the cells were washed with 2 mL pre-warmed BSS and then incubated 
for 24 hours at 37°C with serum-free MEM containing [methyl-
3H]-choline chloride 
(1 µCi/mL).    After  this  time,  all  labelled  medium  was  removed  and  the  cells  were 
washed 3 times with 2 mL of BSS and allowed to equilibrate with 1.7 mL serum-free 
MEM for 1 hour.  At the end of this equilibration period the plates were removed from  Chapter 2  Serum and surfactant secretion 
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Figure  2.2  Phase  contrast  photomicrograph  of  a  typical  19-day  foetal  type  II 
pneumocyte culture 
 
Type II pneumocytes were isolated from 19-day foetal rats and cultured as described in 
section 2.2.4.  A phase contrast photomicrograph was taken after 96 hours of culture 
using a Kodak Ektachrome 160 tungsten film in an Olympus Model OM-2 camera, 
under  conditions  established  using  an  Olympus  Model  IMP-2  inverted  phase 
microscope.    The  overall  magnification  (including  photographic  enlargement)  was 
x 760.  
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the incubator and two plates (the equilibrium plates), which represent secretion at zero 
time, were placed on ice. The media was removed immediately from these plates and 
the cells were washed three times with 0.83 mL of BSS.  The media and the washings 
were combined and placed on ice. Control plates were established by adding 34.5 µL of 
sterile water  (the vehicle) to two plates.  The remaining plates received 17.5 µL of the 
agent to be examined and 17 µL vehicle.  Both control and test plates were incubated 
for a further three hours, before being placed on ice.  The medium was removed and the 
cells washed three times with 0.83 mL BSS.  The medium and washings from each plate 
were combined and were vortexed briefly prior to centrifugation for 2 minutes at 1000 g 
(2100 rpm) in a GRP centrifuge (Beckman Instruments, Palo Alto, CA, USA) at 4°C to 
sediment any detached cells.  The top 3.5 mL of each tube was removed and used for 
lipid extraction.  The cells from the plates were removed from each plate by scraping 
with a polyethylene scraper into 0.8 mL of water and 1.0 mL of methanol, followed by a 
further scraping with 1.0 mL of methanol. 
2.2.5.2 Extraction of lipid from the media and cells 
An aliquot of 50 µL of L-3-phosphatidylcholine 1,2-di[1-
14C] palmitoyl ([
14C]-DPPC) 
(approximately  10,000  dpm),  as  a  recovery  standard,  and  20  µL  (2.5  mg/mL 
L-α-phosphatidylcholine), as a carrier, were added to each 3.5 mL of collected media 
and  to  the  cell  extracts.    The  method  of  lipid  extraction  employed  a  chloroform: 
methanol: water ratio of 2.0 : 2.0 : 1.8,  respectively, as described previously (Bligh and 
Dyer, 1959).  To the media extracts was added 13.125 mL of chloroform : methanol 
(1:2) and the tubes were vortexed and left to stand for ten minutes.  Subsequently, 
4.375 mL of chloroform and 4.375 mL of water were added with intervening mixing at 
ten-minute intervals.  Chapter 2  Serum and surfactant secretion 
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Chloroform (1.0 mL) was added to the cell extracts, which already had 0.8 mL of water 
and 2.0 mL of methanol added during the cell harvesting procedure.  The mixtures were 
vortexed and allowed to stand for 10 minutes.  A further 1.0 mL of chloroform and 
1.0 mL  of  water  were  added  to  achieve  a  chloroform  :  methanol  :  water  ratio  of  
2.0 : 2.0 : 1.8.  The mixtures were then left to settle at 4°C overnight in capped tubes to 
prevent evaporation. 
The following day aliquots of the bottom layer of each tube (approximately 8.0 mL 
from each of the media lipid extractions and 0.4 mL of cell lipid extractions) were 
transfered to polyethylene counting vials.  The solvent was evaporated from these vials 
under air at 37°C in a Pearce Reacti-Therm III drier for a minimum of 4 hours.  Then, 
3.0 mL of Optiphase ‘HiSafe’ II scintillant was added to each vial and the contents 
vortexed  prior  to  the  determination  of  radioactivity  in  a  Beckman  LS  6500  Liquid 
Scintillation counter (Beckman Instruments Nuclear Division, Fullerton, CA, USA) in 
which  the  levels  of  both 
3H  and 
14C  were  measured.    Results  were  expressed  in 
disintegrations per minute and corrected for the recovery of 
14C.  Media 
3H counts were 
also corrected for the fact that only a 3.5 mL aliquot, from a total volume of 4.2 mL, 
was extracted.  The amount of [
3H]-phospholipids secreted by cells was then calculated 
as follows :  
  Media dpm  100 
             % Secretion       =  X  
                                            Media dpm + Cellular dpm  1 
2.2.5.3  Determination  of  phospholipid  composition  in  media  and 
cells 
Quantitative  analysis  of  phospholipids  was  achieved  by  using  thin-layer 
chromatography (TLC) on Whatman silica gel LK6DF plates  (Whatman International 
Ltd, Maidstone, UK).  Before the experiment, the plates were activated in an oven at Chapter 2  Serum and surfactant secretion 
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110°C for 1 hour.  Chloroform:methanol (2:1 v/v; 100 µL) was used to dissolve the 
samples  prior  to  application  onto  the  plates.    Each  sample  was  applied  with  a 
micropipette onto the plates as a narrow streak on a 1-cm wide lane, 3 cm from the 
bottom of the plate.  The plate was then placed into a chromatographic chamber lined 
with  Whatman  3MM  paper  wetted  with  the  developing  solvent 
CHCl3 : CH3OH : 7 M NH4OH (65:35:5 v/v/v) as described by Finkelstein et al. (1983).  
After  10  minutes,  chromatography  was  initiated  by  the  addition  of  100  mL  of 
developing solvent to the bottom of the chamber.  The solvent front was allowed to rise 
to within 0.5-1.0 cm of the top of the plate.  The average running time was 1-1.5 hours.  
The plates were then dried and exposed to iodine vapour.  Phospholipids were identified 
using  purified  phospholipid  standards  and  their  location  marked  on  the  plate.    The 
phospholipids  were  isolated  by  scraping  the  silica  gel  directly  into  a  teflon  glass 
homogeniser and subsequently extracting with 3 mL of CHCl3 : CH3OH : formic acid : 
water (19.4 : 19.4 : 0.4 : 0.8 v/v/v/v), according to the method of Gross et al. (1979). 
 2.2.6 Separation of serum proteins 
2.2.6.1  Purification  of  serum  proteins  using  HiTrap  Heparin-
Sepharose affinity column 
Aliquots (250 µL) of either lipoprotein-free serum or secretory PLA2 (160 units) were 
applied to a HiTrap Heparin-Sepharose column (1 x 5cm) previously equilibrated with 
0.02 M NH4HCO3, pH 7.5.  The column was washed with 40 mL degassed 0.02 M 
NH4HCO3, pH 7.5 at a flow rate of 1 mL/min (using a Gilson Minipuls 2 peristaltic 
pump) prior to eluting the bound material with a 60 mL linear gradient of 0-3.0 M NaCl 
in 0.02 M NH4HCO3, pH 7.5.  Fractions (2 mL) were collected and tested for protein 
content, by measuring the absorbance at 280 nm, and for salt concentration.  The eluted Chapter 2  Serum and surfactant secretion 
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fractions were then lyophilised and resuspended in 1mL 0.02 M NH4HCO3, pH 7.5 
prior to desalting as outlined in section 1.9.  Each fraction was then resuspended in 
50 µL of BSS and applied to type II pneumocytes for 3 hours to test their effect on the 
rate of phospholipid secretion and on deacylation of the secreted PC to lyso-PC.  
2.2.6.2  Purification  of  serum  proteins  using  BioGel  P-60 
chromatography 
An aliquot (2.5 mL) of lipoprotein-free serum, dissolved in 0.02 M NH4HCO3, pH 7.5, 
was  applied  to  a  Bio-Gel  P-60  chromatography  column  (98  x  2.5  cm)  previously 
equilibrated with 0.02 M NH4HCO3, pH 7.1.  Fractions were collected at a flow rate of 
2 mL per hour using a Bio-Rad fraction collector (Model 2110, 100/120 VAC) and a 
Gilson  Minipuls  2  peristaltic  pump  (Gilson  Medical  Electronics,  Villiers  le  Bel, 
France).  After lyophilization, the fractions were redissolved in 500 µL BSS and tested 
for their effect on the rate of phospholipid secretion and the phospholipid composition 
when  directly  applied  to  foetal  rat  type  II  pneumocytes  in  culture,  as  described  in 
section 2.2.5. 
2.2.6.3 Purification of serum proteins using CL-6B DEAE-Sepharose 
chromatography 
Aliquots  (2.5  mL)  of  either  lipoprotein-free  serum  or  secretory  PLA2  (1600  units) 
previously exposed to heat treatment at 60°C for 30 min, were applied to a DEAE-
Sepharose column (2.7 x 45 cm) equilibrated with 0.025 M KCl in 0.02 M NH4HCO3, 
pH 7.5.  Fractions (4 mL) were collected at a flow rate of 15 mL per hour using a 
Bio-Rad  fraction  collector  (Model  2110,  100/120VAC)  and  a  Gilson  Minipuls  2 
peristaltic pump (Gilson Medical Electronics, Villiers 1e Bel, France).  The first 80 
fractions were collected prior to a linear gradient of KCl in NH4HCO3 being applied.  Chapter 2  Serum and surfactant secretion 
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Each fraction was tested for protein content, by measuring the absorbance at 280 nm, 
and salt concentration, using a Buchler digital chloridometer.  After lyophilization the 
fractions were redissolved in 1 mL of 0.02 M NH4HCO3 and the KCl removed using a 
PD-10 Sephadex G-25 column for rapid desalting (as described in section 2.2.9).  Prior 
to determining the extent of hydrolysis of secreted phosphatidylcholine from cultured 
type II pneumocytes, fractions were lyophilised again and redissolved in 500 µL BSS 
and applied directly to culture plates as described in section 2.2.5. 
2.2.6.4 Native PAGE electrophoresis 
Lipoprotein-free serum (LFS, 20 µL) or an equivalent volume of various commercially-
available human serum albumin (HSA) preparations (50 mg/mL) were loaded on to a 
10% polyacrylamide slab gel.  Prior to electrophoresis, a gel-loading buffer (0.5 M Tris-
HCl, containing 5% (v/v) glycerol, 0.5% (w/v) bromophenol blue, pH 6.8) was added to 
each sample.  The gel tanks were buffered with electrode running buffer (0.025 M Tris 
with 0.192 M glycine, pH 8.3).  Electrophoresis was carried out at a constant voltage of 
200  V  for  approximately  2.5  hours  in  a  Bio-Rad  Protean  II  Slab  Cell  (Bio-Rad 
Laboratories Inc., Hercules CA, USA).  After electrophoresis, the PAGE gel was fixed 
for  30  min  in  a  solution  of  40%  methanol and  10%  acetic acid  in  deionised  water 
containing  0.018%  formaldehyde.    Following  fixation,  the  gels  were  washed  in  a 
solution containing 10% ethanol for a total of 15 minutes, with three solution changes.  
The  gels  were  then  treated  with  2.4  mM  Na2S2O3  solution  for  1  minute  prior  to  a 
10-minute exposure to 3.5 mM AgNO3 containing 0.028% formaldehyde.  Finally, the 
gels were rinsed with distilled water for 1-5 minutes, with two solution changes and 
placed in developer reagent (0.17 M Na2CO3, containing 0.018% formaldehyde) until 
the desired band intensity was obtained.   Chapter 2  Serum and surfactant secretion 
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2.2.6.5 SDS Polyacrylamide gel electrophoresis      
Lipoprotein-free serum (LFS, 20µL) or equivalent volumes of various commercially- 
available HSA preparations (50 mg/mL) were loaded on to a 12% polyacrylamide slab 
gel. Prior to electrophoresis a gel-loading buffer (0.5M Tris-HCl, pH 6.8, 20% (v/v) 
glycerol, 0.5% (w/v) bromophenol blue, 2% (w/v) SDS, 5% (v/v) mercaptoethanol) was 
added to each sample and the sample-buffer mixture was heated at 95°C for 5 min.  The 
gel  tanks  were  buffered  with  electrode  running  buffer  (0.025  M  Tris  with  0.192 M 
glycine, 1% (w/v) SDS, pH 8.3).  Electrophoresis was carried out at a constant voltage 
of  200V  for  approximately  2.5  hours  in  a  Bio-Rad  Ready  Protean  II  xi  Slab  Cell 
(Bio-Rad Laboratories Inc., Hercules, CA, USA).  After electrophoresis, the gel was 
stained in 0.1% (w/v) Coomassie Blue R-250 for 30 min and washed in destaining 
buffer (40% methanol, 10% acetic acid) for 1-3 hours.  
2.2.6.6 Preparative gel electrophoresis  
Lipoprotein-free serum (200 µL) was mixed 1:2 with sample buffer (0.5 M Tris-HCl, 
5%  (v/v) glycerol, 0.5% (w/v) bromophenol blue, pH 6.8).  The gel tanks were buffered 
with  electrode  running  buffer  (0.025  M  Tris  with  0.192 M  glycine,  pH  8.3).  
Electrophoresis  was  carried  out  using  the  discontinuous  buffer  system  of  Ornstein-
Davis (1964) at a constant voltage of 200 V for approximately 2.5 hours in a Bio-Rad 
Protean II  Slab Cell (Bio-Rad Laboratories Inc., Hercules, CA, USA).  Following the 
electrophoresis, the gel slab was equilibrated in harvesting buffer (0.02 M NH4HCO3, 
pH 7.5) for 30 min to allow an exchange of buffers and minimise swelling of the gels 
during elution. After the equilibration the gel slab was placed on a Whole Gel Eluter 
(Bio-Rad Laboratories Inc., Hercules, CA, USA) and the electro-elution of the separated 
proteins was carried out at 250 mA constant current for 45 min.  When the elution was Chapter 2  Serum and surfactant secretion 
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completed,  reverse  current  (250  mA)  was  applied  to  the  Whole  Gel  Eluter  for  15 
seconds to dislodge protein bound to the cellophane membrane.  Thirty fractions were 
collected from the preparative slab gel.  Each fraction was tested for protein content by 
measuring  the  absorbance  at  280  nm  prior  to  determining  its  effect  on  lyso-PC 
generation from secreted phospholipids as described in section 2.2.5.  
2.2.6.7 Isoelectric focusing (IEF) 
IEF was carried out using a Bio-Rad ready gel, cast with Bio-Lyte Ampholytes that 
allows  fractionation  of  proteins  in  the  pI  range  of  3-10.    Prior  to  IEF,  a  Bio-Rad 
gel-loading buffer (50% (v/v) glycerol) was added to each sample. The upper chamber 
was buffered with cathode buffer (20 mM lysine, 20 mM arginine) while the lower 
chamber was filled with IEF anode buffer (7 mM phosphoric acid).  The samples were 
run against Bio-Rad IEF standards containing proteins ranging in pI from 4.45 to 9.6.  
Electrophoresis was carried out for 2.5 hours using the recommended stepwise power 
conditions from 100 V for 60 minutes, 250 V for 60 minutes and 500 V for 30 minutes 
in a Mini –Protean II Slab Cell (Bio-Rad Laboratories Inc., Hercules CA, USA).  After 
electrophoresis, the IEF gel was fixed for 30 minutes in a solution of 40% methanol and 
10%  acetic  acid  in  deionised  water  containing  0.018%  formaldehyde.    Following 
fixation,  the  gels  were  washed  in  a  solution  containing  10%  ethanol  for  a  total  of 
15 minutes,  with  three  solution  changes.    The  gels  were  then  treated  with  2.4  mM 
Na2S2O3  solution  for  1  minute  prior  to  a  10-minute  exposure  to  3.3  mM  AgNO3 
containing 0.028% formaldehyde.  Finally, the gels were rinsed with distilled water for 
1-5  minutes,  with  two  solution  changes  and  placed  in  developer  reagent  (0.17  M 
Na2CO3,  containing  0.018%  formaldehyde)  until  the  desired  band  intensity  was 
obtained.   Chapter 2  Serum and surfactant secretion 
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2.2.7 In vitro assay for serum PLA2-like activity 
The method for in vitro measurement of PLA2-like activity was based on that described 
by Petrovic et al. (2001).  1,2 bisheptanoylthio-glycerophosphocholine (1,2 bisHGPC) 
was dissolved in ethanol at a concentration of 25 mg/mL.  Aliquots (100 µL) were 
transferred  into  glass  screw  cup  tubes  and  dried  under  N2.    The  dry  1,2  bisHGPC 
residue was stored at -20°C.  Immediately before assay, the substrate was resuspended 
in 1.9 mL of assay buffer (150 mM KCl, 10 mM CaCl2, 50 mM Tris-HCl, pH 7.5) prior 
to the addition of 0.4 mL of 1 mM 5,5’-dithiobis-2-nitrobenzoic acid (DTNB).  The 
resulting mixture was vortexed vigorously for 1min and used as a substrate solution 
(190 µL) in the enzyme assay (final substrate concentration 2 mM).  After the addition 
of 10 µL of the sample being assayed, the mixtures were incubated in microtiter plates 
at room temperature for a minimum of 1 hour.  The absorbance at 415nm and 595nm 
was then determined using a Bio-Rad 550 microplate reader  (Bio-Rad Laboratories 
Inc., Hercules CA, USA).  A typical standard curve is shown in Figure 2.3 
2.2.8 Separation of lipoproteins from human serum 
2.2.8.1  Separation  of  serum  lipoproteins  using  self-generating 
gradients of iodixanol 
Human serum (6 mL) was mixed with 50% iodixanol (2 mL) to give a final iodixanol 
concentration of 12.5% (w/v) and 5mL of this mixture was transferred to Quick-seal 
centrifuge tubes.  The sample was underlaid with a cushion of 20% (w/v) iodixanol 
(0.5mL)  before  the  tubes  were  overlaid  with  buffered  saline.    The  tubes  were 
centrifuged at 70,000 rpm at 4°C for 189 min (using slow acceleration to 600 rpm and 
no brake during deceleration from 1000 rpm) in a Beckman L8-70M ultracentrifuge 
using a T-70 rotor (Beckman Instruments Inc, Fullerton CA, USA).  Fractions (250 µL)  Chapter 2  Serum and surfactant secretion 
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Figure  2.3    Typical  standard  curve  for  the  determination  of  PLA2-like  activity 
using  1,2  bisheptanoyl-thioglycerophosphocholine  (1,2  bisHGPC)  in  an  in  vitro 
assay. 
 
The hydrolysis of thioPC by the PLA2-like activity of LFS was measured using the 
spectrophotometric assay described in section 2.2.7.  The extent of hydrolysis is plotted 
as a function of the concentration of LFS.  The results represent the means ± SEM of six 
independent determinations.  
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were collected from the bottom of the tube.  Iodixanol is widely used as an imaging 
agent for injection into humans and has been shown to be inert, non-toxic to cells and 
non-inhibitory to enzymes (Ford et al., 1994; Graham et al., 1996).  Thus, separated 
serum proteins (LDL, HDL and VLDL and serum proteins) were easily identified by 
electrophoresis on alkaline buffered agarose gels  (pH 8.8) and then tested for PLA2-like 
activity on type II pneumocytes and in an in vitro assay as described in sections 2.2.5 
and 2.2.7, respectively.  
2.2.8.2 Confirmation of identification of serum lipoproteins using gel 
electrophoresis 
Separated  lipoproteins  were  analysed  by  electrophoresis  within  24h  of  separation.  
Aliquots of each fraction (2 µL) were applied to individual slits on a Serbia Hydragel 
Lipo + Lp(a) agarose gel and allowed to equilibrate for 5 min to facilitate complete 
diffusion of the lipoproteins into the gel.  The gel was then placed on a Serbia horizontal 
apparatus (Serbia K20, PN 1400 Serbia Inc, Norcross, GA, USA) with the gel facing 
down. The gel was dipped about 1 cm into the buffer (Tris 7.2 g/L, barbital 1.84 g/L, 
sodium barbital 10.3 g/L, sodium azide 0.1 g/L) on each side.  Commercially available 
human plasma lipoproteins were simultaneously run as standards. Electrophoresis was 
carried  out  for  1.5  hours  with  a  constant  voltage  (50  V)  (initial  current  per  gel, 
23 ± 4 mA). After the electrophoresis was completed the gel was dried in an oven at 
80°C for 20 min and stained (15 min) with Sudan Black (160 mL absolute ethanol, 
140 mL distilled water, 2 mL of the Sudan Black (6.6 g/L in dimethyl formamide).  
Each  gel  was  destained  for  exactly  5  min  in  destaining  solution  (45  mL  absolute 
ethanol,  55 mL  distilled  water).    A  typical  migration  profile  of  lipoproteins  using 
Hydragel electrophoresis is shown in Figure 2.4. 
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Figure 2.4  Electrophoretogram of lipoproteins isolated from human serum. 
 
Separated lipoprotein fractions from human serum (10 µL) were applied to individual 
slits on a Serbia Hydragel Lipo + Lp(a) agarose gel (the arrow indicates the position of 
application).  Commercially available human plasma lipoproteins were simultaneously 
run as standards.  Electrophoresis was carried out for 1.5 hours with a constant voltage 
(50 V) (initial current per gel, 23 ± 4 mA).  The separated lipoproteins were detected by 
staining  with  Sudan  Black  as  outlined  in  section  2.2.8.2  (lanes  1-7  represent, 
respectively, HDL std, LDL std, VLDL std, human serum and HDL, LDL and VLDL 
separated from human serum). Note that the separation of LDL and VLDL in serum is 
not as obvious as that obtained with commercially available standards (lanes 2 and 3), a 
result which is presumably due to their interaction with other serum components. Chapter 2  Serum and surfactant secretion 
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2.2.9 Desalting  of protein solutions  using Sephadex G-25 gel 
filtration  
Salt  removal  from  sample  preparations  was  achieved  using  5  mL  PD-10  columns 
packed with Sephadex G-25 gel (Amersham Pharmacia Biotech Pty Ltd, New South 
Wales, Australia).  Briefly, each sample was lyophilized, resuspended in 1mL of sample 
buffer  (0.02  M  NH4HCO3,  pH  7.5)  and  then  loaded  onto  a  column  previously 
equilibrated with 20 mL of buffer (0.02 M NH4HCO3, pH 7.5).  The column was then 
washed with 10 mL of the same buffer.  The first 2.5 mL were discarded, then a 3 mL 
fraction was collected and assayed for protein content by measuring the absorbance at 
280nm and for salt concentration using a Buchler digital chloridometer as detailed in 
section 1.10.  Protein yields in this fraction was typically greater then 95% with no salt 
contamination present.  A typical chromatogram is shown in Figure 2.5. 
2.2.10 Determination of chloride concentration  
Quantitative determination of chloride ion content was measured against 0-0.6 M KCl 
standards using the method recommended by the manufacturer of the chloridometer.  
Vials containing 4 mL of acid reagent (6.4 mL of HNO3, 100 mL acetic acid in 900 mL 
distilled water) and 4 drops of gelatine reagent (0.1g thymol blue, 0.1g thymol, 6.0 g 
gelatin in 1000 mL of distilled water) were placed on the vial holder of a Buchler digital 
chloridometer (Buchler 4-2500, Labconco Corporation, Kansas City, MO, USA).  Prior 
to titration, 100 µL of each sample was added. Total titration time was typically of 20 
second duration.  A typical chloride standard curve is shown in figure 2.6. 
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Figure  2.5    Typical  chromatogram  showing  the  removal  of  KCl  from  albumin 
preparations. 
 
A PD-10 column containing Sephadex G-25 was equilibrated with 0.02 M NH4HCO3, 
pH  7.5.    A  1.0  mL  sample  consisting  of  bovine  albumin  (1  mg)  dissolved  in  KCl 
solution (0.4 M, 1 mL) was applied to the column, which was then washed with 0.02 M 
NH4HCO3, pH 7.5.  Fractions of 1 mL were collected and assayed for protein content 
by measuring the absorbance at 280 nm () and for salt concentration () as detailed in 
section  2.2.10.    The  results  represent  the  mean  ±  SEM  of  three  independent 
determinations.  
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Figure  2.6    Typical  standard  curve  for  the  determination  of  chloride  ion 
concentration. 
 
Standards  (0-0.6  M)  of  KCl  were  prepared  according  to  the  procedure  detailed  in 
section 2.2.10.  Chloride ion was plotted as a function of milliequivalents of chloride 
per  liter  (mEq/L).    The  results  represent  the  mean  of  ±  SEM  of  four  independent 
determinations. 
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2.2.11 Protein assay  
The protein concentration was measured using a Bio-Rad BCA Protein Assay, prepared 
to the manufacturer’s instructions.  Reagent B was initially diluted with 50 volumes of 
Reagent  A  and  1.9  mL  of  this  reaction  mixture  was  added  to  each  of  the  test  and 
standard samples that had been prepared.  Standards were prepared using a 1.0 mg of 
bovine  serum  albumin  per  mL,  standard  solution  and  the  addition  of  aliquots  of 
10-100µL of this solution yielded standards of 10-100 µg.  Distilled water was added to 
make the volume up to 100 µL prior to the addition of 1.9 mL of the reaction mixture.  
A typical standard curve is shown in Figure  2.7.  
2.2.12  Expression of results and statistical analysis 
The  level  of  secretion  was  expressed  as  the  percentage  of  radiolabelled  cellular 
phospholipids that were secreted into the medium during a 3-hour incubation.  The 
composition of the secreted phospholipids was ascertained by determining the % of the 
phospholipids that were lyso-PC, sphingomyelin or PC after their separation by thin-
layer  chromatography  (Note  that  these  are  the  only  phospholipids  that  would  be 
radiolabelled with the precursor [
3H]-choline).  Although variations between replicate 
cultures of the same batch of cells were always small, the rate of secretion sometimes 
varied quite markedly between different batches of cells.  Subsequently, this was shown 
to be due to variations in the cell density of the type II cell cultures at the time of 
measuring  the  rate  of  secretion  (data  not  shown).    Thus  statistical  analyses  were 
performed  using  the  paired  Student’s  t-test  except  for  the  in  vitro  measurement  of 
PLA2-like  activity,  which  was  analysed  using  multivariate  analysis  of  variance 
(MANOVA). 
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Figure 2.7  A typical protein standard curve for the BCA Protein Assay. 
 
Standards  (0-100  µg)  of  bovine  serum  albumin  were  prepared  according  to  the 
procedure  detailed  in  section  2.2.11.    After  assay  the  absorbance  at  582  nm  was 
determined using a Beckman DU50 UV-Visible spectrophotometer.  Each data point is 
the mean of duplicate samples. 
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2.3  Results 
2.3.1 Effect of human serum on phospholipid secretion 
Previous  reports  (Dobbs  et  al.,  1982;  Cott  et  al.,  1987)  demonstrated  that  serum 
supplementation  enhanced  phosphatidylcholine  secretion  from  type  II  cells  derived 
from adult lungs. In this study it has been shown that the addition of human serum 
stimulates secretion of phospholipids from foetal type II pneumocytes into the media by 
8.7-fold (Fig. 2.8). 
To determine which component of serum is responsible for this enhanced secretion a 
novel  method  of  separating  plasma  components  was  employed.    Iodixanol,  which 
generates a gradient when centrifuged, has a very low toxicity in biological systems and 
enzyme assays can be carried out in its presence.  The data presented in Figure 2.9 
demonstrate  that  plasma  proteins  other  than  lipoproteins  are  the  principle  agent 
stimulating  secretion  (p<0.001).  High-density  lipoproteins  (HDLs)  are  a  serum 
component that also stimulates phospholipid secretion, but with a lesser effect than the 
plasma  proteins  (p<0.002).  Low-density  lipoproteins  (LDLs)  and  very  low-density 
lipoproteins (VLDLs) had no significant effect on the level of secretion. 
Given  this  marked  effect  of  the  plasma  protein  fraction  on  the  rate  of  secretion  of 
phospholipids, commercially available lipoprotein-free serum (LFS) was also examined 
for its effect upon secretion. The results depicted in Figure 2.10 show that LFS also 
significantly  enhanced  phospholipid  secretion  (5.6-fold,  p<0.001)  although  its  effect 
was somewhat less than that of whole serum (p<0.001).  This effect of LFS on lipid 
secretion into the media was evident as early as 30 min after its addition (p<0.001), at 
which time there was a significant elevation that reached a plateau after three hours of 
exposure (Fig. 2.11).  This effect was concentration-dependent with a stimulatory effect Chapter 2  Serum and surfactant secretion 
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Figure 2.8  Effect of human serum (HS) on the secretion of phospholipids from 
cultured foetal type II pneumocytes. 
 
Foetal type II pneumocytes were grown in culture for 72 hours prior to incubation for 
24 hours with [
3H]-choline in serum-free MEM to label total cellular phospholipids.  
The cells were then thoroughly washed with BSS and equilibrated for one hour at 37ºC 
in serum-free MEM.  Human serum (    ) was then added to a final concentration of 4%.  
An equivalent volume of water  (    ) was added to control plates.  The percentage of 
total cellular [
3H]-phospholipids secreted into the media in the subsequent three hours 
was determined using the method detailed in section 2.2.5.  Values are the mean ± SEM 
for three independent experiments.  
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Figure 2.9  Effect of serum proteins (SP), HDL, LDL and VLDL on phospholipid 
secretion into the media by foetal type II pneumocytes in culture. 
 
Type II cells were isolated from the lungs of 19-day foetal rats and, after reaching 
confluence, were incubated for a further 24 hours with [
3H]-choline in serum-free MEM 
in order to label cellular phospholipids.  The cells were then thoroughly washed with 
BSS and equilibrated for one hour at 37°C in serum-free MEM prior to the addition of 
human serum proteins or the indicated human serum lipoproteins (separated as detailed 
in section 2.2.8) to a final concentration equivalent to that of 4% serum (i.e. taking into 
account the volume of serum from which they were derived and the dilution they were 
subjected to when added to the cultures).  An equivalent volume of water was added to 
the control plates.  The cells were then incubated for a further 3 hours.  The extent of 
phospholipid  secretion  by  type  II  pneumocytes  was  then  immediately  determined.  
Values represent the mean ± SEM for 3 independent experiments.  
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Figure 2.10  Effect of human serum (HS) or lipoprotein-free serum (LFS) on the 
secretion of phospholipids from cultured foetal type II pneumocytes. 
 
Foetal type II pneumocytes were grown in culture for 72 hours prior to incubation for 
24 hours with [
3H]-choline in serum-free MEM to label total cellular phospholipids.  
The cells were then thoroughly washed with BSS and equilibrated for one hour at 37ºC 
in serum-free MEM.  Human serum (    )  or LFS (    ) were then added to a final 
concentration of 4%.  An equivalent volume of water  (    ) was added to control plates.  
The  percentage  of  total  cellular  [
3H]-phospholipids  secreted  into  the  media  in  the 
subsequent  three  hours  was  determined  using  the  method  detailed  in  section  2.2.5.  
Values are the mean ± SEM for three independent experiments.  
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being evident at a LFS concentration as low as 0.5% (p<0.02) and appeared to be close 
to maximal at 4.0%, at which concentration it induced a 4.6-fold increase (Fig. 2.12). 
When the effect of serum (human) on the composition of the secreted phospholipids 
was examined (Fig. 2.13) it was observed that serum significantly increased the level of 
lysophosphatidylcholine (lyso-PC) within the media phospholipids from 4.3% to 28.2% 
(a  6.6-fold  increase;  p<0.001)  with  a  concomitant  decline  in  the  level  of 
phosphatidylcholine (PC) from 85.6% to 63.9% (p<0.001).  Given this result, the effect 
of  human  serum  lipoproteins  and  LFS  on  the  lyso-PC  content  of  the  media 
phospholipids was examined.  The data presented in Figure 2.14 clearly demonstrate 
that  lipoprotein-free  serum  significantly  increased  the  lyso-PC  levels  in  media 
phospholipids (6.9-fold; p<0.001).  There was also a small, but significant, elevation in 
the level of media lysophosphatidylcholine when the cells were exposed to HDL and 
LDL (2.6-fold (p< 0.01) and 1.7-fold (p< 0.02), respectively).  The results presented in 
Figure 2.15 demonstrate that the addition of LFS to the cells not only led to a significant 
elevation in the lysophosphatidylcholine content (5.4-fold; p<0.001) but also caused a 
corresponding  decline  in  the  level  of  phosphatidylcholine  (PC)  in  the  media 
phospholipids (0.77-fold; p< 0.001).  In contrast, there was no significant effect upon 
the sphingomyelin content (p>0.05).  These data suggest that a component of serum, 
possibly a phospholipase A2 (PLA2), is responsible for deacylation of PC, converting it 
to lyso-PC.  
The enhanced level of lyso-PC that was observed could have been due to an effect of 
lipoprotein-free serum on the surfactant phospholipids within the cells prior to secretion 
or  to  a  deacylation  of  PC  after  secretion  had  occurred.    However,  when  type  II 
pneumocytes were incubated   in   the   presence   of   LFS, the cellular phospholipid 
composition showed no significant change  (p>0.5)  (Fig. 2.15).   Moreover, the level of  Chapter 2  Serum and surfactant secretion 
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Figure  2.11    Time  course  of  phospholipid  secretion  by  cultured  foetal  type  II 
pneumocytes in response to lipoprotein-free serum. 
 
Confluent cultures of type II pneumocytes, isolated as described in section 2.2.4 were 
incubated with [
3H]-choline for 24 hours in order to label cellular phosphatidylcholine.  
The cells were then washed thoroughly and equilibrated for 1 hour at 37°C in serum-
free MEM prior to the addition of 4% lipoprotein-free serum (    ) or water (    ).  
Subsequently, the rate of phospholipid secretion into the medium was determined at the 
indicated times using the method described in section 2.2.5.  The data points are the 
mean ± SEM of three experiments. 
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Figure  2.12    Effect  of  lipoprotein-free  serum  concentration  on  the  secretion  of 
phospholipids from cultured foetal type II pneumocytes. 
 
Lung type II pneumocytes were isolated as described in section 2.2.4.  The cells were 
then  grown  in  culture  for  72  hours  and  subsequently  incubated  for  24  hour  with 
[
3H]-choline  in  serum-free  MEM  in  order  to  label  the  cellular  phospholipids.    The 
culture plates were then thoroughly washed with BSS and equilibrated for one hour at 
37°C in serum -free MEM. The cells were then incubated for a further 3 hours in serum-
free MEM containing the indicated concentrations (0%, 0.5%, 1%, 2%, 4%, 8%) of 
lipoprotein-free serum.  The extent of phospholipid secretion by type II pneumocytes 
was determined as described in section 2.2.5.  The data represent the mean ± SEM of 4 
separate experiments. 
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Figure    2.13    Composition  of  phospholipids  secreted  from  foetal  type  II 
pneumocytes in presence of human serum. 
 
Foetal type II pneumocytes was isolated as described in section 2.2.4.  Cells were grown 
in culture for 72 hours and then incubated for a further 24 hours with [
3H]-choline in 
serum-free MEM.  At the completion of that incubation, culture plates were thoroughly 
washed with BSS and equilibrated for one hour at 37ºC in serum-free MEM.  Human 
serum (     ) was then added to test plates to a final concentration of 4%.  An equivalent 
aliquot of the vehicle (water) was added to the control plates (    ).  After further 3 hours 
incubation, the media phospholipids were extracted (section 2.2.5.2) and separated by 
thin-layer chromatography (section 2.2.5.3).  The data represent the mean ± SEM for 
three separate experiments.  
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Figure  2.14    Effect  of  LFS  and  human  serum  lipoproteins  on  the 
lysophosphatidylcholine (lyso-PC) content of the phospholipids secreted by foetal 
type II pneumocytes in culture. 
 
Foetal  type  II  pneumocytes  were  isolated  and  cultured  as  outlined  in  section  2.2.4.  
After growth for 72 hours the cells were incubated with [
3H]-choline in serum-free 
MEM.  The culture plates were then thoroughly washed with BSS and equilibrated for 
one hour at 37°C in serum-free MEM.  Human LFS or the indicated separated human 
serum lipoproteins (as detailed in section 2.2.8) were then added to the plates to a final 
concentration equivalent to that of 4% serum.  A similar aliquot of vehicle (water) was 
added to the control plate.  After a further 3 hours incubation the media phospholipids 
were extracted and the lyso-PC content determined, as outlined in section 2.2.5.3.  The 
results represent the mean ± SEM of 3 separate experiments.  
 
 
 
0
5
10
15
20
25
30
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L
y
s
o
P
C
(
%
 
o
f
 
l
a
b
e
l
l
e
d
 
l
i
p
i
d
 
i
n
 
m
e
d
i
a
)
Control    LFS     HDL    LDL     VLDLChapter 2  Serum and surfactant secretion 
          74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.15    Comparison  of  the  media  and  cellular  phospholipids  in  type  II 
pneumocytes incubated in the absence or presence of lipoprotein-free serum. 
 
Foetal type II pneumocytes were isolated and cultured as described in section 2.2.4.  
The cells were grown in culture for 72 hours prior to incubating them for 24 hours with 
[
3H]-choline in serum-free MEM to label the cellular phospholipids.  The plates were 
then  thoroughly  washed  with  2  mL  BSS  and  equilibrated  for  one  hour  at  37°C  in 
serum-free MEM.  LFS was subsequently added to the test plate to a final concentration 
of 4% (    ).  A similar aliquot of the vehicle (water) was added to the control plate (    ). 
After  a  further  3  hours,  the  media  and  cellular  phospholipids  were  extracted  and 
subjected  to  thin-layer  chromatography,  as  described  in  sections  2.2.5.2  and  2.2.5.3 
respectively.  The data represent the mean ± SEM for three separate experiments. 
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lyso-PC within the type II cells was very low (<1.0%) in both the absence and presence 
of lipoprotein-free serum.  These findings suggest that the hydrolysis of PC takes place 
outside the cell after secretion of the phospholipids. 
Since  lipoprotein-free  serum  is  a  strong  positive  effector  for  secretion  of  surfactant 
(Fig. 2.12) and acts to alter the composition of the secreted phospholipids (Fig. 2.15), 
the effect of the lipoprotein-free serum concentration on the lyso-PC content of the 
secreted lipids was examined.  It was apparent that, when the serum concentration was 
0.5%  or  greater  there  was  a  significant  elevation  (p<0.001)  in  the  level  of  lyso-PC 
(Fig. 2.16) in the secreted phospholipids.  This effect of LFS appeared to be close to 
being saturable at 4% serum, at which concentration there was a 4.6-fold increase of 
lyso-PC.  
2.3.2  Chromatographic  separation  of  the  lipoprotein-free  serum 
components 
Given that secretory PLA2, specifically its carboxy-terminal region, has a high affinity 
for  heparin  (Horigome  et  al.,  1987;  Kim  et  al.,  1995),  a  HiTrap  heparin-Sepharose 
column was used in an attempt to characterise the LFS component responsible for the 
conversion of PC to lyso-PC.  The results presented in Figure 2.17 show that, whereas 
the  secretory  form  of  PLA2  bound  to  the  column  and  required  salt  to  elute  it,  the 
PLA2-like activity in LFS had quite different chromatographic properties and did not 
bind to the column. 
An attempt was then made to separate the serum enzyme responsible for pulmonary 
surfactant inactivation using a Bio-Gel P-60 column (Fig. 2.19).  The justification for 
using this chromatographic technique was based  on  the  assumption  that  the serum  
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Figure  2.16    Effect  of  lipoprotein-free  serum  concentration  on  the 
lysophosphatidylcholine  (lyso-PC)  content  of  the  phospholipids  secreted  by 
cultured foetal type II pneumocytes. 
 
Foetal  type  II  pneumocytes  were  isolated  and  cultured  as  outlined  in  section  2.2.4.  
After growth for 72 hours, the cells were incubated with [
3H]-choline in serum-free 
MEM.  The culture plates were then thoroughly washed with BSS and equilibrated for 
one hour at 37°C in serum-free MEM.  LFS was then added to test plates to the final 
concentration of 0.5%, 1%, 2%, 4% and 8%.  A similar aliquot of vehicle (water) was 
added to the control plate.  After a further 3 hours incubation the media phospholipids 
were extracted and the lyso-PC content determined, as outlined in section 2.2.5.3.  The 
results represent the mean ± SEM of 3 separate experiments.  
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Figure 2.17  Chromatographic separation of the PLA2-like activity of LFS and a 
commercially available form of secretory PLA2 using a HiTrap Heparin-Sepharose 
column. 
Aliquots (250µL) of either lipoprotein-free serum (  ) or 160 units of secretory PLA2 
(  ) were applied to a HiTrap Heparin-Sepharose column (1 x 5cm) previously pre-
equilibrated with 0.02 M NH4HCO3, pH 7.5.  The column was washed with 40 mL 
0.02 M NH4HCO3, pH 7.5 at a flow rate of 1 mL/min prior to eluting the bound material 
with a 60 mL linear gradient of 0-3.0 M NaCL in NH4HCO3, pH 7.5.  Fractions (2 mL) 
were collected and tested for protein content by measuring the absorbance at 280 nm 
and for salt concentration, as outlined in sections 2.2.11 and 2.2.10, prior to determining 
the  extent  of  hydrolysis  of  the  phosphatidylcholine  secreted  from  cultured  type  II 
pneumocytes as described in section 2.2.5.3. 
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Figure 2.18  Chromatographic separation of protein standards. 
 
Bovine serum albumin (10 mg;  ), ovalbumin (10 mg;  ) and carbonic anhydrase 
(3 mg;  ) were each dissolved in 2.5 mL of 0.02 M NH4HCO3, pH 7.1 prior to separate 
chromatographic  elution  on  a  BioGel  P-60  column  (98  x  2.5  cm)  equilibrated  with 
0.02 M NH4HCO3, pH 7.1.  The column was run at a constant flow rate of 2 mL/h and 
2 mL  fractions  were  collected.    Each  fraction  was  analysed  for  protein  content  by 
measuring the absorbance at 280 nm. 
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Figure 2.19  Chromatographic separation of the serum component responsible for 
lysophosphatidylcholine production in secreted media phospholipids. 
 
Foetal type II pneumocytes were isolated as described in section 2.2.4.  Cells were 
grown in culture for 72 hours and then incubated for 24 hours with [
3H]-choline in 
serum-free  MEM.    The  culture  plates  were  then  thoroughly  washed  with  BSS  and 
equilibrated for one hour at 37°C in serum-free MEM.  Lipoprotein-free serum was 
dissolved in 0.02 M NH4HCO3, pH 7.1 and chromatographed on a BioGel P-60 column 
as described in section 2.2.6.2.  Each fraction was lyophilised and redissolved in BSS 
and added to separate culture plates to a final concentration equivalent to 4% serum.  
The plates were incubated for a further 3 hours at 37°C and the phosphatidylcholine 
(PC;  ), sphingomyelin (  ) and lyso-PC (  ) content of the secreted phospholipids 
determined as outlined in section 2.2.5.3.  Each of the three major fractions was plotted 
as a percentage of the total media phospholipids. 
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enzyme  might  have  a  molecular  weight  lower  than  60  kDa  whereas  the  major 
component of serum, namely albumin, has a molecular weight of 66 kDa.  In addition, 
protein standards of known molecular weight were subjected to chromatography on the 
same Bio-Gel P-60 column in order to calibrate the column (Fig 2.18).  The results 
presented in Figure 2.19 clearly demonstrate that the serum component, which has an 
ability to stimulate secretion of phospholipids from type II pneumocytes and a capacity 
to convert PC into lyso-PC, has an almost identical elution profile to that of albumin 
after passage through a Bio-Gel P-60 column.  Moreover, as would be anticipated, the 
enzyme activity co-eluted with a high proportion of the total serum protein (data not 
presented).  
As ion-exchange chromatography has been previously used to purify PLA2 (Lindahl et 
al., 1989) the chromatographic elution of both the LFS component and the secretory 
form of PLA2 from a DEAE-Sepharose CL-6B column was examined.  Whereas the 
enzyme activity of LFS is adsorbed to the column and eluted at a KCl concentration of 
0.18-0.20 M, the secretory form of PLA2 is eluted at a much lower KCl concentration 
(0.08-0.13  M).    Thus,  the  combined  data  demonstrate  that  the  LFS  enzyme,  which 
stimulates  the  production  of  lyso-PC  and  co-elutes  with  albumin  (Fig.  2.20A),  is 
biochemically distinct from the secretory form of PLA2 (Fig. 2.20B). 
2.3.4  The  inhibitory  effect  of  EGTA  on  the  serum-enhanced 
generation of lyso-PC in the secreted phospholipids 
Ethylene glycol tetraacetic acid (EGTA) has been widely used in many biochemical 
assays as a chelator of Ca
2+.  Thus, various concentrations of this chelating agent were 
evaluated for their effect on the LFS induced generation of lyso-PC in the media.  As 
shown in Figure 2.21, the inhibitory effect of EGTA is concentration-dependent and the  
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Figure 2.20  Chromatographic separation of the PLA2-like activity of LFS and a 
commercially available secretory PLA2 using DEAE Sepharose column. 
 
Aliquots (2.5 mL) of either lipoprotein-free serum (  ) or 1600 units of secretory PLA2 
(   )  previously  exposed  to  heat  treatment  at  60°C  for  30  min,  were  applied  to  a 
DEAE-Sepharose column (2.7 x 45 cm) equilibrated with 0.025 M KCL in 0.02 M 
NH4HCO3, pH 7.5.  The column was run at a constant flow rate of 15 mL/h and 220 
fractions (4 mL) were collected.  The first 80 fractions were collected prior to a linear 
gradient of KCl in 0.02 M NH4HCO3, pH 7.5 being applied.  Each fraction was tested 
for protein content by measuring the absorbance at 280 nm and salt concentration (as 
outlined in sections 2.2.11 and 2.2.10) prior to determining the extent of hydrolysis of 
the phosphatidylcholine secreted from cultured type II pneumocytes as described in 
section 2.2.5.3.  
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Figure 2.21  The inhibitory effect of EGTA on serum-enhanced generation of lyso-
PC in the secreted phospholipid pool of cultured foetal type II pneumocytes. 
 
Foetal type II pneumocytes were grown in culture for 72 hours prior to incubation for 
24 hours with [
3H]-choline in serum-free MEM to label the total cellular phospholipids. 
The cells were then thoroughly washed with BSS and equilibrated for one hour at 37°C 
in serum-free MEM.  LFS (4% final concentration) was added to the cultures in the 
presence of the indicated concentrations of EGTA. An equivalent volume of water was 
then  added  to  the  control  plates.    After  a  further  3  hours  incubation  the  media 
phospholipids  were  extracted  and  the  lyso-PC  content  determined,  as  described  in 
section.2.2.5.3.  The data represent the mean ± SEM of three experiments.  
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serum PLA2-like activity was largely eliminated at a EGTA concentration of 5 mM 
(p<0.01).  These findings demonstrate that the serum enzyme, which stimulates the 
hydrolysis of phosphatidylcholine in secreted surfactant, is Ca
2+-dependent.  
2.3.5  The  effect  of  specific  PLA2  inhibitors  on  the  lipoprotein-free 
serum effect 
Competitive inhibitors of the different forms of PLA2 have been tested in an attempt to 
characterise the form of the enzyme present in LFS.  p-Bromophenacyl bromide (BPB) 
(Liu,  1999)  and  aristolochic  acid  (ASA)  (Vondran  et  al.,  1997)  have  been  used  as 
specific  inhibitors  of  the  secretory  form  of  PLA2  whereas  palmitoyl  trifluoromethyl 
ketone (PACOCF3) (Liu, 1999) is a competitive inhibitor of some Ca
2+-independent 
forms of PLA2.  The data presented in Table 2.1 indicate that these inhibitors have no 
significant effect upon the activity of the serum enzyme activity.  
2.3.6  Electrophoretic  separation  of  lipoprotein-free  serum  and  of 
various commercially-available albumins 
An  attempt  was  made  to  electrophoretically  separate  the  serum  proteins,  and  in 
particular the PLA2-like activity, using native PAGE.  Lipoprotein-free serum (LFS), 
human serum albumin fraction V (HSA V), crystallized human serum albumin (HSA C) 
and human serum albumin globulin- and fatty acid-free (HSAGF), were exposed to 
polyacrylamide gel electrophoresis (PAGE).  As presented in Figure 2.22, all of the 
protein  preparations  had  multiple  bands  indicating  that  alternative  separation 
techniques, based on different molecular attributes of the serum factor (s), need to be 
employed to differentiate it from albumin. 
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  Secretion 
(% of total cellular 
phospholipids) 
Lyso-PC 
(% of secreted 
phospholipids) 
 
Control  
LFS  
10  µM BPB 
LFS + 10 µM BPB 
 
0.56 ± 0.16 
1.24 ± 0.18 
0.49 ± 0.09 
1.24 ± 0.21 
 
4.75 ± 1.03 
      25.72 ± 0.68 
5.99 ± 0.88 
      25.52 ± 1.10 
 
Control  
LFS  
10 µM ASA 
LFS + 10 µM ASA 
 
0.27 ± 0.02 
0.97 ± 0.16 
0.26 ± 0.11 
0.96 ± 0.23 
 
7.22 ± 0.75 
      29.20 ± 1.91 
7.03 ± 0.09 
      28.44 ± 2.66 
 
Control 
LFS  
10 µM PACOCF3 
LFS + 10 µM PACOCF3 
0.38 ± 0.09 
1.18 ± 0.03 
0.26 ± 0.03 
1.07 ± 0.01 
5.68 ± 0.31 
      25.57 ± 0.27 
4.54 ± 0.39 
      25.89 ± 0.06 
 
 
Table 2.1  Effect of exposure of lipoprotein-free serum to PLA2-specific inhibitors 
on enhanced secretion and on lysophosphatidylcholine (lyso-PC) content of media 
phospholipids. 
 
Lung type II pneumocytes were isolated as described in section 2.2.4.  The cells were 
then  grown  in  culture  for  72  hours  and  subsequently  incubated  for  24  hours  with 
[
3H]-choline  in  serum-free  MEM  in  order  to  label  the  cellular  phospholipids.    The 
culture plates were then thoroughly washed with BSS and equilibrated for one hour at 
37°C in serum-free MEM.  The cells were then incubated for a further 3 hours in MEM 
containing 4% LFS (final concentration) with or without the PLA2-specific inhibitors 
p-bromophenacyl bromide (BPB), aristolochic acid (ASA), palmitoyl trifluoromethyl 
ketone  (PACOCF3).    A  similar  aliquot  of  vehicle  (water)  was  added  to  the  control 
plates.    The  extent  of  phospholipid  secretion  and  the  percentage  of  lyso-PC  in  the 
secreted phospholipids were then determined as outlined in section 2.2.5.  The results 
represent the mean ± SEM of three separate experiments.  Chapter 2  Serum and surfactant secretion 
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Figure  2.22    Native  polyacrylamide  gel  electrophoresis  of  LFS  and  various 
commercially-available albumins. 
 
Lipoprotein-free serum (LFS, 20µL) or equivalent volumes of various commercially 
available HSA preparations (50 mg/ml) were loaded on to a 10% polyacrylamide slab 
gel.  Electrophoresis was carried out using the discontinuous buffer system of Ornstein-
Davis (1964) at a constant voltage of 200 V for approximately 2.5 hours and employing 
a running buffer of 0.025 M Tris with 0.192 M glycine, pH 8.3.  The separated proteins 
were  detected  by  silver  staining  as  outlined  in  section  2.2.6.4.    Arrow  on  the  gel 
indicates the migration of bovine serum albumin standard. 
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2.3.7  The  effect  of  various  human  albumin  preparations  on 
phospholipid secretion and the level of lyso-PC in media from type II 
cells 
 
Evidence for the association of PLA2-like activity with commercially available albumin 
has  been  previously  demonstrated  (Elsbach  and  Pettis,  1973;  Langton  and  Dench, 
1991).  When type II pneumocytes were incubated with human serum albumin fraction 
V (HSA V), human serum albumin, crystallised (HSA C) and human serum albumin, 
globulin-free and fatty acid-free (HSA GF) there was a significant change in the rate of 
phospholipid secretion and lyso-PC content of the media (Fig. 2.23).  When the media 
was  supplemented  with  25  mg/mL  albumin  (HSA  V,  HSA  C,  HSA  GF)  there  is  a 
marked increase in the phospholipid secretion (2.28-fold (p<0.03), 1.83-fold (p<0.03) 
and 1.57-fold (p<0.02), respectively) and in the level of lysophosphatidylcholine in the 
media  (2.5-fold  (p<0.03),  2.0-fold  (p<0.005)  and  1.8-fold  (p<0.005),  respectively).  
These  effects  of  the  various  albumin  preparations  were  found  to  be  concentration-
dependent  and  a  significant  increase  was  observed  at  albumin  concentrations  of 
25 mg/mL or greater (Fig. 2.23). 
2.3.8  Preparative  electrophoresis  of  the  serum  component 
responsible for hydrolysis of phosphatidylcholine 
Conventional analytical electrophoresis was used to separate and elute the serum protein 
components.  In this elution step, proteins were mobilized from the gel and eluted into 
an electrode solution using a reverse electric field to achieve a high degree of recovery 
(92.5%, data not presented).  The results of the electroelution are shown in Figure 2.24 
and demonstrate that the factor responsible for the hydrolysis of phosphatidylcholine 
eluted as a single peak (fraction 13), which corresponded with the major protein peak.  Chapter 2  Serum and surfactant secretion 
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Figure 2.23  Effect of HSA fraction V, HSA crystallised and HSA globulin-free on 
phospholipid  secretion  and  lysophosphatidylcholine  content  of  the  media 
phospholipids secreted by foetal type II pneumocytes in culture.  
 
Type II cells were isolated from the lungs of 19-day foetal rats and, after reaching 
confluence, were incubated for a further 24 hours with [
3H]-choline in serum-free MEM 
in order to label cellular phospholipids.  The cells were then thoroughly washed with 
BSS and equilibrated for one hour at 37°C in serum-free MEM prior to the addition of 
the  indicated  concentrations  of  different  preparations  of  albumin.    An  equivalent 
volume of water was added to the control plates (i.e. 0 mg HSA/mL).   The cells were 
then incubated for a further 3 hours.  The extent of phospholipid secretion by type II 
pneumocytes  was  then  determined  (A)  and  the  lyso-PC  content  of  the  secreted 
phospholipids  determined  (B)  as  described  in  section  2.2.5.    Values  are  the 
mean ± SEM for 3 independent experiments.  Chapter 2  Serum and surfactant secretion 
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Figure 2.24  Preparative electrophoresis of the serum component responsible for 
lysophosphatidylcholine production in secreted media phospholipids. 
 
Lipoprotein-free  serum  (175  µL)  was  loaded  onto  a  10%  polyacrylamide  slab  gel.  
Electrophoresis was carried out using the discontinuous buffer system of Ornstein and 
Davis (1964) at a constant voltage of 200 V for approximately 2.5 hours and employing 
a running buffer of 0.025 M Tris with 0.192 M glycine, pH 8.3.  Thirty fractions were 
isolated from the preparative slab gel as outlined in section 2.2.6.6.  Each fraction was 
tested  for  protein  content  by  measuring  the  absorbance  at  280  nm  (    )  prior  to 
determining its effect on the lyso-PC content of the secreted phospholipids (  ), as 
described  in  section  2.2.5.3.    The  data  presented  are  the  means  of  four  separate 
experiments.  
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2.3.9 IEF electrophoresis of LFS, HSA fraction V and LFS partially 
purified on DEAE-Sepharose 
The data presented in Figure 2.25 shows that both LFS and HSA, when subjected to IEF 
electrophoresis,  yielded  a  similar  double  protein-banding  pattern.    The  predominant 
band (upper band) corresponded to a pI of ~4.5, which is equivalent to that of albumin, 
however, since this was a denaturing gel, it was not possible to assign the PLA2-like 
activity (responsible for PC hydrolysis) to either of the two bands.  
2.3.10 The effect of LFS, human serum albumin fraction V (HSA V) 
and  recombinant  human  serum  albumin  (rHSA)  on  phospholipid 
secretion and the conversion PC to lyso-PC 
Because  each  of  the  commercially  available,  serum-derived  albumins  contain  other 
serum components, either bound to or co-eluting with albumin, a distinction between a 
direct  effect  of  albumin  or  of  a  co-eluting  serum  component  was  not  possible.  
However, recombinant human serum albumin (rHSA), which is devoid of these other 
components,  was  shown  to  be  equally  as  effective  as  HSA  V  in  stimulating  the 
production of lyso-PC in the media (Fig. 2.26B) (5.3-fold increase compared to control, 
p<0.005).  This suggests that the PLA2-like activity that is principally responsible for 
the production of lyso-PC is, in fact, an inherent activity of albumin.  In contrast to its 
effect on lyso-PC production, rHSA had a significantly smaller effect on phospholipid 
secretion from foetal type II pneumocytes than did LFS (Fig. 2.26A).  This suggests that 
components other than albumin may be responsible for the enhanced level of secretion. 
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Figure 2.25  Separation by isoelectric focusing of components of LFS, partially 
purified LFS (using DEAE-Sepharose) and HSA fraction V. 
 
IEF was carried out using a Bio-Rad ready gel, cast with Bio-Lyte ampholytes that 
allow fractionation of proteins in the pI range of 3-10.  Prior to IEF, each sample was 
subjected to preparative PAGE (as outlined in section 2.2.6.6) to partially purify the 
PLA2-like activity.  HSA fraction V (1.25 µL, lane 2), LFS after partial purification on 
DEAE-Sepharose (1.25 µL, lane 3) and LFS (0.5 µL, lane 4) were loaded on to an IEF 
gel. The samples were run against Bio-Rad IEF standards (lanes 1 and 5) containing 
proteins with a pI in the range 4.45 to 9.6.  The three standards with pI values of 4.45-
4.75, 5.1 and 6.0 are marked with an arrow.  Electrophoresis was carried out for 2.5 
hours  using  the  recommended  power  conditions  described  in  section  2.2.6.7.    The 
separated proteins were then detected using a silver staining protocol, as described in 
section 2.2.6.7.  
6.0  → 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Figure 2.26  Effect of LFS, HSA fraction V and rHSA on cellular phospholipid 
secretion  and  lyso-PC  production  in  the  secreted  media  of  foetal  type  II 
pneumocytes in culture.  
 
Foetal type II pneumocytes were grown in culture for 72 hours prior to incubation for 
24 hours with [
3H]-choline in serum-free MEM to label cellular phospholipids.  The 
cells were then thoroughly washed with BSS and equilibrated for one hour at 37°C in 
serum-free  MEM  prior  to  the  addition  of  a  70  µL  aliquot  of  LFS  (      ,  61  mg 
protein/mL), HSA fraction V  (    , 50 mg/mL) or  rHSA (    , 50 mg/mL), as outlined in 
section 2.2.5.1.  An equivalent volume of water was added to the control plates.  After a 
further 3 hours incubation, the percentage of total cellular [
3H]-phospholipids secreted 
into the media (A) and the lyso-PC content of the secreted phospholipids (B) were 
determined,  as  described  in  sections  2.2.5.2  and  2.2.5.3,  respectively.    The  results 
represent the mean ± SEM for 3 separate experiments.  
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2.3.11 Effect of serum and its components on the in vitro generation 
of lyso-phospholipid from a thio-glycerophospholipid 
The  generation  of  lyso-phospholipids  from  1,2-bis-heptanoylthio-
glycerophosphocholine (1,2-bisHGPC) in vitro was also used to assess the presence of 
PLA2-like activity.  Interaction of 1,2-bisHGPC with 5% serum (final concentration) led 
to  the  liberation  of  a  free  thiol  which,  when  reacted  with  a  thiol-sensitive  reagent, 
resulted in the formation of a chromophore proportional to the extent of hydrolysis of 
the phospholipid.  As is evident from Figure 2.27, the addition of 5% serum resulted in 
a  3.5-fold  increase  (p<0.001)  and  there  is  a  linear  relationship  between  serum 
concentration and phospholipid hydrolysis. 
To  further  characterize  the  human  serum  PLA2-like  activity,  the  effect  of  various 
concentrations of the chelating agent ethylene glycol tetraacetic acid (EGTA) on this 
activity  was  appraised  using  the  in  vitro  assay.    The  data  presented  in  Figure  2.28 
confirm the previous observations made using cultured cells (Fig. 2.21) and show that 
the serum PLA2-like activity was markedly reduced by the addition of EGTA and that 
this inhibitory effect was concentration-dependent and significant at a concentration of 
1 mM (p<0.001). Thus the serum PLA2-like activity detected in this assay is clearly 
calcium dependent.  The data presented in Table 2.2 also confirm the observations made 
previously  (Table  2.1)  that  the  serum  PLA2-like  activity  was  not  inhibited  by 
p-bromophenacyl  bromide  (BPB)  (p>0.05),  aristolochic  acid  (ASA)  (p>0.05)  and 
palmitoyl trifluoromethyl ketone (PACOCF3) (p>0.05) when tested in vitro. 
The in vitro effect of LFS, HSA fraction V and recombinant HSA on lysophospholipid 
generation  from  the  thio-glycerophospholipid  was  shown  to  be  analogous  to  their 
effects on the enhanced levels of lyso-PC in the media of cultured cells (Fig. 2.26B).  
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Figure 2.27  Effect of LFS on the generation of lysophospholipids from a thio-
glycerophospholipid in vitro. 
 
1,2-Bis-heptanoylthioglycerophosphocholine (1,2-bisHGPC, 2 mM) dissolved in assay 
buffer  was  incubated  with  the  indicated  concentrations  of  lipoprotein-free  serum  in 
microtiter plates at 25°C for 2 hours.  The PLA2-like enzyme activity results in the 
generation  of  a  free  thiol  on  the  lysophospholipid,  which  is  measured 
spectrophotometrically at 415 nm.  The data represent the mean ± SEM of five separate 
experiments. 
 
 
 
 
 
 
 
 
 
 Chapter 2  Serum and surfactant secretion 
          94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.28  The effect of EGTA concentration on the in vitro PLA2-like activity of 
lipoprotein-free serum. 
 
1,2-bisHGPC  (2  mM)  was  dissolved  in  assay  buffer  containing  the  indicated 
concentrations of EGTA.  A 10 µL aliquot of lipoprotein-free serum was then added 
and incubated in microtiter plates at 25°C for 120 minutes.  Interaction of 1,2-bisHGPC 
with the serum enzyme results in cleavage of the sn-2 fatty acid generating a free thiol 
on  the  lysophospholipid,  which  is  detected  at  a  wavelength  of  415  nm  using  a 
microplate reader. The data represent the mean ± SEM of three separate experiments.  
 
 
 
 
 
 Chapter 2  Serum and surfactant secretion 
          95 
 
 
 
Production of free thiol on 
lysophospholipids 
(absorption at 415 nm) 
 
Control 
 
0.002 ± 0.002 
LFS  0.413 ± 0.023 
LFS  + 10 µM BPB  0.425 ± 0.025 
LFS + 10 µM ASA  0.431 ± 0.014 
LFS + 10 µM PACOCF3  0.414 ± 0.035 
 
 
Table 2.2  Effect of exposure of lipoprotein-free serum to PLA2-specific inhibitors 
on the PLA2 activity determined in vitro. 
 
To 2 mM 1,2-bisHGPC, dissolved in thiol-sensitive reagent, was added 10 µL of human 
lipoprotein-free  serum  (LFS)  with  or  without  the  PLA2-specific  inhibitors 
p-bromophenacyl bromide (BPB), aristolochic acid (ASA) or palmitoyl trifluoromethyl 
ketone (PACOCF3).  The mixtures were then incubated in microtiter plates at 25°C for 
2 hours.  An equivalent volume of water was added to control plates.  The PLA2-like 
enzyme activity present in the LFS results in an enhanced level of free thiol on the 
lysophospholipid, which is measured at a wavelength of 415 nm.  The data represent the 
mean ± SEM of three separate experiments. 
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As is evident from Figure 2.29 rHSA was shown to be as efficient as LFS in stimulating 
the  production  of  the  free  thiol  (5.7-fold  increase  compared  to  control,  p<0.001) 
whereas,  HSA  fraction  V  had  a  smaller  effect  on  the  liberation  of  thio-
lysophospholipids.  
2.3.12 The effect of exposure to BALF from ARDS-patients on lyso-
PC content of the phospholipids secreted by foetal II pneumocytes 
It has been shown that bronchoalveolar lavage fluid (BALF) phospholipase A2 activity 
is increased in human adult respiratory distress syndrome (ARDS) (Kim et al., 1995; 
Arbibe et al., 1997).  In this study increased PLA2-like activity was detected in BALF 
from patients with ARDS.  BALF from patient 1 resulted in an elevated level of lyso-
PC (3.2-fold) whereas when type II pneumocytes were incubated in the presence of 
BALF from patient 2 the media phospholipids showed a much lower increase in the 
lysophosphatidylcholine level (1.4-fold; Table 2.3).  Moreover, this PLA2-like activity 
in  BALF  correlated  positively  with  the  protein  concentration  of  the  BALF.    For 
comparison, the addition of 4 % LFS enhanced the content of lyso-PC in the media by 
4.4-fold.  
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Figure  2.29    Effect  of  LFS,  HSA  fraction  V  (HSA  V)  and  recombinant  HSA 
(rHSA) on the generation of lysophospholipids from a thio-glycerophospholipid in 
vitro. 
 
1,2-bisHGPC  (2  mM)  dissolved  in  assay  buffer  was  incubated  with  10  µL  of  LFS 
(61 mg protein pro/mL) or 10µL of either HSA V and rHSA (50 mg/mL) in microtiter 
plates at 25°C for 2 hours.  The PLA2-like enzyme activity results in an elevation of the 
free thiol on the lysophospholipid, which is measured at 415 nm.  The data represent the 
mean ± SEM of three separate experiments. 
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  Protein concentration in 
BALF  
(mg/mL) 
 
Lyso-PC 
(% of total 
phospholipids) 
 
Control  
 
 
N/A 
 
  5.84 ± 0.37 
 
Patient 1 BALF 
 
2.217 
 
18.66 ± 1.03 
 
 
Patient 2 BALF 
 
0.192 
 
  8.41 ± 0.41 
 
LFS 
 
N/A 
 
25.82 ± 1.19 
 
 
Table  2.3    Effect  of  exposure  to  BALF  from  ARDS  patients  on 
lysophosphatidylcholine (lyso-PC) content of media phospholipids secreted from 
type II pneumocytes. 
 
Aliquots (2 mL) of BALF samples from ARDS patients, as provided by clinicians from 
Sir  Charles  Gairdner  Hospital,  were  lyophilised  and  resuspended  in  500  µL  BSS.  
Foetal type II pneumocytes were isolated and cultured as described in section 2.2.4.  
After  72  hours  in  culture  the  cells  were  incubated  for  a  further  24  hours  with 
[
3H]-choline in serum-free MEM to label cellular phospholipids.  The cells were then 
thoroughly washed with BSS and equilibrated for a further one hour at 37°C in serum-
free MEM.  Duplicate plates were then exposed to 70 µL of resuspended BALF sample.  
Equivalent volumes of water (control) or LFS were added to additional plates.  After a 
further  3  hours  incubation,  the  media  phospholipids  were  extracted  and  the 
lysophosphatidylcholine content determined, as described in section 2.2.5.  The data 
represent the mean ± SEM of two experiments.  
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2.4. Discussion 
Pulmonary  surfactant  is  essential  for  normal  lung  function.    Through  its  ability  to 
adsorb  rapidly  to  the  alveolar  surface  at  an  equilibrium  spreading  pressure  of 
~47 mN.m
-1  (surface  tension  ~23  mN.m
-1)  and  reduce  surface  tension,  surfactant 
increases  lung  compliance,  thereby  reducing  the  work  of  breathing  (Goerke,  1998; 
Perez-Gil and Keough, 1998; Piknova et al., 2002).  The ability of surfactant films to 
attain  surface  pressures  approaching  70  mN.m
-1  (surface  tension  0  mN.m
-1)  during 
dynamic  lateral  compression  stabilises  lung  alveoli  at  end  expiration  by  preventing 
alveolar collapse and counteracting transudation of fluid from interstitial spaces.  The 
essential  role  of  pulmonary  surfactant  in  normal  lung  function  is  illustrated  by  the 
proven efficacy of exogenous surfactant to act as a replacement in the treatment of 
neonatal  respiratory  distress  (NRDS)  (Smyth  et  al.,  1983;  Griese,  1999;  Jobe  and 
Ikegami, 2000; Suresh and Soll, 2002; Amato et al., 2003; Chotigeat et al., 2008).  It is 
also evident that dysfunctional surfactant contributes to the pathophysiology associated 
with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) (Murray 
et al., 1988; Griese, 1999; Maneta-Peyret et al., 2001; Nakos et al., 2001; Panda et al., 
2004).  Although the initiating events leading to ALI and ARDS have been investigated 
in detail, the proximate causes of surfactant dysfunction in these syndromes have not 
been  identified.    Furthermore,  the  effect  of  surfactant  inactivation  on  the  structural 
organization of surfactant at the air-water interface has not been reported (Griese, 1999; 
Piknova et al., 2002).   
Various lung injuries lead to leakage of blood components into the alveolar space. The 
resulting  interference  with  pulmonary  surfactant  functions,  for  example  impaired 
surface activity, has been previously described in both in vivo (Seeger et al., 1985; 
Seeger et al., 1993) and in vitro studies and results from a deficiency of functional Chapter 2  Serum and surfactant secretion 
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surfactant (Holm et al., 1988), which could be reversed by application of hydrophilic 
polymers of surfactant proteins (Zasadzinski et al., 2005).  Extracted bronchial fluid 
(lavage) from ARDS patients shows elevated levels of serum and inflammatory proteins 
(Stephenson et al., 1988; Nakos et al., 1997) and the ratio of soluble proteins to lung 
surfactant in lavage correlates with the severity and outcome of ARDS (Doyle et al., 
1999; Warriner et al., 2002). These observations suggest that serum components have a 
significant adverse effect on pulmonary surfactant function. 
In this study it has been shown that alveolar type II pneumocytes can be isolated from 
foetal rat lungs as relatively homogeneous cell preparations using the method of Dobbs 
et al. (1986b).  Type II pneumocytes, isolated in this way and grown in culture, have 
been shown to increase their rate of secretion of surfactant-associated phospholipids in 
response to the addition of human serum (Figure 2.8).  The effect of serum on the 
development of type II cells has been demonstrated in Scott’s studies (Scott, 1987) and 
serum supplementation of cell cultures has been shown to increase cell propagation of 
foetal rabbit primary cell lines.  In contrast, cultures grown in a serum-free environment 
maintained a constant cell number of approximately 1.0 x 10
4 cells/well and displayed a 
very low level of [
3H]-choline incorporation into disaturated phosphatidylcholine (PC).  
Cell monolayers exposed to 10% charcoal-stripped foetal bovine serum demonstrated a 
relatively constant population density, which was consistently 50% greater than that 
observed in serum-free cultures (Scott, 1987).  In contrast, monolayers exposed to 10% 
foetal bovine serum, which had not been treated with charcoal, exhibited a dramatic 
increase in cell number/well.  At the end of the 6-day period the final cell density 
approached 2.0 x 10
5 cells/well.  Additionally, morphological examination, using light 
microscopy,  revealed  that  the  lamellar-body  ultrastructure  was  more  appropriately 
maintained and that more multivesicular bodies were present in serum-supplemented Chapter 2  Serum and surfactant secretion 
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adult rat cell cultures (Cott et al., 1987).  Since these multivesicular bodies have been 
suggested as being involved in the intracellular transport and assembly of synthetised 
and  endocytosed  surfactant  materials,  the  apparent  increase  in  the  number  of  these 
organelles in cells grown in the presence of serum is an indication that serum influences 
surfactant phospholipid synthesis (Cott et al., 1987). 
Type  II  pneumocytes  express  both  the  classical  Low  Density  Lipoprotein  receptor 
(LDL-R) and High Density Lipoprotein binding protein (HDL-BP).  LDL and HDL 
have been shown to stimulate surfactant secretion in adult rat type II cells and this effect 
can be mimicked by apolipoprotein E (apo-E) and apo-AI, the respective ligands for 
LDL-R and HDL-BP (Voyno-Yesenetskaya et al., 1993).  Increases in phosphoinositide 
hydrolysis, cytosolic free Ca
2+ concentration, and the activity of membrane-associated 
protein kinase C precede LDL- and HDL-stimulated secretion in type II cells suggesting 
that  receptor-stimulated  activity  of  phospholipase  C  is  an  early  event.    Receptor-
stimulated activation of phospholipase C is commonly regulated by guanine nucleotide 
binding proteins (G-proteins).  The observations by Pian and Dobbs (1997) suggest that 
receptor-mediated  activation  of  a  G  protein  is  required  for  the  LDL-  and  HDL 
stimulation of secretion. 
The data presented in Figure 2.9 indicate that, in this study, the secretion of surfactant 
phospholipids  from  foetal  type  II  cells  was  elevated  when  the  HDL-  and  LDL-
containing fractions of human serum were added to the cultures.  However, a much 
greater response was observed (2.8 fold increase) when cultures were exposed to the 
plasma protein-containing fraction, which was devoid of lipoproteins.  Thus, the present 
study suggests that a number of serum components may be responsible for the observed 
stimulation with whole serum (Figure 2.10). Chapter 2  Serum and surfactant secretion 
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A time course of the stimulatory effect of lipoprotein-free serum showed that the level 
of phospholipid secretion depends profoundly upon the duration of exposure to serum.  
Although the rate of phospholipid secretion plateaued after 3 hours of incubation in the 
presence of serum and vehicle, the stimulatory effect of serum was evident at all times, 
even  after  only  30  minutes  exposure  (Figure  2.11).    This  stimulatory  effect  of 
lipoprotein-free  serum  was  shown  to  be  concentration-dependent  with  a  significant 
effect being evident at all concentrations greater than 0.5%.  As with the time course 
study,  the  effect  of  increasing  the  concentration  of  lipoprotein-free  serum  on 
phospholipid secretion gradually plateaued.  
In this context it is relevant that Dobbs and colleagues (1987) have demonstrated that 
surfactant itself plays a role in regulating its own secretion.  Both the lipid components 
and the surfactant-associated proteins (Mr 26,000-36,000; SP-A) inhibit secretion, but to 
different extents (Dobbs et al., 1987).  At a concentration of 100 µg/mL surfactant 
lipids inhibit secretion by approximately 40%.  In contrast, SP-A was shown to be more 
potent  and  inhibited  phospholipid  secretion  at  a  concentration  as  low  as  0.1µg/mL 
(Dobbs et al., 1987).  At a concentration of 1.0 µg/mL, SP-A reduced to basal levels the 
rate of secretion induced by the secretagogues terbutaline, phorbol 12-myristate 13-
acetate and the ionophore A23187 (Dobbs et al., 1987).  As both surfactant lipids and 
SP-A are capable of inhibiting surfactant secretion, it is possible that as these surfactant 
components  accumulate  within  the  media  they  prevent  any  further  secretion,  thus 
accounting for the time course and concentration curves reaching a plateau. 
Another aspect that has became apparent from this study is that the presence of serum in 
the media leads not only to a greater rate of secretion of surfactant phospholipids but 
also  causes  a  5.4-fold  elevation  in  the  lysophosphatidylcholine  content  with  a 
corresponding  decline  in  the  level  of  phosphatidylcholine  (PC)  in  the  media Chapter 2  Serum and surfactant secretion 
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phospholipids (0.77-fold).  Clinical studies have linked an elevated level of lyso-PC in 
BALF with the incidence of ARDS (Gregory et al., 1991; Vadas et al., 1992a; O'Hare et 
al., 1997).  This is supported by another study, which has shown that the intratracheal 
administration of lyso-PC via the airways to near-term newborn rabbits thus resulting in 
an increased level of lyso-PC in the air spaces, interferes with lung function by several 
pathophysiological mechanisms.  These include destabilisation of the alveolar film of 
surfactant phospholipids, direct toxic action on the lung epithelium with increased lung 
permeability and further inactivation of surfactant by plasma proteins leaking into the 
air  spaces  from  areas  of  epithelial  injury  (Grossmann  et  al.,  1999).    However,  the 
mechanism(s) leading to the generation of lyso-PC during lung injury is still unknown.  
A  metabolic  step  in  the  production  of  lyso-PC  involves  phospholipases  A2  (PLA2).  
Arbibe et al. (1998) demonstrated a direct relationship between PLA2 expression and 
acute generation of lysophospholipids and fatty acids.  Administration of LY311727, a 
specific PLA2 inhibitor, reduced by 60% the mass of free fatty acid and lyso-PC content 
in BALF (Arbibe et al., 1998).  A similar pattern was observed after the intratracheal 
administration of recombinant guinea pig PLA2 and was accompanied by a 50-60% loss 
of surfactant phospholipid content, suggesting that surfactant is a major lung target of 
PLA2 (Arbibe et al., 1998).  Recent studies suggest that plasma lipoproteins are a major 
source of PLA2 and, more specifically, that this enzyme activity is physically associated 
with HDL (Petrovic et al., 2001).  In addition, another lipoprotein-associated PLA2, 
which has been characterised as platelet activating factor acetylhydrolase (PAF-AH), 
has been shown to be associated with the low density lipoproteins (LDLs) present in 
plasma under normal physiological conditions (Stremler et al., 1989; Stafforini et al., 
1997).  Chapter 2  Serum and surfactant secretion 
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The current study has demonstrated that the effect of human lipoprotein-free serum 
leads to a much greater elevation of lyso-PC (6.9-fold) in comparison with the effects of 
HDL and LDL on hydrolysis of secreted phospholipids.  This suggests that another 
PLA2-like  enzyme  is  present  in  plasma  and  is  responsible  for  the  deacylation  of 
phosphatidylcholine.    The  current  study  has  demonstrated  that  the  hydrolysis  of 
pulmonary surfactant phosphatidylcholine occurs after the surface-active phospholipid 
material has been secreted (Figure 2.15). 
Phospholipase A2 activity is important for normal lung function, as PLA2 is involved in 
the remodelling of surfactant.  Phosphatidylcholine species containing unsaturated fatty 
acids are hydrolysed by PLA2 and subsequently reacylated with saturated fatty acids by 
acyl-CoA  lysophosphatidylcholine  acyltransferase  (Irvine  and  Dawson,  1979).  
However, several lines of evidence suggest that PLA2 may also be a potent mediator of 
acute lung injury.  Clinical studies have linked the secretory form of PLA2 (sPLA2) with 
lung  inflammation,  since  elevated  levels  of  sPLA2  activity  have  been  found  in  the 
plasma  (Vadas  and  Pruzanski,  1986)  of  patients  with  sepsis  and  pancreatitis,  two 
conditions associated with ARDS.  The products of PLA2 action, namely free fatty acids 
(Hallman  et  al.,  1982)  and  lyso-PC  (Casals  et  al.,  1989;  Arbibe  et  al.,  1998),  are 
elevated in the plasma and BALF of patients with conditions that predispose to ARDS.  
In studies documented by Kim and colleagues (1995), the PLA2 activity in BALF was 
resolved into heparin binding and non-binding activities.  The PLA2 bound to heparin 
was  identified  as  a  secretory  group  of  PLA2  with  approximate  molecular  mass  of 
14 kDa,  while  the  second  PLA2  activity  (non-binding  form)  was  found  to  have  a 
molecular mass of 80-90 kDa.  In the current study, it has been demonstrated that the 
serum PLA2-like activity responsible for the conversion of PC to lyso-PC had quite 
different chromatographic properties to that of the secretory form of PLA2 and did not Chapter 2  Serum and surfactant secretion 
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bind to a heparin column (Figure 2.17).  Moreover, the serum PLA2-like enzyme has an 
almost identical elution profile to that of albumin after passage through a Bio-Gel P-60 
column (Figure 2.19), suggesting that its molecular weight is similar to that of albumin, 
that is 66 kDa. 
On the basis of previous findings, it was considered that the unidentified enzyme(s) 
might be separable from other serum components using ion-exchange chromatography, 
which relies on charge-charge interactions between the proteins and the immobilized 
charges on the resin.  The PLA2 activity of lipoprotein-free serum again co-elutes with 
albumin  and  its  elution  is  significantly  different  from  the  secretory  form  of  PLA2 
(Fig. 2.20A and B).  This finding showed that this separation technique was not suitable 
for  the  purification  of  the  enzyme  and  alternative  purification  techniques  were 
evaluated.  Figure 2.21 clearly demonstrates that the serum PLA2-like enzyme activity 
is  calcium-dependent,  as  was  the  secretory  form  of  PLA2  isolated  from  erythrocyte 
membranes of sheep (Kramer et al., 1978), rabbit (Kim et al., 1991), rat (Aarsman et 
al., 1985) and human (Kramer et al., 1989), as well as human platelets and synovial 
fluid (Kramer et al., 1986; Reynolds et al., 1992).  Thus, in this respect, it has a similar 
attribute to that of the secretory PLA2 family, however, the above-mentioned findings 
revealed that it is distinct and does not belong to this group.  Furthermore, the serum 
PLA2-like  activity  is  neither  inhibited  by  4-bromo-phenacyl  bromide  (Longo  et  al., 
1999) nor aristolochic acid (Vondran et al., 1997), both of which have previously been 
reported to inhibit the calcium-dependent secretory form of PLA2 (Table 2.1). 
Albumin is the most abundant serum protein accounting for 55-60% of the total protein. 
In humans, it consists of a single polypeptide chain of 585 amino acids with a molecular 
weight  of  66  kDa  (Peters,  1996c).    It  is  produced  in  the  liver  and  has  numerous 
functions in the body, the most important of which is maintaining intravascular colloid Chapter 2  Serum and surfactant secretion 
          106 
osmotic pressure thus preventing water leaking from the vasculature into the interstitial 
fluid.    The  structure  of  the  albumin  molecule  is  such  that  it  can  incorporate  many 
different substances.  It is a flexible molecule, and bound compounds can be buried 
within  the  structure.    Most  strongly  bound  are  medium  sized  hydrophobic  organic 
anions, including long-chain fatty acids, bilirubin and haematin.  Less hydrophobic and 
smaller substances are bound specifically but with lower affinity, such as ascorbate or 
D-tryptophan  (Peters,  1996a).    Other  endogenous  compounds  that  bind  to  albumin 
include  bile  acids,  eicosanoids,  copper,  zinc,  calcium,  magnesium,  folate  and 
aquacobalamin.  Albumin is also a secondary or tertiary carrier for some substances that 
have specific binding proteins, for example, steroids, vitamin D and thyroxine (Peters, 
1996a).  Apart from its vital role in transporting endogenous compounds and drugs, 
albumin is also involved in the metabolism of endogenous substances such as lipids and 
eicosanoids, because of the avidity with which these compounds bind to albumin.  For 
instance, lipoprotein lipase activity in adipose tissue is influenced by the avidity with 
which fatty acids, freed from lipids in fat stores, bind to available albumin (Peters, 
1996b).    Under  physiological  conditions,  albumin  also  has  a  significant  antioxidant 
potential.    It  has  been  shown  that  physiological  solutions  of  human  serum  albumin 
inhibit the production of oxygen free radicals by polymorphonuclear leukocytes (Holt et 
al., 1984). This may be related to the abundance of sulfhydryl (-SH) groups on the 
albumin  molecule.    These  are  important  scavengers  of  oxidising  agents,  such  as 
hypochlorous  acid  (HOCL)  formed  from  the  enzyme  myeloperoxidase,  which  is 
released by activated neutrophilis (Hoye et al., 1972; Tullis, 1977).  Studies by Giles 
and Czuprynski  (2003) have shown that serum albumin has an inhibitory effect upon 
Blastomyces dermatitidis.  Blastomycosis occurs following inhalation of B. dermatitidis 
conidia, which changes into a pathogenic yeast form in the lungs resulting in pulmonary Chapter 2  Serum and surfactant secretion 
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infection,  which  leads  to  disseminated  lung  disease.    However,  the  most  important 
function of albumin is associated with the maintenance of intravascular colloid osmotic 
pressure (COP).  COP ensures fluid stays within the vasculature instead of leaking into 
the  interstitial  fluid.    Conversely,  an  increase  in  serum  COP  increases  the  osmotic 
gradient in the serum so that fluid drifts from the interstitial fluid into the intravascular 
space, promoting drier lungs in patients in shock, which predisposes them to pulmonary 
edema  and  acute  respiratory  distress  syndrome.    Leaking  capillaries  and  pulmonary 
edema  severely  injure  the  lung,  which  leads  to  respiratory  failure  (Call,  2005).  
Biophysical studies of lung surfactant deliberately mixed with serum proteins showed 
that  albumin,  at  sufficiently  high  concentration,  inactivated  the  surface  activity  of 
replacement lung surfactant by competitive adsorption, which reduce or block the entry 
of active surfactant components into the air-water interface (Holm et al., 1985; Mbagwu 
et al., 1999; Warriner et al., 2002).  
The  current  study  has  demonstrated  for  the  first  time  that  albumin  leads  to  both 
increased secretion of pulmonary surfactant phospholipids from type II cells and to an 
elevation in the lyso-PC content of the media phospholipids (Figure 2.23).  The latter 
implies  that  human  serum  albumin  has  associated  PLA2-like  activity,  which  is  in 
agreement  with  previous  findings  that  reported  an  association  between  serum  PLA2 
activity and several commercially-available albumin preparations (Elsbach and Pettis, 
1973; Etienne et al., 1980).  A study by Langton and Dench (1991) confirmed this 
association by demonstrating that, whereas a single zone of PLA2 activity was detected 
when purified human PLA2 was subjected to agarose electrophoresis, an additional zone 
of  PLA2  activity  was  observed  when  the  purified  enzyme  was  mixed  with  serum 
albumin (fraction V) prior to electrophoresis.  This additional zone of PLA2 activity 
corresponded to the position of migration of the albumin. Furthermore, when serum Chapter 2  Serum and surfactant secretion 
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from  acute  pancreatitis  patients,  which  had  elevated  levels  of  PLA2  activity,  was 
subjected  to  ultrafiltration  the  PLA2  activity  did  not  completely  separate  from  the 
albumin-containing  fraction  (as  would  be  expected  from  the  difference  in  their 
molecular weights).  This led Langton and Dench (1991) to suggest that, by binding 
PLA2, albumin might provide a protective “buffer” against small increases in PLA2.  
Elsbach and Pettis (1973) suggested that this interaction between PLA2 and albumin is 
likely to involve hydrophobic binding. 
In a recent review, Kragh-Hansen et al. (2002) pointed out that human serum albumin 
has been attributed with a number of enzymatic activities, including an esterase activity.  
Given that PLA2 is an esterase activity, although with a different substrate specificity to 
that  of  general  esterases,  it  would  appear  reasonable  to  suggest  that  human  serum 
albumin might possess a PLA2 activity.  However, Chapuis et al. (2001) have suggested 
that the esterase-like activity of human serum albumin is likely to be the result of it 
being contaminated with cholinesterase, as is evident from the fact that the two proteins 
can be separated using affinity chromatography.  Thus, before arguing that a particular 
enzymatic activity is an intrinsic activity of albumin, one needs to be convinced that the 
activity detected is not the result of contamination.  
On the basis of our previous findings, it was hypothesised that recombinant human 
albumin  (rHSA)  would  be  devoid  of  PLA2-like  activity  as  it  is  produced  using  a 
mammalian cell line grown under conditions devoid of any human- or animal-derived 
serum and is therefore not likely to be bound with PLA2.  However, the present study 
has revealed that exposure of type II pneumocytes to rHSA also stimulates the secretion 
of phospholipids and is almost as effective as lipoprotein-free serum in enhancing the 
level of lyso-PC in the media (Fig. 2.26A and B).  The latter observation implies that 
rHSA is able to directly generate lyso-PC and suggests that the PLA2 may be an innate Chapter 2  Serum and surfactant secretion 
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activity of albumin.  Such a proposal is supported by the results obtained using the in 
vitro assay, which revealed that the rate of thio-glycerophospholipid hydrolysis was 
elevated upon addition of rHSA (Figure 2.29).  Although this study has convincingly 
shown  that  albumin  significantly  enhances  both  the  rate  of  secretion  of  surfactant 
phospholipids  from  type  II  pneumocytes  and  hydrolysis  of  phosphatidylcholine  to 
lysophosphatidylcholine, it remains to be firmly established whether the latter effect is 
the result of an intrinsic activity of albumin or is the consequence of the albumin having 
previously bound PLA2.  
In  summary,  although  inhibition  of  pulmonary  surfactant  by  albumin  has  been  the 
subject of numerous studies and albumin has been shown to competitively interfere with 
the  generation  of  a  phospholipid  film  at  the  air:  liquid  interface  (Zuo  et  al.,  2008; 
Zasadzinski  et  al.,  2010;  Sarrasague  et  al.,  2011),  the  mechanism(s)  by  which  this 
protein inactivates surfactant lipids remains controversial. Our observation that serum 
contains an albumin-associated PLA2-like activity, which leads to the accumulation of 
lyso-PC in secreted surfactant phospholipids, may be another attribute of albumin that 
contributes  to  the  development  of  ARDS  and  the  reduced  efficacy  of  exogenous 
surfactants that is known to occur in the treatment of this condition. 
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3.1  Introduction 
 
It is nearly 40 years since Liggins and Howie (1972) first reported the maturational 
benefits of antenatal corticosteroid treatment of mothers at risk of preterm delivery.  
Administration of betamethasone to the mothers for 24 hours prior to delivery resulted 
in a decreased rate of mortality (3.2%) as compared to controls (15%).  Since then, 
many  studies  have  reported  on  the  clinical  benefits  of  antenatal  corticosteroid 
administration in the prevention of RDS.  Crowley in association with the Cochrane 
Collaboration  reviewed  15  randomised  trails  conducted  between  1972-1994,  and 
concluded that  antenatal corticosteroids, given  between  48  hours  and  7  days  before 
preterm  delivery,  significantly  decreased  the  incidence  of  RDS,  intraventricular 
haemorrhage, and infant death (Crowley, 1995).  Moreover, cytokines and chemokines, 
important markers and mediators of inflammation, have been suggested to play a crucial 
role in the development of chronic lung disease of prematurity (Ozdemir et al., 1997).  
Studies of bronchioalveolar lavage fluid (BALF) from preterm infants have shown that 
the  high  levels  of  cytokines  and  chemokines,  that  are  present  at  this  stage,  can  be 
suppressed by dexamethasone treatment (Waisman et al., 1998).  After treatment with 
glucocorticoids the number of inflammatory cells also significantly decrease.  Another 
study of patients with adult respiratory distress syndrome had also shown evidence of 
biological efficacy for prolonged glucocorticoid supplementation (Meduri et al., 2003). 
Another important mechanism by which glucocorticoids stimulate lung maturation is 
via  enhancement  of  developmental  structural  changes.    Antenatal  corticosteroid 
treatment stimulated cellular differentiation and caused maturation of the pulmonary 
epithelial cells (Torday, 1990; Vyas and Kotecha, 1997; Morrison and Orgeig, 2009) 
and  volume  density  by  stimulating  the  morphological  appearance  of  type  II Chapter 3  Glucocorticoids and lung development 
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pneumocytes (Odom et al., 1988).  A possible mechanism to explain glucocorticoid-
enhanced  differentiation  of  lung  cells  is  through  inhibition  of  DNA  synthesis,  as 
measured by a decreased rate of thymidine incorporation into DNA (Massaro et al., 
1985).  Inhibition of DNA synthesis not only leads to inhibition of cell proliferation but 
is  also  considered  to  induce  a  stimulation  of  cell  differentiation.    This  effect  of 
glucocorticoids may be the result of an increase in the activity of aminopeptidase N, a 
factor that regulates cell growth and differentiation (Tangada et al., 1995).  Besides cell 
maturation, glucocorticoids also cause other structural changes in the developing lung.  
For instance, in the later stages of intrauterine lung development the thinning of both the 
alveolar wall and septa, combined with vascular changes, is important in permitting an 
effective  gas  exchange  system  to  develop.  Glucocorticoids  cause  a  decrease  in  the 
interstitial tissues of the lung with a consequent decrease in alveolar wall thickness, thus 
facilitating gas-exchange after birth (Pinkerton et al., 1997).  Apart from the ability of 
glucocorticoids to suppress an inflammatory response and to stimulate lung maturation, 
their major clinical effect is to markedly stimulate surfactant synthesis. In studies with 
foetal  human  and  rat  lung,  dexamethasone  has  a  pronounced  dose-dependent 
stimulatory effect on the level of SP-B and SP-C mRNA (Liley et al., 1989; Samtani et 
al., 2006) and a concomitant inhibitory effect on SP-A gene expression (Odom et al., 
1988).    These  results  have  been  attributed  to  the  possible  biphasic  effect  of 
glucocorticoids  observed  in  vitro  where  low  concentrations  (e.g.  1  nM)  produce 
stimulation,  whereas  higher  concentrations  (e.g.  100 nM)  cause  an  inhibitory  effect.  
Dexamethasone  inhibition  is  blocked  by  the  glucocorticoid  antagonist,  RU-486, 
suggesting a role for the glucocorticoid receptor in dexamethasone inhibition of the 
SP-A  promoter  activity  (Alcorn  et  al.,  2004).    Interestingly,  the  enhanced  rate  of 
synthesis of surfactant phospholipids in response to glucocorticoids is not the result of a Chapter 3  Glucocorticoids and lung development 
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direct interaction of the steroid with type II pneumocytes, despite the fact that these 
cells are able to specifically bind to the steroid (Ballard, 1989).  Rather, the response to 
glucocorticoids is dependent on the production by lung fibroblasts of a low molecular 
weight protein, fibroblast-pneumocyte factor (FPF), which then specifically stimulates 
surfactant synthesis in type II alveolar cells in vitro (Smith, 1978; Post and Smith, 1984; 
Post et al., 1984b; Post et al., 1986) and accelerates lung maturation in vivo (Smith, 
1979).  This was originally suggested by the observation that cultures of enriched type 
II pneumocytes respond minimally to glucocorticoids (Smith, 1978) when compared 
with cultures consisting of a mixed monolayer of both type II pneumocytes and lung 
fibroblasts (Smith, 1978; Floros et al., 1985; Post et al., 1986; Scott and Das, 1993; 
Shannon  et  al.,  2001).    In  early  in  vivo  studies  of  the  effect  of  glucocorticoid 
administration  on  maturation  of  the  rabbit  foetal  lung,  Farrel  and  Zachman  (1973) 
observed  an  enhanced  rate  of  synthesis  of  phosphatidylcholine,  an  effect  that  was 
blocked by prior administration of cycloheximide but not actinomycin D, leading these 
authors to conclude that the steroid exerted its effect at the translational level.  Later, 
Gross  et  al.  (1983)  and  Floros  et  al.  (1985)  observed  an  inhibition  of  the 
dexamethasone-induced stimulation of surfactant lipid synthesis by both actinomycin D 
and cycloheximide and concluded that both RNA and protein synthesis are required for 
the glucocorticoid effect.  These results suggest that cortisol induces in lung fibroblasts 
an  enhanced  de novo  synthesis  of  fibroblast-pneumocyte  factor  mRNA  and  a 
consequent increase in the synthesis of the fibroblast-pneumocyte factor protein.  In 
summary, fibroblasts are the primary site of glucocorticoid action, producing fibroblast-
pneumocyte factor (FPF), which subsequently stimulates surfactant synthesis by type II 
pneumocytes.    This  production  of  FPF  by  fibroblasts  appears  to  be  organ  specific 
(Smith, 1978) but not species specific (Smith, 1981) and is only produced during a Chapter 3  Glucocorticoids and lung development 
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discrete period of gestation (Torday, 1984; Ballard, 1989). In mid-gestation, cultured 
human  lung  fibroblasts  responded  with  enhanced  growth  when  exposed  to 
glucocorticoids, whereas those cultured from larynx, trachea, esophagus and skin are 
inhibited by similar treatment (Smith et al., 1973).  There is also evidence that such 
steroids have a stimulatory effect on foetal pulmonary cellular growth in early gestation 
but enhance maturation and slow growth as term approaches (Smith et al., 1974).  It is 
relevant that the concentration of glucocorticoid in the foetal plasma rises just prior to 
the prenatal increase in surfactant synthesis (Kitterman et al., 1981).  The decrease in 
surfactant  in  rats  treated  with  metyrapone,  an  11β-hydroxylase  inhibitor  that  blocks 
cortisol production, suggests an important role for endogenous cortisol in stimulating 
surfactant  production  (Sosenko  et  al.,  1986).    The  generation  of  FPF  is  absolutely 
dependent on the presence of glucocorticoids (Smith, 1978) and it has been shown that 
the production of FPF in response to glucocorticoids is greater in fibroblasts derived 
from  female  animals  (Torday,  1984),  suggesting  a  sex-linked  modulation  of  the 
response.    The  production  of  FPF  by  foetal  lung  fibroblasts  has  been  shown  to  be 
maximal just prior to the onset of lung maturation (Smith et al., 1974) and biochemical 
activity of FPF has been detected in human amniotic fluid collected at 27-40 weeks of 
gestation (Seybold and Smith, 1980).  It has been demonstrated that the stimulatory 
effect of fibroblast-pneumocyte factor on phosphatidylcholine formation by foetal type 
II pneumocytes is mediated by an increased conversion of choline phosphate into CDP 
choline, a reaction catalysed by phosphocholine cytidylyltransferase (Post et al., 1986). 
However, since the composition of surfactant lipids is not altered when type II cells are 
stimulated  by  FPF  (Post  and  Smith,  1984)  it  would  appear  that  the  peptide  has  a 
generalised effect on surfactant lipid synthesis.   Chapter 3  Glucocorticoids and lung development 
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The  multiple  physiological  effects  of  glucocorticoids  are  mediated  through  the 
activation  of  a  unique  intracellular,  predominately  cytoplasmic  receptor,  termed  the 
glucocorticoid receptor (GR) (Ballard and Ballard, 1974; Pujols et al., 2002).  This 
receptor binds to glucocorticoids with an exceptionally high affinity and specificity.  It 
has been demonstrated that “knockout” mice congenitally deficient in GR (Cole et al., 
1995) and rats treated in utero with a glucocorticoid antagonist (Guettari et al., 1990) 
exhibit lethal lung immaturity at birth.  The cellular GR concentration is considered to 
be  a  limiting  factor  in  this  signal  transduction  pathway  and  the  cellular  and 
transcriptional sensitivity to glucocorticoids is directly proportional to the cellular GR 
concentration (Okret et al., 1991; Oakley and Cidlowski, 1993).  It is therefore expected 
that regulation or modulation of the GR level might have a marked effect upon lung 
maturation.   
Glucocorticoids have also been shown to induce an increase in the level of β-adrenergic 
receptors both in vivo (Barnes and Karliner, 1982) and in organ cultures of foetal lung 
cells  (Giannopoulos  and  Sommers  Smith,  1982).    In  order  to  exert  their  effect, 
glucocorticoids enter the cell and bind to the cytoplasmic glucocorticoid receptor, which 
upon being bound to the steroid then translocates to the nucleus, where the steroid-
receptor  complex  binds  to  glucocorticoid  response  elements  upstream  from  the 
promoter region of the β-adrenoreceptor gene, resulting in an increased transcription 
and thus increased synthesis of the β-adrenergic receptor (Van der Velden, 1998).  It is 
relevant that previous in vitro (Smith, 1977) and in vivo (Rasmusson et al., 1988b; 
Kudlacz and Soltkin, 1990) studies of the foetal lung have shown that β-adrenergic 
agents enhance the rate of surfactant secretion from type II cells.  Furthermore, it has 
been  shown  using  cultured  cell  lines  that  an  increase  in  the  level  of  β-adrenergic Chapter 3  Glucocorticoids and lung development 
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receptors  strongly  correlates  with  an  increased  efficacy  of  β-agonists  in  stimulating 
surfactant secretion (Dobbs and Mason, 1979; Rasmusson et al., 1988a). 
A  number  of  clinical  trials  have  shown  that  male  infants  do  not  respond  to 
glucocorticoid treatment as well as females of the same gestational age (Papageorgiou 
et al., 1981; Perelman et al., 1986).  The present study tested the hypotheses that this 
sex-specific  difference  might  be  due  to  (1)  a  diminished  level  of  glucocorticoid 
receptors,  (2)  a  reduced  production  of  FPF  by  lung  fibroblasts  in  response  to 
glucocorticoids,  (3)  a  lower  ability  of  FPF  to  enhance  the  activity  of  β-adrenergic 
receptors  in  type  II  cells  or  (4)  a  reduced  capacity  of  type  II  cells  to  respond  to 
β-agonists when the cells are derived from the lungs of male foetuses.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3  Glucocorticoids and lung development 
      116 
3.2 Materials and Methods 
3.2.1 Animals 
Nineteen-day  pregnant  rats  of  the  Wistar  albino  strain  of  Rattus  norvegicus  were 
obtained from the Animal Resource Centre, Western Australia.  Gestational age was 
determined  as  detailed  in  section  2.2.1.    Sex  of  the  foetuses  was  determined  by 
differences in the external genitalia, which can be recognised on day 17 of gestation.  
The small oval urogenital orifice is larger in males than in females and the genital 
swellings are better developed in males.  Also, the distance between the rectum and the 
urogenital sinus is greater in male rat foetuses.  The testicles from randomly selected 
male foetuses were then collected and the specimens were analysed in the Murdoch 
University Histopathology Laboratory.  A photomicrograph of a 19-day foetal male 
testicle is shown in Figure 3.1. 
3.2.2 Materials 
Many of the reagents used, particularly those used in the isolation and culture of type II 
pneumocytes,  have  been  listed  in  section  2.2.2.    In  addition,  [1,2,4,6,7-
3H]-
dexamethasone  (70-110  Ci/mmol)  and  1-[4,6-propyl-
3H]dihydroalprenolol 
(96 Ci/mmol)  were  purchased  from  the  Radiochemical  Centre,  Amersham, 
Buckinghamshire, UK.  Cytochrome C, cyanocobalamin, insulin (chain B, oxidised), 
aprotinin, ()-isoproterenol hydrochloride, ICI 118551 ((±)-1-[2,3-(dihydro-7-methyl-
1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol  hydrochloride),  CGP  20712A 
((±)-2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl] 
phenoxy]propyl]  amino]ethoxy]-benzamidemethane-sulfonate  salt)  were  products  of 
Sigma Chemicals, St Louis, Missouri, USA.  Acetic acid and propylene glycol were  
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Figure 3.1  Photomicrograph of a foetal rat testicle. 
 
Reproductive tissue from a foetal rat designated as a male was microscopically analysed 
using a Zeiss photomicroscope III after staining with haematoxylin/eosin.  The above 
photomicrograph established that it was, indeed, testicular tissue. 
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purchased  from  Ajax  Chemicals,  Auburn,  New  South  Wales,  Australia.    Aldrich 
Chemical Co., Milkwaukee, USA supplied the 3,5-diaminobenzoic acid and ascorbic 
acid  was  obtained  from  BDH  Chemicals,  Port  Fairy,  Victoria,  Australia.  
Phenylmethylsulphonyl fluoride was a product of Calbiochem-Behring Pty Ltd, New 
South Wales, Australia.  Finally, GF/A glass-fibre filters were obtained from Whatman 
Ltd, Maidstone, UK.  
3.2.3 Methods 
3.2.3.1 Isolation of lung fibroblasts 
The procedures for the preparation of materials for cell culture, isolation of type II 
pneumocytes and their subsequent growth in culture were as detailed in section 2.2.4.  
Lung fibroblast cultures were prepared in a slightly different manner.  Briefly, after the 
lung cells were isolated and resuspended in MEM+ pre-warmed to 37°C (2 lungs per 
mL), the cells were plated (6 lungs per plate) onto 60 mm diameter 3002 tissue culture 
plates  (Falcon  Labware,  Becton  Dickinson,  Lincoln  Park,  New  Jersey,  USA)  and 
incubated for 30 minutes at 37°C in a humidified water-jacketed CO2 incubator.  After 
incubation, the non-adhering cells were brought into suspension by gently swirling the 
culture  dish.    These  non-adhering  cells  were  used  for  the  preparation  of  type  II 
pneumocyte cultures as detailed in section 2.2.4.  The adhering cells were supplemented 
with Eagle’s MEM containing 10% charcoal-treated newborn calf serum and grown for 
15 days, by which time they yielded confluent fibroblast cultures without any trace of 
pneumocytes.    A  photomicrograph  of  a  typical  fibroblast  culture  after  15  days  of 
incubation is shown in Figure 3.2. 
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Figure  3.2  Phase  contrast  photomicrograph  of  a  typical  19-day  foetal  type  II 
pneumocyte culture 
 
Pulmonary fibroblast were isolated from 19-day foetal rats and cultured as described in 
section 3.2.3.1.  A phase contrast photomicrograph was taken after 15 days of culture 
using a Kodak Ektachrome 160 tungsten film in an Olympus Model OM-2 camera, 
under  conditions  established  using  an  Olympus  Model  IMP-2  inverted  phase 
microscope.    The  overall  magnification  (including  photographic  enlargement)  was 
x 760.  
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3.2.3.2 Preparation and use of fibroblast-conditioned media 
Lung fibroblast cultures were maintained for 15 days in MEM supplemented with 10% 
charcoal-treated newborn calf serum, by which time they were near confluent.  At this 
time, the fibroblast cultures were washed twice with 2 mL BSS and the media changed 
to  1.7  mL  of  serum-free  MEM  to  which  was  added  100 nM dexamethasone  (final 
concentration).   Control  plates were  established by  adding  an  equivalent volume of 
vehicle  (propylene  glycol)  to  the  serum-free  MEM.    After  a  24-hour  exposure,  the 
media were collected and stored in sterile screw-capped tubes at -80ºC.  At the time of 
use, the conditioned media were thawed, heated at 65ºC for 1 hour (to reduce inhibitory 
activity), filter sterilised using a 0.22 µm Millipore GS filter and diluted 1:4 with serum-
free MEM supplemented with the appropriate additive (either 100 nM dexamethasone 
or propylene glycol).  Aliquots of the diluted media (3 mL) were then applied to type II 
pneumocyte  cultures  for  21  hours  to  test  for  the  effect  on  the  rate  of  disaturated 
phosphatidylcholine synthesis.  
 
3.2.3.3 Determination of phosphatidylcholine synthesis 
After the type II pneumocytes had been exposed for 21 hours to fibroblast-conditioned 
media,  a  further  0.5  mL  of  serum-free  MEM  containing  7  µCi  [methyl-
3H]-choline 
chloride was added to each plate and the incubation continued for a further 6 hours.  
The medium from each plate was then removed and discarded.  The cells were then 
washed twice with BSS (1 mL) and harvested using a polyethylene scraper into BSS.  
The cells were sedimented by centrifugation at 1000g (2100 rpm) for 2 minutes, and the 
supernatant removed.  The cells were re-suspended in 400 µL of BSS and sonicated in a 
Braunsonic  1510  sonicator  (B.Braun,  Melsungen,  AG),  which  was  fitted  with  a Chapter 3  Glucocorticoids and lung development 
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microprobe, at 25 watts for 10 seconds.  Duplicate aliquots of 50 µL were taken for 
DNA estimation and a further of 200 µL was subjected for lipid extraction and analysis. 
Specifically, the cellular extract was transferred into a glass screw-capped tube and 
2 mL of methanol, 1 mL of chloroform and 0.6 mL of BSS were added.  To increase the 
amount of radioactive lipid recovered, carrier phosphatidylcholine (20 µL, 2.5 mg / mL 
chloroform)  was  added.    A  tracer  amount  (approx.  10,000  dpm)  of  1,2 di [1-
14C]-
palmitoyl L-3 phosphatidylcholine was also added as a recovery standard to the cellular 
extract prior to extracting the lipids.  The tubes were then thoroughly vortexed and 
incubated for 10 minutes at room temperature.  Subsequently, 1 mL of chloroform and 
1 mL  of  water  were  added  at  ten-minute  intervals  with  intervening  mixing.    The 
resultant mixture was then left to settle at 4ºC overnight.  The following day aliquots 
(400 µL) of the bottom (chloroform) layer of each tube were transferred to polyethylene 
counting vials.  The lipid extracts were dried and then counted in a Beckman LS 6500 
Liquid  Scintillation  counter  (Beckman  Instruments  Nuclear  Division,  Fullerton,  CA, 
USA)  after  the  addition  of  3  mL  of  Optiphase  “HiSafe”II  scintillant.  
Phosphatidylcholine synthesis was expressed as dpm / µg DNA. 
3.2.3.4 Heat treatment of fibroblast-conditioned media 
Aliquots (1.7 mL) of serum-free MEM, previously conditioned by fibroblasts in the 
presence of 100 nM of dexamethasone or an equivalent volume of propylene glycol, 
were separately pre-incubated for 1 hour at 60, 65, 70, 75, 80 and 100ºC.  The media 
were then filter sterilised and diluted 1:4 with serum-free MEM supplemented with the 
appropriate  additive  (either  100  nM  dexamethasone  or  propylene  glycol)  and 
immediately assayed for their ability to stimulate the phospholipid synthesis in cultured 
type  II  pneumocytes  (see  section  3.2.3.3).  The  effect  of  heat  treatment  of  FCM  at Chapter 3  Glucocorticoids and lung development 
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various temperatures on its ability to induce elevated level of DSPC synthesis in type II 
pneumocytes is shown in Figure 3.3. 
3.2.3.5 Partial purification of fibroblast-conditioned media 
A BioGel P-30 chromatography column (120 x 1.6 cm) was equilibrated with 1 M 
acetic acid at a flow rate of 2 mL/h using a Gilson Minipuls 2 peristaltic pump (Gilson 
Medical Electronics, Villiers le Bel, France).  An aliquot of 20 mL of serum-free MEM, 
previously conditioned by fibroblasts in the presence of 100 nM dexamethasone (as 
described in section 3.2.3.2), was lyophilised, resuspended in 2 mL of elution buffer 
(1 M acetic acid) and applied to the BioGel P-30 chromatography column.  Fractions 
(2 mL) were collected using a Bio-Rad fraction collector (Model 2110).  Each fraction 
was tested for protein content, by measuring the absorbance at 280 nm in a Beckman 
DU-50  spectrophotometer  (Beckman  Instruments,  Palo  Alto,  CA,  USA).    After 
lyophilization, the fractions were redissolved in 0.1 M HCl, and neutralised with 0.1 M 
NaOH  and  analysed  for  their  ability  to  stimulate  synthesis  of  surfactant  lipids  (as 
detailed  in  section  3.2.3.3)  when  directly  applied  to  cultured,  foetal  rat  type  II 
pneumocytes.  To estimate the molecular weight of the partially purified stimulatory 
factor (fibroblast pneumocyte factor) standards, of various molecular weights, were also 
subjected to chromatography on the same column. 
3.2.3.6 Determination of glucocorticoid receptor levels in rat foetal 
lung 
3.2.3.6.1 Preparation of cytosol 
Foetal lungs were removed and homogenised in 2 volumes of ice-cold homogenisation 
buffer (50 mM Tris-HCl, 0.25 M sucrose, 3 mM MgCl2, 10 mM Na2MoO4, 2 mM 
dithiothreitol, pH 7.6).  Aliquots (175 µL) of this mixture were transferred into Airfuge  Chapter 3  Glucocorticoids and lung development 
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Figure 3.3    Effect of  heat  treatment of  fibroblast-conditioned  media at  various 
temperatures  on  its  ability  to  induce  elevated  levels  of  surfactant  phospholipid 
synthesis in type II pneumocytes. 
 
Primary cultures of lung fibroblasts were grown to confluence, and then incubated for 
24 hours  with  serum-free  MEM  with  (test),  or  without  (control),  100  nM 
dexamethasone.    The  media  were  then  collected  and  heated  at  the  indicated 
temperatures for 1 hour.  They were then diluted 1:4 with serum-free MEM with the 
corresponding concentration of dexamethasone.  The conditioned medium containing 
dexamethasone was then tested for its ability to stimulate phospholipid synthesis in type 
II  pneumocytes  above  that  of  cells  exposed  to  conditioned  medium  without 
dexamethasone  (see  Section  3.2.3.3).    The  data  represent  the  mean  ±  SEM  of  six 
independent determinations.  
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tubes.  The homogenate was then centrifuged at 29 psi for 12 minutes at 4ºC in a 
Beckman  L5-50  Airfuge  (Beckman  Instruments,  Palo  Alto,  CA,  USA)  and,  after 
discarding the upper lipid layer, the cytosol was removed for receptor assay. 
Cultured cells (type II pneumocytes and lung fibroblasts) were washed twice with 1 mL 
BSS, harvested into BSS using a polyethylene scraper and collected by centrifugation 
for  2  minutes  at  1000g  (2100  rpm)  in  a  GRP  Beckman  centrifuge  (Beckman 
Instruments, Palo Alto, CA, USA) at 4ºC.  The cell pellet was resuspended in 5 volumes 
of ice-cold homogenisation buffer (50 mM Tris-HCl, 0.25 M sucrose, 3 mM MgCl2, 
10 mM Na2MoO4, 2 mM dithiothreitol, pH 7.6) and sonicated in a Braunsonic 1510 
sonicator (B.Braun, Melsungen, AG) equipped with a microprobe at an output power of 
25 watts for 10 seconds.  Duplicate 10 µL aliquots were taken for DNA estimation and 
the remaining homogenate was then centrifuged at 29 psi for 12 minutes at 4ºC in a 
Beckman  L5-50  Airfuge  (Beckman  Instruments,  Palo  Alto,  CA,  USA)  to  prepare 
cytosol.  
3.2.3.6.2 Determination of glucocorticoid receptor activity 
An  aliquot  of  the  cytosol  (100  µL)  was  incubated  with  25  µL  of  300  nM 
[
3H]-dexamethasone in the presence of 25 µL of 0.3 mM of unlabeled dexamethasone 
or  an  equivalent  volume  of  vehicle  (propylene  glycol).    The  resulting  mixture  was 
incubated on ice for three hours with occasional mixing.  Subsequent estimation of 
protein-bound radioactivity was made using the hydroxylapatite method of Pavlik and 
Coulson (1976).  To the incubation mixture 300 µL of a 10% slurry of hydroxylapatite 
was added and the mixture incubated on ice for a further 45 minutes with occasional 
mixing.  Homogenisation buffer (2 mL) was added and, after mixing, the samples were 
centrifuged at 1000g (2100 rpm) for 5 minutes at 4ºC.  The pellet was washed twice by Chapter 3  Glucocorticoids and lung development 
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resuspending in 2 mL of buffer followed by centrifugation prior to directly counting the 
hydroxylapatite by resuspending it in 3 mL of Optiphase “HiSafe” II scintillant. 
Specific receptor binding, expressed as fmole [
3H]-dexamethasone bound/µg DNA, was 
determined  by  subtracting  the  dpm  bound  in  the  presence  of  excess  unlabelled 
dexamethasone (non-specific binding) from dpm bound in its absence (total binding). 
As is evident in Table 3.1 all cytosol preparations need to be assayed fresh as frozen 
cytosol  showed  a  substantial  loss  of  glucocorticoid  receptor  activity  in  type  II 
pneumocytes.    The  data  presented  in  Table  3.2  shows  that  there  is  a  significant 
difference in glucocorticoid receptor activity in adult and in 19-day foetal lung extracts. 
3.2.3.7 Fluorometric assay of DNA 
The duplicate 10 and 50 µL aliquots of the cellular extracts (from the glucocorticoid 
receptor  and  DSPC  synthesis  assays,  respectively)  were  dried  in  an  oven  at  50ºC.  
Highly-polymerised calf thymus DNA was dissolved in water to a concentration of 
0.1 mg/mL and standards prepared in duplicate containing 0, 2, 4, 6, 8, 10 µg of DNA.  
The amount of DNA was determined by the procedure of Hinegardner (1971).  Briefly, 
100 µL of a solution of 3,5 diaminobenzoic acid (0.4 g/mL water) was added to the 
tubes, which were then vortexed and incubated at 50ºC for 45 minutes.  The reaction 
was then terminated by the addition of 1.5 mL of 1 M HCl.  The DNA content was 
determined against the DNA standards by measuring the fluorescence using a Perkin-
Elmer LS-50 spectrofluorometer (Perkin-Elmer Ltd, UK) at an excitation wavelength of 
415 nm and an emission wavelength of 505 nm with a 10 nm slit width.  A typical 
standard curve is shown in Figure 3.4. 
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Sex of foetal rats 
 
Glucocorticoid receptor activity 
(pmol [
3H]-dexamethasone bound/mg DNA) 
 
   
Fresh cytosol 
 
Frozen cytosol 
 
Loss of 
glucocorticoid 
activity due to 
freezing (%) 
 
Male 
 
 
0.92 ± 0.02 
 
0.30 ± 0.06 
 
67.0 
 
Female 
 
1.11 ± 0.02 
 
0.39 ± 0.11 
 
68.9 
 
 
 
Table  3.1 Effect of freezing of cytosol preparations on glucocorticoid receptor 
activity in type II pneumocytes derived from male and female rat foetuses. 
 
Type II pneumocytes from male and female 19-day old foetal rats were isolated and 
grown in culture to confluence as detailed in section 2.2.4.  After 3 days in culture the 
cells were washed twice with 2 mL BSS and incubated for a further 24 hours in serum-
free MEM.  The cells were then harvested and cytosol prepared.  The prepared cytosol 
was divided into two portions.  One was tested for glucocorticoid activity on the day of 
preparation and the other after 8 days of storage at -80°C.  The specific binding of 
[
3H]-dexamethasone  was  determined  as  described  in  section  3.2.3.6.    The  results 
represent the mean ± SEM of three separate cell preparations.  
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Cytosol from whole lung extract 
Glucocorticoid receptor activity 
(pmol [
3H]-dexamethasone bound/mg DNA) 
 
 
 
19-day female foetus 
 
 
0.960 ± 0.06 
Adult female 
 
0.154 ± 0.11 
 
 
Table 3.2  Glucocorticoid receptor activity in lung cytosol from female adult and 
19-day old rat foetuses. 
 
Lungs from female adult rats and 19-day old female rat foetuses were isolated. Lung 
homogenates  were  prepared  and  the  cytosol  fractions  incubated  with  50  nM 
[
3H]-dexamethasone for 3 hours at 4°C.  Specific glucocorticoid receptor binding was 
determined  using  the  hydroxylapatite  method  as  detailed  in  section  3.2.3.6.2.    The 
results represent the mean ± SEM of three separate lung preparations.  
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Figure  3.4  Typical standard curve for the fluorometric assay of DNA. 
 
Standards containing the indicated amounts of highly polymerised calf thymus DNA 
were assayed by the method of Hinegardner (1971) as described in section 3.2.3.7.  The 
results represent the mean ± SEM of three independent determinations. 
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3.2.3.8    Determination  of  β–adrenergic  receptor  activity  in  type  II 
pneumocytes  
Type II pneumocytes were isolated from 19-day rat lungs as detailed in section 2.2.4 
and  plated  onto  Falcon  24-well  tissue  plates  (Falcon  Labware,  Becton  Dickinson, 
Lincoln Park, New Jersey, USA) (8 lungs/24-well plate).  Type II pneumocytes cultures 
were maintained for 72 hours in serum-supplemented MEM before they were washed 
with 1 mL of BSS.  The cells were incubated for a further 24 hours with serum-free 
MEM containing dexamethasone (final concentration 100 nM) dissolved in propylene 
glycol or the equivalent volume of vehicle or fibroblast-conditioned media prepared as 
described  in  section  3.2.3.2.    Following  this  incubation  the  cells  were  analysed  for 
β-adrenergic receptor activity. 
After 24-hours of exposure, the medium was removed and the type II cells were washed 
with  170  mM  Tris-HCl  buffer,  pH  7.6  containing  the  protease  inhibitor, 
phenylmethylsulphonyl fluoride (10 µM) and air dried for 2 hours.  The cells were then 
incubated  with  5  nM  of  the  β-adrenoreceptor  radioligand  1-[4,6-propyl-
3H]-
dihydroalprenolol solubilised in the same buffer.  Non-specific binding was estimated in 
the presence of 10 µM ()-propranolol.  After 150 minutes of incubation (by which 
time  binding  of  [
3H]-DHA  was  virtually  complete,  see  Figure  3.5),  the  type  II 
pneumocytes  were  washed  three  times  with  2  mL  Tris-HCl  buffer,  wiped  onto 
Whatman GF/A glass-fibre filter papers and transferred to polyethylene counting vials.  
Three mL of Optiphase ‘HiSafe’ II scintillant was added to each vial and the contents 
vortexed  prior  to  the  determination  of  radioactivity  in  a  Beckman  LS  6500  Liquid 
Scintillation  counter  (Beckman  Instruments  Nuclear  Division,  Fullerton,  CA,  USA).  
Four wells, not used in the above assay, were dried at 50ºC and assayed for DNA, as 
described  in  section  3.2.3.7.     The  specific  receptor  binding,  expressed  as  fmole  Chapter 3  Glucocorticoids and lung development 
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Figure 3.5  Time course of binding of [
3H]-dihydroalprenolol to cultured foetal 
type II pneumocytes. 
 
Type II pneumocytes were isolated from 19-day foetal rats as described in section 2.2.4.  
After 72 hours in culture, the cells were incubated for a further 24 hours with fibroblast-
conditioned media from lung fibroblasts previously exposed to 100 nM dexamethasone 
and prepared as described in section 3.2.3.2.  Specific binding of [
3H]-dihydroalprenolol 
(DHA) was determined by incubating the cells with 3.5 nM [
3H]-DHA in the absence 
(total  binding)  and  presence  (non-specific  binding)  of  10  µM  ()-propranolol,  as 
outlined in section 3.2.3.8.  Each data point is the mean of quadruplicate determinations 
of two separate experiments.  
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1-[4,6-propyl-
3H]dihydroalprenolol bound/µg DNA, was determined by subtracting the 
dpm bound in the presence of ()-propranolol (non-specific binding) from dpm bound 
in its absence (total binding).  Figure 3.6 demonstrated the concentration-dependent 
inhibition  of  1-[4,6-propyl-
3H]dihydroalprenolol  binding  to  type  II  pneumocytes  by 
()-propranolol. 
3.2.3.9 Influence of the β-agonist, ()-isoproterenol, on secretion of 
surfactant lipids from type II pneumocytes 
The rate of surfactant phospholipid secretion from cultured type II cells in response to 
()-isoproterenol was measured as detailed in section 2.2.5.  A 10 mM stock solution 
of the β-agonist was prepared in 0.01 M HCl and stored for several weeks at 4ºC.  Prior 
to use this stock was diluted in a solution containing 20 µg ascorbate/ mL and aliquot 
added to the type II pneumocyte cultures such that the final ascorbate concentration was 
0.1  µg/mL.    In  order  to  assess  the  effect  of  FCM  and/or  dexamethasone  on  the 
responsiveness of type II cells to ()-isoproterenol the experiment was conducted via 
slightly different procedure.  After 24 h in culture the medium was replaced with either 
fresh MEM containing 10% charcoal-treated newborn calf serum or FCM, prepared as 
described in section 3.2.3.2. After a further 24 hours in culture, the type II cells were 
supplemented with [methyl-
3H]-choline chloride (1 µCi/mL) and with either 0.1% (final 
concentration)  propylene  glycol  or  dexamethasone  (final  concentration  100  nM) 
dissolved in propylene glycol. Following 24 hours incubation with [
3H]-choline, the 
cultures were washed with BSS to remove unincorporated choline and any detached 
cells before adding to the corresponding plates 1.7 mL serum-free MEM or fibroblast-
conditioned media, with or without dexamethasone, for 1 hour.  The cells were allowed 
to equilibrate at 37ºC in a CO2-incubator for 1 hour prior to removing one plate for each  Chapter 3  Glucocorticoids and lung development 
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Figure 3.6  Competition of 1-[4,6-propyl-
3H]-dihydroalprenolol (DHA) binding to  
β-adrenoreceptors by (—)-propranolol. 
 
Type II pneumocytes were isolated from 19-day foetal rats as described in section 2.2.4.  
After 72 hours in culture the cells were incubated with 3.5 nM [
3H]-DHA in the absence 
and presence of 10 nM-100 µM (—)-propranolol for 2.5 hours before specific binding 
of [
3H]-dihydroalprenolol (DHA) was determined, as outlined in section 3.2.3.8.  The 
results are the mean ± SEM of three separate experiments.   
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treatment in order to determine the amount of total lipids in the media and the cellular 
content of DSPC at zero time.  To the remaining plates (two for each treatment) was 
added either 10
-7 M ()-isoproterenol or an equivalent volume of vehicle.  After a 
further 3 hours the rate of secretion of surfactant phospholipids from type II cells was 
determined as previously described in section 2.2.5 
3.2.3.10 Expression of results and statistical analysis 
After  correcting  for  recovery  during  the  lipid  isolation  procedure,  the  rate  of 
incorporation of [methyl-
3H]-choline chloride into disaturated phosphatidylcholine is 
expressed  as  dpm  incorporated  per  µg  DNA.  Although  variations  between  replicate 
cultures of the same batch of cells were always small, the rate of secretion sometimes 
varied quite markedly between different batches of cells.  Subsequently, this was shown 
to be due to variations in the cell density of the type II cell cultures at the time of 
measuring  the  rate  of  synthesis  (data  not  shown).    Thus  statistical  analyses  were 
performed using the paired Student’s t-test unless otherwise specified. 
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3.3 Results 
3.3.1  Effect  of  dexamethasone  on  disaturated 
phosphatidylcholine synthesis by cultured type II pneumocytes 
Direct exposure of the type II cells to 100 nM dexamethasone had no significant effect 
on  the  rate  of  choline  incorporation  into  surfactant  lipids  (Table  3.3).    When  the 
mixed-sex type II pneumocytes were incubated with media, previously conditioned by 
mixed-sex  lung  fibroblasts  in  the  presence  of  100  nM  dexamethasone,  there  was  a 
17.3% increase (p<0.01) in the rate of surfactant lipid synthesis.  When the mixed-sex 
type II cells were exposed to media, previously conditioned by male-derived fibroblasts 
in the presence of 100 nM dexamethasone, there was a smaller increase (12.5%) in 
surfactant  lipid  synthesis  (Table  3.3).    In  contrast,  when  the  mixed-sex  type  II 
pneumocytes  were  exposed  to  media,  previously  conditioned  by  female-derived 
fibroblasts in the presence of 100 nM dexamethasone, the increase in surfactant lipid 
synthesis was 24.9%.  As seen in Table 3.4, there was only a modest increase (19.0%) 
in the level of surfactant lipid synthesis when both the type II cells and the fibroblasts 
were  derived  from  only  male  foetuses.    The  greatest  increase  in  surfactant  lipid 
synthesis  (47.6%)  was  observed  when  female-derived  type  II  pneumocytes  were 
exposed to media conditioned by female-derived fibroblasts in the presence of 100 nM 
dexamethasone.    Figure  3.7  summarises  these  observations  by  illustrating  that 
dexamethasone only enhances surfactant lipid synthesis in an indirect manner through 
its effects upon lung fibroblasts.  Moreover, the response to dexamethasone is greatest 
when both the fibroblasts and type II pneumocytes are derived from female foetuses.  
Since  there  is  no  sex-linked  difference  in  the  amount  of  DNA  per  plate  (data  not 
shown), the greater response observed with the cells derived from female foetuses could  Chapter 3  Glucocorticoids and lung development 
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Medium  Phosphatidylcholine 
synthesis 
(dpm incorporated/µg DNA) 
Effect of 
dexamethasone 
(% increase) 
 
Minimal essential medium 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
 
 
42,442 ± 3,771  
37,858 ± 2,953  
 
 
 
 
-10.8 (NS) 
Fibroblast-conditioned 
medium (Mixed-sex cultures) 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
Fibroblast-conditioned 
medium (Male-derived) 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
Fibroblast-conditioned 
medium (Female-derived) 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
 
 
41,546 ± 1,989  
48,723 ± 1,706  
 
 
 
49,130 ±1,512 
55,270 ±2,617 
 
 
 
46,015 ±5,001 
57,466 ±3,591 
 
 
 
 
17.3 (p < 0.01) 
 
 
 
 
12.5 (p < 0.04) 
 
 
 
 
24.9 (p < 0.03) 
 
 
Table 3.3  Pulmonary surfactant synthesis by mixed-sex cultures of foetal type II 
pneumocytes in response to media conditioned by cultures of fibroblasts derived 
from male, female and mixed sexes. 
Primary  cultures  of  mixed-sex  or  homogeneous  male-  or  female-derived  lung 
fibroblasts were grown to confluence and then incubated in serum-free MEM, with or 
without 100 nM dexamethasone, for 24 hours. The media were then collected, heated at 
65°C for 1 hour (to reduce inhibitory activity) and filter sterilised. The filtrates were 
diluted  1:4  with  serum-free  MEM  (containing  100  nM  dexamethasone  where 
appropriate) and tested for their effect on the rate of [
3H]-choline incorporation into 
disaturated phosphatidylcholine (DSPC) by mixed-sex type II pneumocytes as detailed 
in section 3.2.3.3.  The data represent the mean ± SEM of four experiments.  
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Medium  Phosphatidylcholine 
synthesis 
(dpm incorporated/µg DNA) 
Effect of 
dexamethasone 
(% increase) 
 
Fibroblast-conditioned 
medium (male-derived culture) 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
 
 
 
29,180 ±    926  
34,733 ± 1,518  
 
 
 
 
19.0 (p < 0.04) 
Fibroblast-conditioned medium 
(female derived culture) 
- Dexamethasone 
+ 100 nM Dexamethasone 
 
 
 
29,637 ± 2,826  
43,757 ± 1,674  
 
 
 
47.6 (p < 0.01) 
 
Table 3.4  Surfactant phospholipid synthesis by type II pneumocytes derived from 
male or female rat foetuses in response to fibroblast-conditioned media produced 
by fibroblasts derived from the same sex. 
 
Primary cultures of homogeneous male- or female-derived lung fibroblasts were grown 
to  confluence,  then  incubated  in  serum-free  MEM  with  or  without  100  nM 
dexamethasone for 24 hours.  The media were then collected, heated at 65°C for 1 hour 
(to reduce inhibitory activity) and filter sterilised to remove detached cells and cellular 
debris.  These were then diluted 1:4 with serum-free MEM and supplemented (where 
appropriate) with dexamethasone to maintain the concentration at 100 nM.  The diluted 
media, were then tested on type II pneumocytes cultures derived from the same sex for 
their effect on PC synthesis as described in section 3.2.3.3.  The data represent the mean 
± SEM of three separate experiments.  
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Figure 3.7  Direct and indirect effect of dexamethasone on choline incorporation 
into PC by enriched cultures of type II pneumocytes.  
 
Primary fibroblast cultures derived from male and female rat lungs were grown to near 
confluence  and  then  incubated  in  serum-free  MEM,  with  or  without  100  nM 
dexamethasone for 24 hours.  The media were then collected, heated at 65°C for 1 hour 
and  filter  sterilised.    These  were  then  diluted  1:4  with  serum-free  MEM  and 
supplemented (where appropriate) with dexamethasone to maintain the concentration at 
100 nM.  The resultant mixtures were then tested for their effect on PC synthesis (see 
section 3.2.3.3) by type II pneumocytes derived from the same sex.  The data represent 
the mean ± SEM of three separate experiments.  
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not have been due to the differences in the cell density of the fibroblast or type II cell 
cultures. 
3.3.2  Chromatographic  separation  of  fibroblast-pneumocyte 
factor from fibroblast-conditioned medium 
To elucidate the factor present in fibroblast-conditioned media that enhanced surfactant 
lipid synthesis in cultured type II cells, an attempt was made to separate this component 
using the technique of gel filtration (Smith, 1979; Post et al., 1986; Scott and Das, 
1993). Analysis of the fractions derived from the chromatographic separation of the 
fibroblast-conditioned  media  on  a  BioGel  P30  column  revealed  that  the  factor 
responsible  for  enhanced  incorporation  of  choline  into  surfactant  lipids  by  type  II 
pneumocytes  elutes  with  a  peak  at  approximately  fraction  47  (Figure  3.8).    This 
corresponds to the position of elution of the aprotinin standard (Figure 3.9) suggesting 
that it has an apparent molecular weight of approximately 6.5 kDa, which is similar to 
that reported for human FPF (Smith, 1978).  Additionally, the elution of this protein in 
1 M  acetic  acid  might  also  suggest  that  this  represents  the  monomeric  form  of  the 
protein.  The elution position of the active component of fibroblast-conditioned media 
was the same for media derived from male- and female-derived fibroblasts implying 
that the same factor was likely to be generated.  Although the earlier data suggested that 
the factor was likely to be in greater concentration in media conditioned by female-
derived fibroblasts, this was not evident in the elution profiles shown in Figure 3.8.  
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Figure 3.8  Chromatographic separation of the stimulatory component of media 
conditioned by male- and female-derived lung fibroblasts in the presence of 100 
nM dexamethasone. 
 
Media,  conditioned  by  (A)  male-  and  (B)  female-derived  lung  fibroblasts  in  the 
presence of 100 nM dexamethasone, were prepared as detailed in section 3.2.3.2.   Each 
conditioned medium (20 mL) was lyophilised and resuspended in 2 mL of elution buffer 
(1 M acetic acid) and then subjected to chromatography on a Bio-Gel P-30 column 
(120 x 1.6 cm).  The column was run at a flow rate of 2 mL/h and 2 mL fractions were 
collected.  Each fraction was tested for its ability to stimulate choline incorporation into 
DSPC by type II pneumocytes derived from the same sex. Chapter 3  Glucocorticoids and lung development 
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Figure  3.9    Chromatographic  separation  of  standards  of  various  molecular 
weights. 
 
Cytochrome C (1.2 mg.mL
-1; 12 kDa;     ), aprotinin (2.5 mg.mL
-1; 6.512 kDa;     ), 
insulin chain B, oxidised (1.5 mg.mL
-1; 3.495 kDa;    ), cyanocobalamin (0.1 mg.mL
-1; 
1.355 kDa;    ), phenol red (0.5%; 354 Da;    ) were each dissolved in 1 M acetic acid 
and  then  subjected  to  chromatography  on  a  Bio-Gel  P-30  column  (120  x  1.6  cm) 
previously equilibrated with elution buffer (1 M acetic acid).  The column was run at a 
flow rate of 2 mL/h and 2 mL fractions were collected.  Each fraction was then analysed 
for the content of the standard by measuring the absorbance at the specified wavelength. 
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Glucocorticoid receptor activity 
(pmol [
3H]-dexamethasone bound/mg DNA) 
 
Sex of foetal rats from which cells  
were derived 
 
  Fibroblasts   Type II cells 
 
Male 
 
0.75 ± 0.06 
 
0.92 ± 0.03 
 
Female 
 
0.82 ± 0.04 
 
1.11 ± 0.02 
 
Table 3.5  Glucocorticoid receptor activity in fibroblasts and type II pneumocytes 
derived from male and female rat foetuses. 
 
Fibroblasts and type II pneumocytes from male and female 19-day foetal rats were 
isolated and subsequently grown in culture as detailed in sections 3.2.3.1 and 2.2.4.  
After 3 days (type II cells) or 15 days (fibroblasts) in culture the cells were washed 
twice with 2 mL BSS and incubated for 24 hours in serum-free MEM.  The cells were 
then harvested, cytosol prepared and the specific dexamethasone binding determined as 
described in section 3.2.3.3.  The results represent the mean ± SEM of three separate 
cell preparations.  
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3.3.3  Glucocorticoid  receptor  activity  in  cultured  foetal 
fibroblasts and type II pneumocytes 
The multiple actions of glucocorticoids are mediated through the activation of a unique 
intracellular, predominately cytoplasmic, receptor, termed the glucocorticoid receptor 
(GR) (Ballard and Ballard, 1974; Pujols et al., 2002).  As is evident from Table 3.5, 
glucocorticoid receptor activity is detectable in foetal lung fibroblasts and there is no 
significant difference in the receptor level of cells derived from either male or female 
foetuses.  In comparison, there is a marginal sex-linked difference in the receptor level 
(p<0.03) in confluent cultures of type II pneumocytes derived from male and female 
animals (males: 0.92 pmol. mg DNA
-1; females: 1.11 pmol. mg DNA
-1). 
Further glucocorticoid receptor assays were conducted in order to determine if cell-
specific and sex-specific differences exist in GR activity in late gestation foetal rat lung.  
As seen in Figure 3.10, glucocorticoid specific binding to foetal lung fibroblasts appears 
to be somewhat lower in cells derived from male foetuses, particularly during the period 
of 17-19 days of gestation. For example, at day 18 the receptor level is 1.23-fold higher 
in  female-derived  fibroblasts  than  in  those  from  males  (p<  0.002).    However,  by 
20 days  of  gestation  there  is  no  difference  in  the  level  of  glucocorticoid  receptor 
between  male-  and  female-derived  fibroblasts.    For  both  sexes  there  was  a  very 
substantial increase in the level of receptor in these cells between the 17
th and 18
th day 
of  gestation  (male-derived  fibroblasts  2.5-fold  increase:  female-derived  fibroblasts 
2.4-fold increase). In contrast to the findings with fibroblasts, there is no significant 
change  in  the  glucocorticoid  receptor  level  in  type  II  pneumocytes  with  advancing 
gestational age (Figure 3.11).  Nor were there any sex-linked differences in GR binding 
except at day 19 of gestation, where male-derived type II cells had a lower receptor 
level (p< 0.005) than those derived from female foetuses.  Chapter 3  Glucocorticoids and lung development 
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Figure 3.10  Glucocorticoid receptor activity in cultured fibroblasts derived from 
male and female rat foetuses at the indicated gestational age. 
 
Fibroblasts from male and female foetal rats of 17-, 18-, 19- and 20-days of gestation 
were isolated and subsequently grown in culture as detailed in section 3.2.3.1.  After 15 
days in culture the cells were washed twice with 2 mL BSS and incubated for 24 hours 
in  serum-free  MEM.    The  cells  were  then  harvested,  cytosol  prepared  and  specific 
dexamethasone  binding  determined  as  described  in  section  3.2.3.6.    The  results 
represent the mean ± SEM of three separate cell preparations.  
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Figure  3.11    Glucocorticoid  receptor  activity  in  cultured  type  II  pneumocytes 
derived from male and female rat foetuses at the indicated gestational age. 
 
Type II pneumocytes from male and female foetal rats of 17-, 18-, 19- and 20-days of 
gestation were isolated and grown in culture to confluence as detailed in section 2.2.4.  
After 3 days in culture the cells were washed twice with 2 mL BSS and incubated for a 
further  24  hours  in  serum-free  MEM.    The  cells  were  then  harvested  and  cytosol 
prepared.  The specific [
3H]-dexamethasone binding was determined as described in 
section  3.2.3.6.    The  results  represent  the  mean  ±  SEM  of  three  separate  cell 
preparations.  
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3.3.4  Effect  of  dexamethasone  and  fibroblast-conditioned 
medium  on  β-adrenergic  receptor  activity  in  the  type  II 
pneumocytes 
Previous reports have shown that glucocorticoids directly influence many steps in the 
β-adrenergic  signalling  pathway,  including  supersensitization  through  increased 
β-agonist stimulation of adenylyl cyclase and up-regulation of β-adrenergic receptor 
(β-AR) gene transcription and receptor expression in lung tissues and cells (Fraser and 
Venter,  1980;  Mak  et  al.,  1995a;  McGraw  et  al.,  1995).    As  has  been  previously 
reported  (Maier et al., 1989), exposure to glucocorticoids results in an increase in high-
affinity β-agonist binding sites in foetal lung cells (Figure 3.12).  When the level of 
β-adrenoreceptor activity was measured in type II pneumocytes that had been derived 
from either male or female foetuses, it was apparent that the receptor concentration was 
higher  in  type  II  cells  derived  from  females  than  from  males  grown  under  similar 
conditions (Figure 3.13).  When the type II cells were directly exposed to 100 nM 
dexamethasone there was a significant increase in the level of β-adrenoreceptor activity 
in  cells  from  both  male  and  female  to  0.27  and  0.29  fmol.µg
-1  DNA,  respectively 
(p < 0.005).  However, when the type II cells were exposed to media that had been 
previously conditioned by fibroblasts from the same gender in the presence of 100 nM 
dexamethasone  there  was  an  even  greater  increase  in  the  level  of  β-adrenoreceptor 
activity to 0.30 and 0.41 fmol.µg
-1 DNA in male and female-derived cells, respectively 
(p  <  0.005).    Thus,  the  greatest  increase  in  β-AR  activity  in  type  II  pneumocytes 
(90.2%) was observed when female-derived type II pneumocytes that were exposed to 
media  that  had  been  conditioned  by  female-derived  fibroblasts  in  the  presence  of 
100 nM dexamethasone.  Chapter 3  Glucocorticoids and lung development 
      146 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  Effect of dexamethasone on β-adrenergic receptor activity in type II 
pneumocytes derived from rat foetuses of mixed sex. 
 
Type II pneumocytes from 19-day foetal rats were isolated and subsequently grown in 
culture as detailed in section 2.2.4.  After 3 days in culture, the cells were washed twice 
with 2 mL BSS and incubated for an additional 24 hours in either serum-free MEM with 
or without 100 nM dexamethasone or fibroblast-conditioned media prepared as detailed 
in section. 3.2.3.2.  The type II cells were then tested for specific β-adrenergic receptor 
activity, as described in section 3.2.3.8.  The results represent the mean ± SEM of three 
separate cell preparations.  
 
 
 
 
 
 
 
 
 Chapter 3  Glucocorticoids and lung development 
      147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  β-Adrenergic receptor activity of cultured type II pneumocytes from 
male  and  female  rat  foetuses  exposed  to  dexamethasone  either  directly  or 
indirectly via fibroblasts derived from foetuses of the same sex. 
 
Type II pneumocytes from male or female 19-day foetal rats were isolated and cultured 
as previously described.  After 72 hours in culture the media were replaced with either 
serum-free MEM with or without 100 nM dexamethasone, or fibroblast-conditioned 
media prepared as detailed in section. 3.2.3.2.  The cells were incubated for a further 
24 hours prior to the cells being analysed for β-adrenergic receptor activity employing 
the method described in section 3.2.3.8.  The data represent the mean ± SEM of four 
separate experiments.  
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3.3.5 Effect of (—)-isoproterenol on the secretion of surfactant 
phospholipids by type II pneumocytes 
The β-agonist (—)-isoproterenol (10
-6M) promoted an enhanced rate of phospholipid 
secretion from foetal rat type II pneumocytes (Figure 3.14).  This effect was evident as 
early as 1 hour after the addition of the β-agonist but was more apparent at 3 hours of 
incubation.  As is evident from the data presented in Figure 3.15, this stimulatory effect 
of (—)-isoproterenol is concentration dependent.  A significant elevation in the rate of 
secretion was evident at all concentrations tested within the range 10
-9-10
-3 M.  Maximal 
stimulation occurred at 10
-6 M, at which concentration there was a 2.1-fold increase 
(p < 0.01) in the rate of secretion.  
When type II cells derived from either male or female foetuses were incubated with 
100 nM dexamethasone, fibroblast-conditioned media or both there was no change in 
the rate of basal surfactant phospholipid secretion (Figure 3.16).  Conversely, when type 
II cells from male and female foetuses were grown in the absence of dexamethasone 
and exposed to 10
-6M (—)-isoproterenol, there was a marked elevation in the rate of 
secretion  of  surfactant  (1.7-fold  and  1.9,  respectively).    This  enhancement  by  the 
β-agonist was significantly greater if the male- and female-derived type II cells were 
previously  exposed  to  100  nM  dexamethasone  (2.2-fold  and  2.3-fold,  respectively).  
When  the  male-  and  female-derived  type  II  pneumocytes  were  exposed  to  media 
conditioned by fibroblasts in the presence of 100 nM dexamethasone, a treatment that 
produced the highest level of β-adrenoreceptor activity in the type II cells, there was an 
even  greater  response  to  (—)-isoproterenol  (3.1-fold  and  3.5-fold,  respectively).  
Figure 3.17 demonstrates that there is indeed a very strong correlation between the level 
of β-adrenoreceptor activity in type II cells and the extent to which (—)-isoproterenol 
stimulates  secretion  of  surfactant  phospholipids.  Moreover, the  data  show  that  the  Chapter 3  Glucocorticoids and lung development 
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Figure  3.14    Time  course  of  phospholipid  secretion  by  cultured  foetal  type  II 
pneumocytes in response to (—)-isoproterenol. 
 
Type II pneumocytes from 19-day foetal rats were isolated and cultured as previously 
described.  The cells were grown in culture for 72 hours prior to a further incubation 
with [
3H]-choline in order to label cellular phospholipids.  After 24 hours incubation, 
the cells were washed thoroughly and equilibrated for 1 hour at 37ºC in serum-free 
MEM  prior  to  addition  of  either  10
-6  M  (—)-isoproterenol  (    )  or  0.01  M  HCL 
containing 20 µg ascorbate/mL (  ).  Subsequently, the rate of phospholipid secretion 
into the medium was determined at the indicated times using the method detailed in 
section 2.2.5.  Values are the means ± SEM for 3 independent experiments. 
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Figure  3.15    Effect  of  (—)-isoproterenol  concentration  on  the  secretion  of 
phospholipids from cultured foetal type II pneumocytes. 
 
Lung type II pneumocytes were isolated as described in section 2.2.4.  The cells were 
then  grown  in  culture  for  72  hours  and  subsequently  incubated  for  24  hour  with 
[
3H]-choline  in  serum-free  MEM  in  order  to  label  the  cellular  phospholipids.    The 
cultured cells were then thoroughly washed with BSS and equilibrated for 1 hour at 
37ºC   in   serum-free  MEM  prior  to  addition  of  the  indicated  concentrations  of 
(—)-isoproterenol.  The percentage of total cellular [
3H]-phospholipids secreted into the 
media in the subsequent 3 hours was determined using the method described in section 
2.2.5.  The values presented are the mean ± SEM for three independent experiments.  
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Figure 3.16  Effect of dexamethasone and medium, conditioned by fibroblasts in 
the  presence  of  dexamethasone,  on  the  (—)-isoproterenol-induced  secretion  of 
surfactant lipids from gender-specific cultures of type II pneumocytes.  
 
Type II pneumocytes from male or female 19-day foetal rats were isolated and cultured 
as previously described.  The cells were grown in culture for 72 hours prior to a further 
incubation with [
3H]-choline and either MEM, with or without 100 nM dexamethasone, 
or  fibroblast-conditioned  media  prepared  as  detailed  in  section  3.2.3.2.  After  an 
additional 24  hours  of  incubation,  the  cells  were washed thoroughly and equilibrated 
for 1 hour at 37ºC in serum-free MEM prior to the addition of either 10
-6 M (—)-
isoproterenol (    ,    ) or 0.01 M HCl containing ascorbate  (    ,    ).  The extent of 
phospholipid secretion by type II pneumocytes was determined as described in section 
2.2.5.  The data represent the mean ± SEM of three separate experiments.  
 
 
 
 
0.0
1.0
2.0
3.0
4.0
 
 
 
 
 
 
 
P
h
o
s
p
h
o
l
i
p
i
d
 
s
e
c
r
e
t
i
o
n
(
%
 
o
f
 
t
o
t
a
l
 
c
e
l
l
u
l
a
r
 
p
h
o
s
p
h
o
l
i
p
i
d
s
)
   MEM +         MEM + DEX    FCM + DEX
Male
0.0
1.0
2.0
3.0
4.0
Female
  MEM +        MEM + DEX    FCM + DEXChapter 3  Glucocorticoids and lung development 
      152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.17  Correlation  between  the  effect  of  (—)-isoproterenol  on  surfactant 
phospholipid secretion and the β-adrenergic receptor activity of male- and female-
derived type II pneumocytes grown under three different conditions. 
 
Type  II  pneumocytes  from  male  (blue  symbols)  or  female  19-day  foetal  rats  (red 
symbols) were isolated and cultured as previously described.  The cells were grown in 
culture for 72 hours prior to a further incubation with [
3H]-choline and either MEM, 
with (    ,    ) or without (    ,    ) 100 nM dexamethasone, or fibroblast-conditioned 
media (    ,    ) prepared as detailed in section 3.2.3.2.  After 24 hours incubation, the 
cells were washed thoroughly and either (i) equilibrated for 1 hour at 37ºC in serum-free 
MEM  prior  to  the  addition  of  10
-6  M  (—)-isoproterenol  to  ascertain  its  effect  on 
surfactant phospholipid secretion, or (ii) analysed for β-adrenergic receptor activity, 
employing the method described in section 3.2.3.8.  The data represent the mean ± SEM 
of three separate experiments.  
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responsiveness is greater under all conditions when the type II pneumocytes are derived 
from  female  foetuses.  Under  all  treatment  conditions  the  lipid  composition  of  the 
surfactant secreted from the type II cells was essentially the same suggesting that there 
was no adverse effect caused by the enhanced level of secretion (Table 3.6).  
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Treatment of type II 
cells prior to exposure 
to isoproterenol 
Composition of phospholipids secreted 
in response to isoproterenol 
(% of choline incorporation) 
  PC  Sphingomyelin  Lyso-PC 
Male 
MEM + 
MEM + DEX 
FCM + DEX 
 
 83.13 ± 0.92 
 83.73 ± 0.20 
82.26 ± 0.24 
 
11.29 ± 0.49 
10.79 ± 0.16 
11.56 ± 0.22 
 
5.58 ± 0.45 
5.48 ± 0.04 
6.18 ± 0.17 
Female 
MEM + 
MEM + DEX 
FCM + DEX 
 
82.67 ± 0.28 
83.80 ± 0.27 
83.75 ± 0.34 
 
11.29 ± 0.05 
10.76 ± 0.10 
10.70 ± 0.38 
 
6.04 ± 0.24 
5.43 ± 0.36 
5.55 ± 0.07 
 
 
 
Table 3.6  Effect of exposure of gender-specific cultures of type II pneumocytes to 
vehicle,  dexamethasone  or  fibroblast-conditioned  medium,  with  and  without 
dexamethasone,  on  the  composition  of  phospholipids  secreted  in  response  to              
(—)-isoproterenol. 
 
Type II pneumocytes from male or female 19-day foetal rats were isolated and cultured 
as previously described.  The cells were grown in culture for 72 hours prior to a further 
incubation with [
3H]-choline and either MEM, with or without 100 nM dexamethasone, 
or fibroblast-conditioned media prepared as detailed in section. 3.2.3.2.  After 24 hours 
incubation, the cells were washed thoroughly and equilibrated for 1 hour at 37ºC in 
serum-free MEM prior to addition of either 10
-6 M (—)-isoproterenol or 0.01 M HCl 
containing  20  µg  ascorbate/mL.    After  a  further  3  hours  incubation,  the  media 
phospholipids  were  extracted  (section  2.2.5.2)  and  separated  by  thin-layer 
chromatography (section 2.2.5.3).  The data represent the mean ± SEM of three separate 
experiments. 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3.4. Discussion 
The  capacity  to  synthesize  pulmonary  surfactant  is  regulated  by  glucocorticoids 
(Liggins, 1969; Giannopoulos, 1975; Smith, 1979; Floros et al., 1985; Ballard, 1989; 
Sullivan and Orgeig, 2001).  In this context glucocorticoids do not exert their effect 
directly on the type II pneumocytes, but rather stimulate lung fibroblasts to produce a 
factor,  termed  fibroblast-pneumocyte  factor  (FPF),  which  is  capable  of  stimulating 
surfactant synthesis by the alveolar type II cells in vitro (Post et al., 1984a; Post and 
Smith, 1984; Samtani et al., 2006) and accelerating lung maturation in vivo (Post et al., 
1986;  Phelps  and  Floros,  1991;  Sweezey  et  al.,  1998).    Previous  studies  have 
investigated the mode of regulating the synthesis of fibroblast-pneumocyte factor in 
primary cultures of foetal rat lung fibroblasts.  The use of metabolic inhibitors and the 
isolation of cell-free translation products from fibroblasts, incubated in the presence or 
absence of dexamethasone, showed that glucocorticoids act at the pre-translational level 
to induce production of FPF and that the primary translation products are biologically 
active (Floros et al., 1985).  In the present study, it has been confirmed that cultures 
enriched  with  type  II  pneumocytes  fail  to  respond  directly  to  dexamethasone,  but 
respond with an enhanced rate of phosphatidylcholine synthesis if the steroid-containing 
media is first conditioned by incubation with lung fibroblast cultures.  Moreover, this 
investigation has also demonstrated that there is a significant sex-linked difference in 
the response to dexamethasone.  This is in agreement with previous findings that there 
is a higher rate of surfactant synthesis in cultures derived from female animals, which is 
attributed  to  a  higher  production  of  FPF  (Torday,  1984).    In  fact,  the  sex-linked 
difference in surfactant production pertains to its lipid moiety (Nielsen et al., 1982; 
Ballard, 1989; McCoy et al., 1999).  The difference in the level of surfactant lipid Chapter 3  Glucocorticoids and lung development 
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correlates with the sex-linked difference in pulmonary expression of the apolipoprotein 
genes, which are involved in lipid transport (Provost et al., 2009). 
When fibroblast-conditioned media were subjected to chromatography on a Bio-Gel 
P-30  column  the  factor  responsible  for  this  stimulatory  effect  (FPF)  was  partially 
purified.    This  clearly  indicates  that  foetal  lung  fibroblasts,  in  response  to 
dexamethasone, produce a factor that stimulates the biochemical activity of the alveolar 
type II pneumocytes.  That there was no gender-based difference in the level of FPF 
induced by dexamethasone (see Fig. 3.8) is in contrast to the finding of Floros et al. 
(1987), who showed that at day 19 of gestation the level of FPF was detectable in media 
that had been conditioned by lung fibroblasts derived from female, but not male, foetal 
rats.  However, it needs to be pointed out that, whilst there was no apparent difference 
in the BioGel P-30 chromatogram (Fig. 3.8), such a gender-based difference is apparent 
in the data presented in Table 3.4. 
 Previous  reports  have  shown  that  glucocorticoids  exert  their  biological  effect  by 
binding to specific glucocorticoid receptors (GR) (Ballard and Ballard, 1974; Bolt et al., 
2001). In most species, including humans, a rise in foetal cortisol production is found to 
occur in late gestation at a time when there is also a high level of expression of GR in 
pulmonary tissue (Ballard et al., 1984; Szabo et al., 1991; Mesiano and Jaffe, 1997).  In 
the present study, lung cells were isolated from animals in the latter stages of gestation 
(17-20  days)  because  it  is  during  this  period  that  type  II  cell  maturation  and 
dexamethasone-induced surfactant phospholipid production take place.  Glucocorticoid 
receptor levels, at days 17-18 of gestation, are significantly higher in fibroblasts from 
female  foetuses  when  compared  to  those  from  male  animals.    This  sex-specific 
difference disappears by day 20 of gestation.  The absence of a sex-linked difference in 
the  GR  levels  of  foetal  type  II  pneumocytes  suggests,  in  agreement  with  previous Chapter 3  Glucocorticoids and lung development 
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studies (Torday, 1984; Sen and Cake, 1991), that the development of the surfactant 
phospholipid  system  is  strongly  influenced  by  mesenchymal-epithelial  cell 
communication in the lung.  The sex-specific differences in the development of the GR 
in fibroblasts may occur through several different mechanisms.  Factors that influence 
male sexual differentiation, specifically androgens and Muellerian inhibiting substance 
(MIS),  are  prime  candidates  for  consideration,  as  they  inhibit  the  acquisition  of 
surfactant synthetic activity during lung development (Floros et al., 1987; Catlin et al., 
1988; Seaborn et al., 2010).  In the present study, the GR-binding activity in male- and 
female-derived lung fibroblasts showed the largest difference at day 18 of gestation, 
when the difference between the serum testosterone levels of male and female foetuses 
is known to be at its greatest (Weisz and Ward, 1980).  Previous evidence from in vitro 
studies  indicated  that  MIS,  a  Sertoli  cell-derived  glycoprotein  made  early  in  the 
ontogeny of the testes, also inhibits lung development (Catlin et al., 1990).  Female 
foetal rats that had been exposed to human recombinant MIS (rMIS) revealed depressed 
disaturated phosphatidylcholine content 48 hours after the injection (Catlin et al., 1990).  
Moreover, the induction of surfactant synthesis is influenced by fibroblast-type II cell 
interactions  (Gross  et  al.,  1979)  and  the  onset  of  these  interactions  is  regulated  by 
transforming  growth  factor-β1  (TGF-β1).    It  has  been  speculated  that  androgens 
mediate  their  inhibitory  effect  on  lung  maturation  through  TGF-β1.    For  example, 
androgen inhibition of fibroblast-type II cell communication has been reversed with 
antibodies to TGF-β1 (Torday and Kourembanas, 1990).  This inhibitory effect of TGF-
β1  on  lung  maturation  is  likely  to  be  mediated  via  a  TGF-β1  receptor,  which  is 
expressed in the foetal lung, but this effect must be overcome with advancing gestation 
as male foetuses ultimately produce surfactant, although at a later stage of gestation 
than that of female foetuses.  The decrease in the level of both TGF-β1 and its receptor Chapter 3  Glucocorticoids and lung development 
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has  been  shown  to  occur  earlier  in  gestation  in  female  foetuses.    Furthermore, 
fibroblasts derived from female animals in the later stage of gestation when treated with 
androgens showed enhanced levels of TGF-β1 receptor (Pereira et al., 1998; Seaborn et 
al., 2010). 
The present study has confirmed the presence of β-adrenergic receptors (β-AR) in foetal 
rat type II pneumocytes, as is evident from the specific binding of the highly selective 
radioligand [
3H]-dihydroalprenolol (DHA). The receptor activity is elevated if the cells 
are  exposed  to  fibroblast-conditioned  media,  but  only  if  glucocorticoids  are  present 
during the conditioning by fibroblasts (Figure 3.13).  The mechanism by which such 
media promote elevated levels of β-adrenergic receptors is not known.  It is possible 
that, in response to dexamethasone, rat foetal lung fibroblasts release into the media a 
factor,  possibly  fibroblast-pneumocyte  factor,  which  induces  the  elevated  level  of 
β-adrenergic receptors in type II cells. 
Sex differences in the concentration of β-adrenergic receptors in foetal lung have been 
detected by Padbury and colleagues (Padbury et al., 1981), who demonstrated that the 
β-adrenergic receptor level in foetal rabbit lung was significantly elevated in females, as 
compared with males, at each gestational age tested and throughout the neonatal period.  
In the present study the direct effect of dexamethasone on the β-adrenergic receptor 
level of cultured type II pneumocytes derived from mixed sexes was relatively modest 
(Fig.  3.12).    When  the  level  of  β-adrenoreceptor  activity  was  measured  in  cultured 
foetal rat type II pneumocytes that had been derived from either male or female foetuses 
it was apparent that the receptor concentration was higher in type II cells derived from 
females foetuses than those from male foetuses (Fig. 3.13).  The receptor activity was 
significantly elevated if the cells were incubated with either dexamethasone (p < 0.05) 
or media conditioned by lung fibroblasts in the presence of dexamethasone (p < 0.01), Chapter 3  Glucocorticoids and lung development 
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however, it should be noted that this effect was much greater when the cells are derived 
from female foetuses.  Whether this difference between male- and female-derived cells 
is at the level of the fibroblasts or type II cells remains to be elucidated.  This is in good 
agreement with the previous observation that glucocorticoids enhance the synthesis of 
the β-adrenoreceptor in cultured human (Fraser and Venter, 1980; Aksoy et al., 2002), 
rat (McGraw et al., 1995) and rabbit (Roberts et al., 1985) lung cells.  Although Fraser 
and Venter (1980) have shown that the receptor density is enhanced by glucocorticoids, 
the concentration of β-AR reached a constant value after 24 hours of glucocorticoid 
exposure.  This observation implies that a steady state has developed, by which time the 
rate of receptor synthesis and degradation are equal.  
Glucocorticoids  have  been  demonstrated  to  regulate  the  β-adrenergic  receptor  level 
through changes in gene expression.  It has been confirmed that the increase in the 
β-AR level results from an increase in the rate of synthesis of new receptors, which in 
turn is preceded by an increased level of β-AR mRNA (Cornett et al., 1998), resulting 
from enhanced transcription of the β-AR gene (Mak et al., 1995b).  In fact, both cyclic 
AMP and glucocorticoid response elements (CREs and GREs, respectively) have been 
identified close to the promoter region of the β-adrenoreceptor gene (Collins et al., 
1990), suggesting the involvement of both of these transcription factors in regulating 
β-receptor  expression.    It  has  been  shown  that  dexamethasone  increases  the 
transcription rate of β2-adrenoreceptor mRNA in human and rat lung tissues (Mak et al., 
1995b; Isohama et al., 1997).  In the 5’flanking region of the β2-adrenoreceptor gene, 
four GREs in rats (Cornett et al., 1998) and five GREs in humans have been identified 
(Mak et al., 1995b).  It has been well characterised that GREs form a complex with 
glucocorticoid receptors to activate or suppress gene expression (Cornett et al., 1998).  
Relevant  to  this  is  the  finding  that  the  dexamethasone-induced  increase  in  the Chapter 3  Glucocorticoids and lung development 
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β-adrenoreceptor mRNA level is significantly suppressed by simultaneous application 
of the glucocorticoid receptor antagonist, RU-486 (Isohama et al., 1997).  
The  increase  in  β-adrenergic  receptors  that  occurs  in  type  II  cells  in  response  to 
glucocorticoids and/or fibroblast-conditioned media has been shown to be associated 
with an enhanced physiological response to the β-agonist, isoproterenol, and there is  
undeniably a very strong correlation between the level of β-adrenoreceptor activity in 
type II cells and the extent to which (—)-isoproterenol stimulates secretion of surfactant 
phospholipids from those cells (Fig. 3.17).  Although it is apparent that dexamethasone 
directly stimulates β-adrenoreceptor levels it is obvious that the greatest response to 
dexamethasone  is  when  the  media  is  conditioned  by  fibroblasts  exposed  to  the 
glucocorticoid (Figure 3.17). In type II pneumocytes derived from both male and female 
foetuses  this  indirect  exposure  to  the  steroid  results  in  the  highest  level  of 
β-adrenoreceptor  activity  and,    as    a    consequence,    the    highest    response    to              
(—)-isoproterenol.  This  observation  suggests  that,  in  this  circumstance,  exposure  of 
fibroblasts  to  dexamethasone  is  resulting  in  the  production  of  a  potent  inducer  of 
β-adrenoreceptors.    It  is  tempting  to  speculate  that  this  factor  may  be  fibroblast-
pneumocyte factor, i.e. the same factor that stimulates surfactant lipid synthesis. 
In the present study it has been shown that in cultured foetal type II cells, grown under 
various  conditions,  there  is  a  very  high  correlation  (r=0.96)  between  the 
β-adrenoreceptor levels and the stimulatory effect of (—)-isoproterenol upon surfactant 
lipid secretion from these cells (Figure 3.17).  It is generally believed that β-agonists 
elevate  the  rate  of  surfactant  release  by  enhancing  the  production  of  the  secondary 
messenger,  cyclic  AMP  (Mak  et  al.,  1995b;  Aksoy  et  al.,  2002).    Binding  of 
β-adrenergic  agonists  to  receptors  activates  adenylyl  cyclase  via  a  stimulatory  G 
protein.  The  resultant  production  of  the  second  messenger  cAMP  activates  protein Chapter 3  Glucocorticoids and lung development 
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kinase  A  and  the  kinase  phosphorylates  cellular  proteins.  The  rise  of  the  cAMP 
concentration and its involvement in stimulating surfactant secretion via β-adrenergic 
receptor activation has been implicated by the observation that isoproterenol causes a 
rise in the cAMP concentration in type II cells (Brown and Langmore, 1981), that the 
stimulation by β-adrenergic agonist is mimicked by the cAMP analogs N
6,O
2-dibutyryl-
cAMP (Brown and Langmore, 1981; Mettler et al., 1981; Gonzales et al., 2002)) and 8-
Br-cAMP  (Dobbs  and  Mason,  1979)  and  that  the  phosphodiesterase  inhibitor 
isobutylmethylxanthine causes both a rise in the cAMP concentration and SPC secretion 
(Dobbs  and  Mason,  1979;  Brown  and  Langmore,  1981).    The  activity  of  adenylyl 
cyclase is regulated through fluctuations in the free Ca
2+ concentration (Dobbs et al., 
1986a).  The stimulation of SPC secretion from isolated type II cells by the calcium 
ionophore A23187 (Dobbs et al., 1986a) may therefore be related to a change in the 
cAMP level.  
This study has also provided evidence that the ability of dexamethasone to increase the 
β-adrenoreceptor level of foetal type II cells is modulated by the gender of the donor 
animal. Thus, dexamethasone has been shown to produce a greater enhancement of 
phosphatidylcholine secretion that may be, at least in part, due to differences in the 
concentration  of  glucocorticoid  receptor,  β-adrenoreceptor  expression  and/or  an 
enhanced response of foetal rat type II cells to β-agonists. The fact that these parameters 
are greater in cells derived from female foetuses might also explain the diminished 
respiratory problems encountered with female neonates. Moreover, it also suggests that 
administration of steroids not only stimulates surfactant synthesis but also potentiates 
the release of surfactant and this effect is also strongly influenced by gender.  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4  General Discussion 
4.1  Inactivation of pulmonary surfactant by serum 
The  leakage  of  plasma  proteins  into  airways  and  alveoli  has  been  associated  with 
several  lung  diseases,  including  acute  respiratory  distress  syndrome  (ARDS).    In 
contrast,  neonatal  respiratory  distress  syndrome  (NRDS)  is  mainly  characterised  by 
primary surfactant deficiency due to immaturity of the lungs (Smyth et al., 1983; Jobe 
and Ikegami, 2000; Suresh and Soll, 2002).  Trans-bronchial application of synthetic 
lung  surfactant  preparations  has  proven  to  be  a  beneficial  treatment  for  premature 
infants  suffering  from  NRDS  and  results  in  a  significant  reduction  in  the  rate  of 
mortality (Suresh and Soll, 2002; Chotigeat et al., 2008).  ARDS, which can affect both 
adults  and  children,  has  a  more  complicated  pathology  than  the  simple  absence  of 
surfactant,  but  shares  many  of  the  symptoms  of  NRDS,  such  as  diminished  lung 
compliance,  a  marked  reduction  in  effective  lung  volume  and  profound  hypoxemia 
(Gunther et al., 1998).  However, clinical trials with the most effective formulations of 
synthetic surfactant that had been used successfully in the treatment of NRDS showed 
that  these  formulations  had  only  a  modest  and  transient  beneficial  effect  when 
administered  to  ARDS  patients  (McIntyre  et  al.,  2000).  Extracted  bronchial  fluid 
(lavage) from ARDS patients were consistently shown to have elevated levels of serum 
proteins (Nakos et al., 1997), and the ratio of soluble proteins to lung surfactant in 
lavage correlates closely with the severity and clinical outcome of patients suffering 
from ARDS {Hallman, 1982).  ARDS lavage also has a markedly reduced activity of 
surfactant as reflected in the speed with which the material adsorbs to the air-water 
interface and the minimum surface tension achieved (Nakos et al., 1997).  Biophysical 
studies  of  lung  surfactant  deliberately  mixed  with  serum  proteins  show,  that  at Chapter 4  General Discussion 
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sufficiently high concentrations of proteins, an ARDS-like depression of lung surfactant 
activity  can  be  obtained.    Centrifugation,  which  removes  contaminating  cells  and 
proteins, restores normal surface activity in vitro (Holm et al., 1985). In the current 
study,  cultured  foetal  rat  type  II  pneumocytes  were  used  as  a  model  to  study  the 
potential  for  a  direct  effect  of  human  serum  components  on  the  rate  of  surfactant 
secretion.    When  the  influence  of  serum  on  secretion  of  choline-containing 
phospholipids was examined in detail it was established that there was a significant 
increase in the amount of lysophosphatidylcholine (lyso-PC) in the medium, which was 
likely to be the result of an hydrolysis of surfactant phosphatidylcholine (PC) by serum 
phospholipases.  Lyso-PC  is  strongly  amphiphilic,  and  it  readily  inserts  into 
phospholipid bilayers, where it can have an adverse effect upon their functionality and 
stability  (Weltzien,  1979;  Niewoehner  et  al.,  1987).    An  increase  in  lung  lyso-PC 
content from ~1.5% to ~2.5% appears to be a critical point at which deleterious changes 
in the alveolar epithelium first became apparent, and further increases between ~4% to 
~5% are associated with surfactant dysfunction and morphological evidence of severe 
cell injury (Niewoehner et al., 1989).  
Phospholipase  A2  (PLA2)  has  been  implicated  in  the  pathogenesis  of  a  variety  of 
pulmonary diseases including ARDS and asthma (Kim et al., 1995; Arbibe et al., 1997; 
Nakos et al., 2005).  Because PLA2 is a lipolytic enzyme, which specifically cleaves 
phospholipids to yield lyso-PC, we reasoned that this enzyme might be responsible for 
the adverse effect of serum on surfactant functionality.  Plasma lipoproteins are the 
major source of PLA2 and are physically associated with HDL (Petrovic et al., 2001).  
However,  this  study  has  evaluated  the  effect  of  lipoprotein-free  serum  on  the 
degradation of DSPC, the major phospholipid component of lung surfactant.  It was 
anticipated that an unidentified enzyme(s) would be able to be separated from other Chapter 4  General Discussion 
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serum  components  using  the  standard  techniques  of  chromatography  and  various 
electrophoretic  techniques.    Unfortunately,  the  activity  responsible  for  the  increased 
lyso-PC production co-eluted with serum albumin.  Albumin is generally regarded as a 
protein with numerous binding and transport functions but is generally considered to be 
devoid of enzyme activity. The current study has demonstrated that albumin leads not 
only  to  increased  secretion  of  pulmonary  surfactant  phospholipids  but  also  to  an 
elevation in the lyso-PC content of the media phospholipids. This particular observation 
warrants  further  investigation.    It  was  then  hypothesised  that  recombinant  human 
albumin  (rHSA)  would  be  devoid  of  PLA2-like  activity  as  it  is  produced  using  a 
mammalian cell line grown under conditions devoid of any human- or animal-derived 
serum and is therefore not likely to be bound with PLA2.  However, the present study 
has revealed that exposure of type II pneumocytes to rHSA also stimulates the secretion 
of phospholipids and is almost as effective as lipoprotein-free serum in enhancing the 
level of lyso-PC in the media.  The latter observation implies that rHSA is able to 
directly generate lyso-PC and suggests that PLA2 may be an innate activity of albumin.   
This study has provided a better understanding of the relationship between the serum 
albumin-induced secretion of pulmonary surfactant and its simultaneous degradation to 
lyso-PC.    Surfactant  lipids  and  proteins  have  long  provided  biomarkers  indicating 
pulmonary maturation before birth and adult susceptibility to lung diseases in paediatric 
and adult patients.  The recognition that plasma proteins and albumin, in particular, 
causes conversion of PC to lyso-PC might provide the rationale for the development of 
novel  treatment  regimes  designed  to  minimise  lung  injury  in  patients  showing 
symptoms of acute respiratory distress syndrome and providing a means of protecting 
infused  synthetic  surfactant  lipids  against  rapid  degradation  by  albumin-associated Chapter 4  General Discussion 
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PLA2. This would be a more likely outcome if a specific, non-toxic inhibitor could be 
identified that would minimise the damaging effect of albumin-associated PLA2.  
Other attempts to improve the therapy used in the treatment of ARDS patients have 
focused  on  the  use  of  anti-inflammatory  substances.  For  example,  it  has  been 
demonstrated that various additives such as polyethylene glycol, dextran, polymyxin, 
chitosan and hyaluronan are effective in vitro and in animal models (Taeusch et al., 
1999; Lu et al., 2002; Zuo et al., 2008; Iwanicki et al., 2010).  One of the beneficial 
aspects of using hyaluronan (HA) is the fact that pulmonary alveolar epithelial cells 
naturally secrete it and therefore it is a normal constituent of the extracellular alveolar 
fluid  lining.    Recent  in  vitro  studies  have  shown  that  HA  reduces  inhibition  of 
pulmonary surfactant exposed to PLA2 by decreasing the PLA2 activity, as measured by 
blocking breakdown of fluorescent dipalmitoyl phosphatidylcholine-N-(4-nitrobenzo-2-
oxa-1,3-diazole)  (Iwanicki  et  al.,  2010).    Based  on  the  possible  anti-inflammatory 
effects of hyaluronan, its ability to reduce PLA2 activity and reduction in surfactant 
inhibition, treatment with hyaluronan concomitantly with surfactant might provide (yet 
another) promising approach to treatment of ARDS.  Another approach described in 
recent papers has focused on the synthesis and use of PLA2-resistant phosphonolipids.  
Two  extremely  surface  active  C16:0  phosphonolipid  analogs  have  recently  been 
reported, two novel C-16:0 sulphur-linked phosphonolipid (SO2-lipid and SO(2)-lipid) 
and  two  ether-linked  phosphonolipids  (C16:0  DEPN-8  and  C16:1  UnDEPN-8).  
Exposure of calf lung surfactant extracts (CLSE) to 0.1 units/mL of PLA2 results in 
severe chemical degradation of lung surfactant phospholipids, with a decrease in the 
level of PC compounds and a substantial increase in lyso-PC (Wang et al., 2003; Notter 
et al., 2007).  In contrast, mixtures of DEPN-8 and SO2-lipid + 1.5% bovine SP-B/C are 
fully resistant to chemical degradation by PLA2 (Notter et al., 2007).  These findings on Chapter 4  General Discussion 
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chemical degradation were directly consistent with the adverse surface behaviour of 
CLSE surfactants on the pulsating bubble surfactometer in the presence of PLA2 while 
mixtures of DEPN-8 and SO2-lipid + SP-B/C (0.75% bovine SP-B and 0.75% SP-C) 
were unaffected by this enzyme (Notter et al., 2007).  Recent research by Walther et al. 
(2007) also defined resistance to PLA2 degradation of fully synthetic lung surfactant 
containing DEPN-8 + (Mini-B) (a 34 amino acid peptide designed to retain the major 
amphipathic regions of human surfactant protein B).  These surfactant preparations may 
eventually prove to have significant advantages in the treatment of ARDS.  Further 
avenues for research might also exist in studying DEPN-8 and/or related products in 
relation to albumin inactivation of pulmonary surfactant.  The identification of serum-
PLA2-like  activity  and  albumin-associated  PLA2  that  are  involved  in  hydrolysis  of 
surfactant phospholipids may be an additional step in gaining a greater understanding of 
the pulmonary surfactant system and potential utility for treating surfactant dysfunction 
in inflammatory lung injury.  
 
4.2  Influence of foetal age and sex on glucocorticoid and β-
adrenergic receptor levels in cultured foetal lung cells 
Glucocorticoids have long been known to influence the maturation of foetal organs, 
particularly those of endodermal origin, such as the gut (Moog, 1953; Henning, 1979), 
liver (Cake et al., 1981), pancreas (Rall et al., 1977) and salivary glands (Kumegawa et 
al.,  1978).    A  similar  dependency  on  glucocorticoids  has  been  demonstrated  in  the 
developing lungs, which is also an endodermally derived organ (Buckingham et al., 
1968; Smith, 1978), and an extensive literature has accumulated.  Despite the fact that 
glucocorticoids have long been known to be involved in maturational events of a variety Chapter 4  General Discussion 
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of tissue the lung is the first organ for which such knowledge has been clinically applied 
(Liggins and Howie, 1972).  
As with many developing organs, the maturation of the embryonic lung is strongly 
dependent on interactions between cells of epithelial and mesenchymal origin. In the 
later  stages  of  foetal  lung  development,  when  hormonal  regulation  is  occurring, 
epithelial-mesenchymal interactions continue to occur, thus modulating some hormonal 
responses. Glucocorticoids stimulate surfactant synthesis in organ cultures or in mixed 
monolayer or organotypic cultures of foetal lung tissue, each of which contains cells 
derived  from  the  various  cell  layers  (Possmayer  et  al.,  1979;  Snyder  et  al.,  1981; 
Ballard et al., 1997; Bolt et al., 2001).  In contrast, when cloned human foetal alveolar 
type  II  cells  were  studied,  the  glucocorticoid  effect  was  found  to  be  very  much 
attenuated (Tanswell and Smith, 1980).  However, when these cells were recombined 
with foetal lung fibroblasts, full stimulation of surfactant synthesis was again apparent 
(Smith, 1979; Floros et al., 1985; Post et al., 1986; Scott and Das, 1993; Shannon et al., 
2001), suggesting that glucocorticoids stimulate surfactant phospholipid indirectly via 
the  lung  fibroblasts.    In  the  current  study,  exposure  of  the  type  II  pneumocytes  to 
medium conditioned by foetal lung fibroblasts, in the presence of glucocorticoids, also 
resulted  in  full  responsiveness.    The  available  evidence  strongly  advocates  that  the 
stimulation  of  pulmonary  phosphatidylcholine  synthesis  is  mediated  via  a  “factor” 
produced by fibroblasts termed fibroblast pneumocyte factor (FPF) (Smith, 1979). 
The  activity  of  the  enzyme  phosphocholine  cytidyltransferase,  which  produces 
CDP-choline, has been shown to be elevated when type II pneumocytes are exposed to 
this peptide (Post et al., 1986) and this leads to a significant increase in the rate of 
synthesis of DSPC in these cells.  Administration of glucocorticoids to either the mother 
or the foetus enhances maturation of the lung (Crowley, 1995, Bolt, 2001), however, Chapter 4  General Discussion 
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this treatment has the drawback of also leading to a decrease in the lung/body weight 
ratio (Possmayer et al., 1977; Ekelund and Enhorning, 1985).  The presence of specific 
glucocorticoid receptors in the foetal rat lung is very strong evidence that this organ is a 
glucocorticoid target tissue.  The beneficial effects of glucocorticoids are less evident 
when the premature infant is a male (Ballard et al., 1980; Kotas and Avery, 1980; 
Torday,  1984).  The  present  study  has  confirmed  that  there  are  sex-specific  and 
gestational age differences in the GR receptor levels of lung fibroblasts but not in the 
type II cells, thus, regulation of the appearance of the glucocorticoid receptor in foetal 
lungs  in  the  later  stages  of  gestation  appears  to  be  both  sex-  and  cell-specific.  
Functional  GR  activity  appears  earlier  in  fibroblasts  derived  from  female  foetuses, 
whereas there is no sex difference in the GR activity of type II pneumocytes in late 
gestation.  The interaction of glucocorticoids with their specific receptor has also been 
shown  to  affect  the  rate  of  surfactant  secretion.    This  study  has  demonstrated  that 
β-adrenergic receptors are present and functional in cultures enriched with foetal type II 
pneumocytes.  The β-adrenoreceptor activity is elevated if the type II cells are exposed 
to glucocorticoids, but even more so, if exposed to media that had been previously 
conditioned by fibroblasts in the presence of glucocorticoids.  Both of these effects were 
more pronounced if the type II cells were derived from female foetuses rather than from 
males and despite the cells being grown under similar conditions.  This observation may 
be especially important because of the clinical observation that in humans, respiratory 
distress syndrome is nearly twice as common and more severe in male versus female 
neonates.  The study has also demonstrated that there is a strong correlation between the 
β-adrenergic  receptor  activity  and  the  ability  of  agonists  to  stimulate 
phosphatidylcholine secretion from type II cells.  The increase in β-adrenergic receptors 
in  female-derived  type  II  cells  in  response  to  glucocorticoids  and/or  fibroblast-Chapter 4  General Discussion 
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conditioned media has also been shown to be associated with an enhanced physiological 
response to a β-agonist, such as (—)-isoproterenol.  Moreover, there is undeniably a 
very strong correlation between the level of β-adrenoreceptor activity in type II cells 
and  the  extent  to  which  (—)-isoproterenol  stimulates  secretion  of  surfactant 
phospholipids.  This implies that the earlier maturation of the lung that occurs in female 
foetuses can be partially accounted for by an enhanced rate of secretion of pulmonary 
surfactant and this is, almost certainly, a result of a greater sensitivity to glucocorticoid-
induced production of β-adrenoreceptors.  
A  recent  study,  using  an  immunoprecipitation  technique,  has  shown  that  fibroblast-
conditioned medium from cultured foetal mouse lung cells contains elevated levels of 
neuregulin-1β (NRG-1β) and that NRG-1β is able to mimic the stimulatory effect of 
FCM (which contains fibroblast pneumocyte factor) on surfactant synthesis by type II 
cells  (Dammann  et  al.,  2003).    Furthermore,  the  stimulatory  effect  of  FCM  was 
inhibited  by  the  addition  of  a  NRG-1β  neutralising  antibody.  The  growth  factor, 
neuregulin-1β,  is  known  to  be  related  to  epidermal  growth  factor,  which  has  been 
previously shown to have a significant impact on surfactant synthesis in type II cells 
(Sen and Cake, 1991) and the two growth factors share the same receptors, known as 
ErbB receptors (Patel et al., 2000; Britsch, 2007).  Moreover, NRG-1β appears to be 
involved in the regulation of the onset of foetal surfactant synthesis (Dammann et al., 
2003) and receptors for NRG-1β have been identified in human foetal lung cells as 
early as 24 weeks of gestation (Bueter et al., 2006).  These receptors have been detected 
on type II pneumocytes (Patel et al., 2000; Hoffmann et al., 2010; Liu et al., 2010) and 
NRG-1β receptor gene expression has been detected in fibroblasts (Citri et al., 2003). 
This implies that NRG-1β is secreted from lung fibroblast cells and likely to act on type 
II cells, in the same manner as FPF (Smith, 1979). Chapter 4  General Discussion 
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Given the recent findings of Dammann et al. (2003), it is suggested that future studies 
should aim to establish whether or not NRG-1β gene expression is enhanced in lung 
fibroblasts if the cells are pretreated with glucocorticoids.  If it is, it would provide 
strong evidence that FPF is, in fact, the growth factor, NRG-1β.  Furthermore, as media, 
conditioned  by  fibroblasts  in  the  presence  of  glucocorticoids,  has  been  shown  to 
stimulate  β-adrenergic  receptor  activity  in  cultured  type  II  cells  and  thus  DSPC 
secretion from these cells, particularly in those derived from female foetuses, it would 
be logical to investigate whether this stimulatory effect is also the result of a direct 
effect of NRG-1β on type II cells.  
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